



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)


(51) International Patent Classification ⁷ : G01N 33/68	A1	(11) International Publication Number: WO 00/28331 (43) International Publication Date: 18 May 2000 (18.05.00)
<p>(21) International Application Number: PCT/US99/26715</p> <p>(22) International Filing Date: 12 November 1999 (12.11.99)</p> <p>(30) Priority Data: 60/108,147 12 November 1998 (12.11.98) US 60/131,284 27 April 1999 (27.04.99) US</p> <p>(71) Applicant: DU PONT PHARMACEUTICALS COMPANY [US/US]; Chestnut Run Plaza, 974 Centre Road, Wilmington, DE 19807 (US).</p> <p>(72) Inventors: ZACZEK, Robert, C.; 18 Roosevelt Way, Avondale, PA 19311 (US). OLSON, Richard, E.; 7 Pelham Road, Wilmington, DE 19803 (US). SEIFFERT, Dietmar, A.; 3719 Highland Drive, Boothwyn, PA 19061 (US). THOMPSON, Lorin, Andrew; 600 Silverside Road, Wilmington, DE 19809 (US).</p> <p>(74) Agent: LARSEN, Scott, K.; Du Pont Pharmaceuticals Company, Legal Patent Records Center, 1007 Market Street, Wilmington, DE 19898 (US).</p>		<p>(81) Designated States: AU, BR, CA, CN, CZ, EE, HU, IL, IN, JP, KR, LT, LV, MX, NO, NZ, PL, SG, SK, TR, VN, ZA, Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE).</p> <p>Published With international search report. Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</p>

(54) Title: USE OF RADIOLIGANDS TO SCREEN INHIBITORS OF AMYLOID-BETA PEPTIDE PRODUCTION





(57) Abstract

This invention relates to a novel method of screening for inhibitors of beta-amyloid production, and thereby identifying such inhibitors as therapeutics for neurological and other disorders involving APP processing and beta-amyloid production. This invention also relates to identifying macromolecules involved in APP processing and beta-amyloid production. Furthermore, inhibitors identified by the screening method of the present invention are useful in the treatment of neurological disorders, such as Alzheimer's disease, which involve elevated levels of A β peptides.

Fluorography



Silver Stain

Immunoblot
anti- PS-1 (N-t.)Immunoblot
anti- PS-1 (C-t.)Fluorography of
Silver Stain

- 1: Starting material
- 2: Flow-through mouse IgG
- 3: Flow-through mAb 361
- 4: Last wash
- 5: Elution

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakistan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

TITLE

USE OF RADIOLIGANDS TO SCREEN INHIBITORS OF AMYLOID-BETA PEPTIDE PRODUCTION

5

FIELD OF THE INVENTION

This invention relates to a novel method of screening for inhibitors of beta-amyloid production, and thereby identifying such inhibitors as therapeutics for neurological and other disorders involving APP processing and beta-amyloid production. This invention also relates to identifying macromolecules involved in APP processing and beta-amyloid production. Furthermore, inhibitors identified by the screening method of the present invention are useful in the treatment of neurological disorders, such as Alzheimer's disease, which involve elevated levels of A β peptides.

BACKGROUND OF THE INVENTION

Alzheimer's disease (AD) is a degenerative brain disorder characterized clinically by progressive loss of memory, temporal and local orientation, cognition, reasoning, judgment and emotional stability. AD is a common cause of progressive dementia in humans and is one of the major causes of death in the United States. AD has been observed in all races and ethnic groups worldwide, and is a major present and future health problem. No treatment that effectively prevents AD or reverses the clinical symptoms and underlying pathophysiology is currently available (for review, Dennis J. Selkoe; Cell Biology of the amyloid (beta)-protein precursor and the mechanism of Alzheimer's disease, Annu Rev Cell Biol, 1994, 10: 373-403).

Histopathological examination of brain tissue derived upon autopsy or from neurosurgical specimens in effected individuals revealed the occurrence of amyloid plaques and neurofibrillar tangles in the cerebral cortex of such patients. Similar alterations were observed in patients with Trisomy 21 (Down's syndrome), and hereditary cerebral hemorrhage with amyloidosis of the Dutch-type. Neurofibrillar tangles are nonmembrane-bound bundles of

abnormal proteinaceous filaments and biochemical and immunochemical studies led to the conclusion that their principle protein subunit is an altered phosphorylated form of the tau protein (reviewed in Selkoe, 1994).

5 Biochemical and immunological studies revealed that the dominant proteinaceous component of the amyloid plaque is an approximately 4.2 kilodalton (kD) protein of about 39 to 43 amino acids. This protein was designated A β , β -amyloid peptide, and sometimes β /A4; referred to herein as A β . In
10 addition to deposition of A β in amyloid plaques, A β is also found in the walls of meningeal and parenchymal arterioles, small arteries, capillaries, and sometimes, venules. A β was first purified, and a partial amino acid reported, in 1984 (Glennner and Wong, Biochem. Biophys. Res. Commun. 120: 885-
15 890). The isolation and sequence data for the first 28 amino acids are described in U.S. Pat. No 4,666,829.

Compelling evidence accumulated during the last decade revealed that A β is an internal polypeptide derived from a type 1 integral membrane protein, termed β amyloid precursor
20 protein (APP). β APP is normally produced by many cells both in vivo and in cultured cells, derived from various animals and humans. A β is derived from cleavage of β APP by as yet unknown enzyme (protease) system(s), collectively termed secretases.

25 The existence of at least four proteolytic activities has been postulated. They include β secretase(s), generating the N-terminus of A β , α secretase(s) cleaving around the 16/17 peptide bond in A β , and γ secretases, generating C-terminal A β fragments ending at position 38, 39, 40, 42, and
30 43 or generating C-terminal extended precursors which are subsequently truncated to the above polypeptides.

Several lines of evidence suggest that abnormal accumulation of A β plays a key role in the pathogenesis of AD. Firstly, A β is the major protein found in amyloid
35 plaques. Secondly, A β is neurotoxic and may be causally related to neuronal death observed in AD patients. Thirdly, missense DNA mutations at position 717 in the 770 isoform of β APP can be found in effected members but not unaffected

members of several families with a genetically determined (familiar) form of AD. In addition, several other β APP mutations have been described in familial forms of AD.

Fourthly, similar neuropathological changes have been

- 5 observed in transgenic animals overexpressing mutant forms of human β APP. Fifthly, individuals with Down's syndrome have an increased gene dosage of β APP and develop early-onset AD. Taken together, these observations strongly suggest that A β depositions may be causally related to the AD.


- 10 It is hypothesized that inhibiting the production of A β will prevent and reduce neurological degeneration, by controlling the formation of amyloid plaques, reducing neurotoxicity and, generally, mediating the pathology associated with A β production. One method of treatment
15 methods would therefore be based on drugs that inhibit the formation of A β in vivo.

- Methods of treatment could target the formation of A β through the enzymes involved in the proteolytic processing of β amyloid precursor protein. Compounds that inhibit β or γ
20 secretase activity, either directly or indirectly, could control the production of A β . Advantageously, compounds that specifically target γ secretases, could control the production of A β . Such inhibition of β or γ secretases could thereby reduce production of A β , which, thereby, could reduce
25 or prevent the neurological disorders associated with A β protein.

- It is believed that several macromolecules, some of which have proteolytic activity, are involved in the
30 processing of amyloid precursor protein (APP). This processing leads to several products including the β -amyloid peptides (A β) believed etiologically important in Alzheimers Disease. We have discovered novel tagged compounds, functional in themselves as A β inhibitors, for use in
35 identifying a site or sites on one or more macromolecules critical to the processing of β APP and the production of A β . We have discovered novel tagged compounds which inhibit the proteolytic activity leading to production of A β by


interacting with one or more macromolecules critical to the processing of APP and the production of A β . We have also discovered a site of action of these tagged compounds using radioisotope tagged derivatives of a compound of Formula (I).

- 5 Three examples of tagged compounds include (I-7T), (I-11T), and (I-43T):



(I-#)

- 10 (I-7) : R** = ^1H ; Y = -O- ;
 (I-7T): R** = ^3H ; Y = -O- ; and
 (I-11): R** = ^1H ; Y = -C(=O)- ;
 (I-11T): R** = ^3H ; Y = -C(=O)- ; and



(I-#)

- 15 (I-43) : R** = ^1H ;
 (I-43T): R** = ^3H .

- 20 The concentration of Compound (I-7) leading to half-maximal inhibition (IC_{50}) of proteolytic activity leading to A β production in HEK₂₉₃ cells expressing APP 695 wt is similar to the concentration leading to half-maximal inhibition (IC_{50}) of Compound (I-7T) binding to membranes derived from
 25 the same cell line. The correlation holds for compounds (I-11T) and (I-43T). Also using a compound of Formula (I), we have discovered a macromolecule containing a binding site of action for compounds of Formula (I) critical to the processing of APP and the production of A β .

Furthermore, we have discovered through competitive binding studies that there is a good correlation between the ability of a series of compounds to inhibit the proteolytic activity leading to production of A β and to inhibit the binding of Compound (I-7T), (I-11T), or (I-43T) to said membranes. Thus, the binding of Compound (I-7T), (I-11T), or (I-43T) to relevant tissues and cell lines, membranes derived from relevant tissues and cell lines, as well as isolated macromolecules and complexes of isolated macromolecules, is useful in the identification of inhibitors of A β production through competitive binding assays. Furthermore, such competitive binding assays are useful in identification of inhibitors of proteolytic activity leading to A β production for the treatment of Alzheimer's disease. Furthermore, such competitive binding assays are useful in identification of inhibitors of proteolytic activity leading to A β production for the treatment of neurological disorders and other disorders involving A β , APP, and/or A β /APP associated macromolecules, and other macromolecules associated with the site of Compound (I-7T), (I-11T), or (I-43T) binding.

SUMMARY OF THE INVENTION

One object of the present invention is to provide a novel method of screening for inhibitors of beta-amyloid production, and thereby identifying such inhibitors as therapeutics for neurological and other disorders involved in APP processing and beta-amyloid production. The method comprises 1) contacting a potential inhibitor of beta-amyloid production and a tagged inhibitor of beta-amyloid production with at least one macromolecule involved in the processing of APP and the production of beta-amyloid peptide, said macromolecule containing a binding site specific for said tagged inhibitor of beta-amyloid production; 2) separating the tagged inhibitor of beta-amyloid production bound to said macromolecule from the tagged inhibitor of beta-amyloid production free from said macromolecule; and 3) determining an inhibitory concentration of the potential inhibitor of beta-amyloid production from the concentration of tagged

inhibitor of beta-amyloid production bound to said macromolecule.

It is another object of the present invention to provide the use of a tagged inhibitor of beta-amyloid production to
5 identify macromolecules involved in APP processing.

It is another object of the present invention to provide the macromolecules involved in APP processing which a tagged inhibitor of beta-amyloid production binds to specifically.

It is another object of the present invention to provide
10 the use of macromolecules involved in APP processing, which a tagged inhibitor of beta-amyloid production binds to specifically, for the identification of inhibitors as therapeutics for neurological and other disorders involved in APP processing and beta-amyloid production.


It is another object of the present invention to provide
15 the use of macromolecules involved in APP processing, which a tagged inhibitor of beta-amyloid production binds to specifically, for the assaying of inhibitors of beta-amyloid production.

It is another object of the present invention to provide
20 pharmaceutical compositions comprising a pharmaceutically acceptable carrier and a therapeutically effective amount of an inhibitor of beta-amyloid production, or a pharmaceutically acceptable salt or prodrug form thereof,
25 identified by the screening assay of the present invention.


It is another object of the present invention to provide a method for treating degenerative neurological disorders involving beta-amyloid production, including Alzheimer's disease, comprising administering to a host in need of such
30 treatment a therapeutically effective amount of an inhibitor of beta-amyloid production, or a pharmaceutically acceptable salt or prodrug form thereof, identified by the screening assay of the present invention.

It is another object of the present invention to provide
35 an inhibitor of beta-amyloid production which interacts with the binding site for a compound of Formula (I-7T) on a macromolecule involved in the production of beta-amyloid peptide.

These and other objects, which will become apparent during the following detailed description, have been achieved by the inventors' discovery that compounds of Formula (I):



(I-#)

(I-7) : $R^{**} = {}^1H$; $Y = -O-$;(I-7T) : $R^{**} = {}^3H$; $Y = -O-$; and(I-11) : $R^{**} = {}^1H$; $Y = -C(=O)-$;(I-11T) : $R^{**} = {}^3H$; $Y = -C(=O)-$; and

(I-#)

(I-43) : $R^{**} = {}^1H$;(I-43T) : $R^{**} = {}^3H$;

bind specifically to a binding site on a macromolecule or a complex of macromolecules involved in APP processing to produce reduction of A β peptide production. For example, the concentration of Compound (I-7) leading to half-maximal inhibition (IC₅₀) of A β production in HEK₂₉₃ cells expressing APP 695 wt is similar to the concentration leading to half-maximal inhibition (IC₅₀) of Compound (I-7T) binding to membranes derived from the same cell line.

FIG. 1 illustrates the correlation between results of the Radioligand Competition Binding Assay and the cross-linking assay of Example 103.

FIG. 2 illustrates a fluorography of a 12% SDS-PAGE after immunoprecipitation of specifically cross-linked polypeptides by presenilin-1 antibodies.

FIG. 3 illustrates isolation of cross-linked polypeptides by presenilin 1 affinity chromatography.

FIG. 4 illustrates a fluorography of a 12% SDS-PAGE after immunoprecipitation of specifically cross-linked polypeptides by presenilin-2 antibodies.

10 DETAILED DESCRIPTION OF PREFERRED EMBODIMENTS

Thus, in a first embodiment, the present invention provides a method of screening for inhibitors of beta-amyloid production comprising,

- 15 1) contacting a potential inhibitor of beta-amyloid production and a tagged inhibitor of beta-amyloid production with at least one macromolecule involved in the processing of APP and the production of beta-amyloid peptide, said macromolecule containing a binding site specific for said tagged inhibitor of beta-amyloid production;
- 20 2) separating the tagged inhibitor of beta-amyloid production bound to said macromolecule from the tagged inhibitor of beta-amyloid production free from said macromolecule; and
- 25 3) determining an inhibitory concentration of the potential inhibitor of beta-amyloid production from the concentration of tagged inhibitor of beta-amyloid production bound to said macromolecule.


30 [2] In a more preferred embodiment the present invention provides a method wherein the tagged inhibitor of beta-amyloid production comprises a radiolabeled inhibitor of beta-amyloid production, a fluorescence labeled inhibitor of beta-amyloid production or a biotin labeled inhibitor of
35 beta-amyloid production.

[3] In a more preferred embodiment the tagged inhibitor of beta-amyloid production comprises a radiolabeled inhibitor of beta-amyloid production.

5 In an even more preferred embodiment the present invention provides a method wherein the tagged inhibitor of beta-amyloid production comprises a tritium or iodine radiolabeled inhibitor of beta-amyloid production.

10 In an even more preferred embodiment the present invention provides a method wherein the tagged inhibitor of beta-amyloid production comprises a tritium labeled inhibitor of beta-amyloid production.

15 In an even more preferred embodiment the present invention, provides a method wherein the tagged inhibitor of beta-amyloid production comprises a compound of the Formula (I):



(I)

wherein:

at least one atom of the compound of the Formula (I) is radiolabeled;

25 Q is -NR¹R²;

R¹, at each occurrence, is independently selected from:

H;

30 C₁-C₆ alkyl substituted with 0-3 R^{1a};

C₃-C₁₀ carbocycle substituted with 0-3 R^{1b};

C₆-C₁₀ aryl substituted with 0-3 R^{1b}; and

5 to 10 membered heterocycle substituted with 0-3 R^{1b};

R^{1a}, at each occurrence, is independently selected from H,
C₁-C₆ alkyl, OR¹⁴, Cl, F, Br, I, =O, CN, NO₂, NR¹⁵R¹⁶,
phenyl, CF₃;
C₃-C₁₀ carbocycle substituted with 0-3 R^{1b};
5 C₆-C₁₀ aryl substituted with 0-3 R^{1b}; and
5 to 10 membered heterocycle substituted with 0-3 R^{1b};

R^{1b}, at each occurrence, is independently selected from H,
OH, C₁-C₆ alkyl, C₁-C₄ alkoxy, Cl, F, Br, I, CN, NO₂,
10 NR¹⁵R¹⁶, or CF₃;

R² is independently selected from H, OH, C₁-C₆ alkyl, C₁-C₆
alkoxy, C₃-C₁₀ carbocycle, C₆-C₁₀ aryl and 5 to 10
15 membered heterocycle;

R³ is C₁-C₆ alkyl substituted with 0-1 R⁴;

R⁴ is H, OH, C₁-C₆ alkoxy, C₁-C₆ alkyl, C₂-C₆ alkenyl, C₂-C₆
alkynyl, C₃-C₁₀ carbocycle, C₆-C₁₀ aryl, or 5 to 10
20 membered heterocycle;

R⁵ is H, OR¹⁴;

C₁-C₆ alkyl substituted with 0-3 R^{5b};
C₁-C₆ alkoxy substituted with 0-3 R^{5b};
25 C₂-C₆ alkenyl substituted with 0-3 R^{5b};
C₂-C₆ alkynyl substituted with 0-3 R^{5b};
C₃-C₁₀ carbocycle substituted with 0-3 R^{5c};
C₆-C₁₀ aryl substituted with 0-3 R^{5c}; or
5 to 10 membered heterocycle substituted with 0-3 R^{5c};

30

R^{5b}, at each occurrence, is independently selected from:
H, C₁-C₆ alkyl, CF₃, OR¹⁴, Cl, F, Br, I, =O, CN, NO₂,
NR¹⁵R¹⁶;
C₃-C₁₀ carbocycle substituted with 0-3 R^{5c};
35 C₆-C₁₀ aryl substituted with 0-3 R^{5c}; or
5 to 10 membered heterocycle substituted with 0-3 R^{5c};

R^{5c}, at each occurrence, is independently selected from H, OH, C₁-C₆ alkyl, C₁-C₄ alkoxy, Cl, F, Br, I, CN, NO₂, NR¹⁵R¹⁶, or CF₃;

5 R⁶ is H;

C₁-C₆ alkyl substituted with 0-3 R^{6a};

C₃-C₁₀ carbocycle substituted with 0-3 R^{6b}; or

C₆-C₁₀ aryl substituted with 0-3 R^{6b};

10 R^{6a}, at each occurrence, is independently selected from H, C₁-C₆ alkyl, OR¹⁴, Cl, F, Br, I, =O, CN, NO₂, NR¹⁵R¹⁶, phenyl or CF₃;

R^{6b}, at each occurrence, is independently selected from H,

15 OH, C₁-C₆ alkyl, C₁-C₄ alkoxy, Cl, F, Br, I, CN, NO₂, NR¹⁵R¹⁶, or CF₃;

W is -(CR⁸R^{8a})_p-;

20 p is 0 to 4;

R⁸ and R^{8a}, at each occurrence, are independently selected from H, C₁-C₄ alkyl, C₂-C₄ alkenyl, C₂-C₄ alkynyl and C₃-C₈ cycloalkyl;

25

X is a bond;

C₆-C₁₀ aryl substituted with 0-3 R^{Xb};

C₃-C₁₀ carbocycle substituted with 0-3 R^{Xb}; or

5 to 10 membered heterocycle substituted with 0-3 R^{Xb};

30

R^{Xb}, at each occurrence, is independently selected from H, OH, C₁-C₆ alkyl, C₁-C₄ alkoxy, Cl, F, Br, I, CN, NO₂, NR¹⁵R¹⁶, or CF₃;

35 Y is a bond or -(CR⁹R^{9a})_t-V-(CR⁹R^{9a})_u-;

t is 0 to 3;

u is 0 to 3;

R⁹ and R^{9a}, at each occurrence, are independently selected from H, C₁-C₆ alkyl or C₃-C₈ cycloalkyl;

5

V is a bond, -C(=O)-, -O-, -S-, -S(=O)-, -S(=O)₂-, -N(R¹⁹)-, -C(=O)NR^{19b}-, -NR^{19b}C(=O)-, -NR^{19b}S(=O)₂-, -S(=O)₂NR^{19b}-, -NR^{19b}S(=O)-, -S(=O)NR^{19b}-, -C(=O)O-, or -OC(=O)-;

10 Z is H;

C₁-C₈ alkyl substituted with 0-2 R¹²;

C₂-C₄ alkenyl substituted with 0-2 R¹²;

C₂-C₄ alkynyl substituted with 0-2 R¹²;

C₆-C₁₀ aryl substituted with 0-4 R^{12b};

15 C₃-C₁₀ carbocycle substituted with 0-4 R^{12b}; or

5 to 10 membered heterocycle substituted with 0-3 R^{12b};

R¹² is C₆-C₁₀ aryl substituted with 0-4 R^{12b};

C₃-C₁₀ carbocycle substituted with 0-4 R^{12b}; or

20 5 to 10 membered heterocycle substituted with 0-3 R^{12b};

R^{12b}, at each occurrence, is independently selected from H, OH, C₁-C₆ alkyl, C₁-C₄ alkoxy, Cl, F, Br, I, CN, NO₂, NR¹⁵R¹⁶, or CF₃;

25

B is a 5 to 10 membered lactam, wherein the lactam is saturated, partially saturated or unsaturated; wherein each additional lactam carbon is substituted with 0-2 R¹¹; and, optionally, the lactam contains a heteroatom selected from -O-, -S-, -S(=O)-, -S(=O)₂-, -N= and -N(R¹⁰)-;

30

R¹⁰ is H, C(=O)R¹⁷, C(=O)OR¹⁷, C(=O)NR¹⁸R¹⁹, S(=O)₂NR¹⁸R¹⁹, S(=O)₂R¹⁷;

35

C₁-C₆ alkyl optionally substituted with R^{10a};

C₆-C₁₀ aryl substituted with 0-4 R^{10b};

C₃-C₁₀ carbocycle substituted with 0-3 R^{10b}; or

5 to 10 membered heterocycle optionally substituted with
0-3 R^{10b};

5 R^{10a}, at each occurrence, is independently selected from H,
C₁-C₆ alkyl, C₃-C₆ cycloalkyl, OR¹⁴, Cl, F, Br, I, =O,
CN, NO₂, NR¹⁵R¹⁶, phenyl or CF₃;

10 R^{10b}, at each occurrence, is independently selected from H,
OH, C₁-C₆ alkyl, C₁-C₄ alkoxy, Cl, F, Br, I, CN, NO₂,
NR¹⁵R¹⁶, or CF₃;

R¹¹ is C₁-C₄ alkoxy, Cl, F, Br, I, =O, CN, NO₂, NR¹⁸R¹⁹,
C(=O)R¹⁷, C(=O)OR¹⁷, C(=O)NR¹⁸R¹⁹, S(=O)₂NR¹⁸R¹⁹, CF₃;
C₁-C₆ alkyl optionally substituted with R^{11a};
15 C₆-C₁₀ aryl substituted with 0-3 R^{11b};
C₃-C₁₀ carbocycle substituted with 0-3 R^{11b}; or
5 to 10 membered heterocycle substituted with 0-3 R^{11b};

20 alternatively, two R¹¹ substituents on the same carbon atoms
may be combined to form a C₃-C₆ carbocycle;

alternatively, two R¹¹ substituents on adjacent carbon atoms
may be combined to form a C₃-C₆ carbocycle or a benzo
fused radical, wherein said benzo fused radical is
25 substituted with 0-3 R¹³;

30 R^{11a}, at each occurrence, is independently selected from H,
C₁-C₆ alkyl, OR¹⁴, Cl, F, Br, I, =O, CN, NO₂, NR¹⁵R¹⁶,
phenyl or CF₃;

R^{11b}, at each occurrence, is independently selected from H,
OH, C₁-C₆ alkyl, C₁-C₄ alkoxy, Cl, F, Br, I, CN, NO₂,
NR¹⁵R¹⁶, or CF₃;

35 R¹³, at each occurrence, is independently selected from H,
OH, C₁-C₆ alkyl, C₁-C₄ alkoxy, Cl, F, Br, I, CN, NO₂,
NR¹⁵R¹⁶, or CF₃;

R¹⁴ is H, phenyl, benzyl, C₁-C₆ alkyl, or C₂-C₆ alkoxyalkyl;

R¹⁵, at each occurrence, is independently selected from H,
C₁-C₆ alkyl, benzyl, phenethyl, -C(=O)-(C₁-C₆ alkyl) and
-S(=O)₂-(C₁-C₆ alkyl);

R¹⁶, at each occurrence, is independently selected from H,
OH, C₁-C₆ alkyl, benzyl, phenethyl, -C(=O)-(C₁-C₆ alkyl)
and -S(=O)₂-(C₁-C₆ alkyl);

R¹⁷ is H, phenyl, benzyl, C₁-C₆ alkyl, or C₂-C₆ alkoxyalkyl;

R¹⁸, at each occurrence, is independently selected from H,
C₁-C₆ alkyl, benzyl, phenethyl, -C(=O)-(C₁-C₆ alkyl) and
-S(=O)₂-(C₁-C₆ alkyl); and

R¹⁹, at each occurrence, is independently selected from H,
OH, C₁-C₆ alkyl, phenyl, benzyl, phenethyl, -C(=O)-(C₁-
C₆ alkyl) and -S(=O)₂-(C₁-C₆ alkyl);

R^{19b} is H, C₁-C₆ alkyl, C₃-C₈ cycloalkyl, phenyl, benzyl or
phenethyl; and

R²⁰ is H or C₁-C₆ alkyl.


In an even further more preferred embodiment the present
invention, provides a method wherein Q of a compound of
Formula (I) is -NH₂.

In an even further more preferred embodiment the present
invention, provides a method wherein R³ of a compound of
Formula (I) is C₃-C₆ alkyl.

In an even further more preferred embodiment the present
invention, provides a method wherein R³ of a compound of
Formula (I) is C₃-C₆ alkyl substituted with about 1 to about
4 ³H;

In an even further more preferred embodiment the present invention, provides a method wherein Q is -NH_2 , and R^3 is $\text{C}_3\text{-C}_6$ alkyl substituted with about 1 to about 4 ^3H .

5 In an even further more preferred embodiment the present invention, provides a method wherein the tagged inhibitor of beta-amyloid production comprises a compound of the Formula (II):




(II)

wherein:


at least one atom of the compound of the Formula (II) is radiolabeled.


15 In an even further more preferred embodiment the present invention, provides a method wherein R^3 , in a compound of Formula (II), is $\text{C}_3\text{-C}_6$ alkyl substituted with about 1 to about 4 ^3H .

20 In a most preferred embodiment the present invention, provides a method wherein the tagged inhibitor of beta-amyloid production comprises a compound of Formula:




or





wherein m is about 2.

5 In a further most preferred embodiment the present invention, provides a method wherein the tagged inhibitor of beta-amyloid production comprises a compound of Formula (I-43T)



(I-43T)

wherein m is about 2.

In yet another preferred embodiment the present invention provides a method wherein the tagged inhibitor of beta-amyloid production comprises a compound selected from US 5,703,129; PCT application WO98/28268; PCT application WO98/22441; PCT application WO98/22433; PCT application WO98/22430; PCT application WO98/22493; PCT application WO98/22494; PCT application WO98/38177; or PCT application WO95/09838; wherein the compound has been tagged for purposes of the invention.

In another preferred embodiment the present invention provides a method wherein at least one macromolecule involved in the processing of APP and the production of beta-amyloid peptide comprises presenilin 1 or a fragment of presenilin 1.

In another preferred embodiment the present invention provides a method wherein at least one macromolecule involved in the processing of APP and the production of beta-amyloid peptide comprises presenilin 2 or a fragment of presenilin 2.

5

In another preferred embodiment the present invention provides a method wherein at least one macromolecule involved in the processing of APP and the production of beta-amyloid peptide comprises either 1) presenilin 1 or a fragment of presenilin 1 or 2) presenilin 2 or a fragment of presenilin 2; but not both.

10

In yet another preferred embodiment the present invention provides a method wherein the inhibitory concentration is half maximal inhibitory concentration.

15

In a second embodiment, the present invention provides a pharmaceutical composition comprising a pharmaceutically acceptable carrier and a therapeutically effective amount of an inhibitor of beta-amyloid production identified by the screening assay of Claim 1 or a pharmaceutically acceptable salt or prodrug form thereof.

20

In a third embodiment, the present invention provides a method for treating degenerative neurological disorders involving beta-amyloid production comprising administering to a host in need of such treatment a therapeutically effective amount of an inhibitor of beta-amyloid production identified by the screening assay of Claim 1 or a pharmaceutically acceptable salt or prodrug form thereof.

25

30

In a preferred third embodiment the degenerative neurological disorder is Alzheimer's Disease.

In a fourth embodiment, the present invention provides a method of identifying a macromolecule involved in APP processing comprising

35


- 1) contacting a tagged inhibitor of beta-amyloid production with material suspected to contain a macromolecule involved in APP processing;
- 2) separating a complex comprising a tagged inhibitor of beta-amyloid production and a macromolecule involved in APP processing; and
- 3) identifying the complex.

In a preferred fourth embodiment the present invention provides a method wherein the tagged inhibitor of beta-amyloid production comprises a radiolabeled inhibitor of beta-amyloid production, a fluorescence labeled inhibitor of beta-amyloid production, a biotin labeled inhibitor of beta-amyloid production, a photoaffinity labeled inhibitor of beta-amyloid production, or any combination of tags thereof in one inhibitor of beta-amyloid production.

In a preferred fourth embodiment the present invention provides a method wherein the tagged inhibitor of beta-amyloid production comprises a radiolabeled inhibitor of beta-amyloid production.

In a more preferred fourth embodiment the present invention provides a method wherein the tagged inhibitor of beta-amyloid production comprises a tritium labeled inhibitor of beta-amyloid production.

In a more preferred fourth embodiment the present invention provides a method wherein the tagged inhibitor of beta-amyloid production comprises a compound of Formula (I):



wherein:

at least one atom of the compound of the Formula (I) is
radiolabeled;

Q is $-NR^1R^2$;

5

R^1 , at each occurrence, is independently selected from:

H;

C_1 - C_6 alkyl substituted with 0-3 R^{1a} ;

C_3 - C_{10} carbocycle substituted with 0-3 R^{1b} ;

10 C_6 - C_{10} aryl substituted with 0-3 R^{1b} ; and

5 to 10 membered heterocycle substituted with 0-3 R^{1b} ;

R^{1a} , at each occurrence, is independently selected from H,

C_1 - C_6 alkyl, OR^{14} , Cl, F, Br, I, =O, CN, NO_2 , $NR^{15}R^{16}$,

15 phenyl, CF_3 ;

C_3 - C_{10} carbocycle substituted with 0-3 R^{1b} ;

C_6 - C_{10} aryl substituted with 0-3 R^{1b} ; and

5 to 10 membered heterocycle substituted with 0-3 R^{1b} ;

20 R^{1b} , at each occurrence, is independently selected from H,

OH, C_1 - C_6 alkyl, C_1 - C_4 alkoxy, Cl, F, Br, I, CN, NO_2 ,

$NR^{15}R^{16}$, or CF_3 ;

R^2 is independently selected from H, OH, C_1 - C_6 alkyl, C_1 - C_6

25 alkoxy, C_3 - C_{10} carbocycle, C_6 - C_{10} aryl and 5 to 10

membered heterocycle;

R^3 is C_1 - C_6 alkyl substituted with 0-1 R^4 ;

30 R^4 is H, OH, C_1 - C_6 alkoxy, C_1 - C_6 alkyl, C_2 - C_6 alkenyl, C_2 - C_6

alkynyl, C_3 - C_{10} carbocycle, C_6 - C_{10} aryl, or 5 to 10

membered heterocycle;

R^5 is H, OR^{14} ;

35 C_1 - C_6 alkyl substituted with 0-3 R^{5b} ;

C_1 - C_6 alkoxy substituted with 0-3 R^{5b} ;

C_2 - C_6 alkenyl substituted with 0-3 R^{5b} ;

C_2 - C_6 alkynyl substituted with 0-3 R^{5b} ;

C₃-C₁₀ carbocycle substituted with 0-3 R^{5c};
C₆-C₁₀ aryl substituted with 0-3 R^{5c}; or
5 to 10 membered heterocycle substituted with 0-3 R^{5c};

- 5 R^{5b}, at each occurrence, is independently selected from:
H, C₁-C₆ alkyl, CF₃, OR¹⁴, Cl, F, Br, I, =O, CN, NO₂,
NR¹⁵R¹⁶;
C₃-C₁₀ carbocycle substituted with 0-3 R^{5c};
C₆-C₁₀ aryl substituted with 0-3 R^{5c}; or
10 5 to 10 membered heterocycle substituted with 0-3 R^{5c};

R^{5c}, at each occurrence, is independently selected from H,
OH, C₁-C₆ alkyl, C₁-C₄ alkoxy, Cl, F, Br, I, CN, NO₂,
NR¹⁵R¹⁶, or CF₃;

15

R⁶ is H;
C₁-C₆ alkyl substituted with 0-3 R^{6a};
C₃-C₁₀ carbocycle substituted with 0-3 R^{6b}; or
C₆-C₁₀ aryl substituted with 0-3 R^{6b};

20

R^{6a}, at each occurrence, is independently selected from H,
C₁-C₆ alkyl, OR¹⁴, Cl, F, Br, I, =O, CN, NO₂, NR¹⁵R¹⁶,
phenyl or CF₃;

- 25 R^{6b}, at each occurrence, is independently selected from H,
OH, C₁-C₆ alkyl, C₁-C₄ alkoxy, Cl, F, Br, I, CN, NO₂,
NR¹⁵R¹⁶, or CF₃;

W is -(CR⁸R^{8a})_p-;

30

p is 0 to 4;

- R⁸ and R^{8a}, at each occurrence, are independently selected
from H, C₁-C₄ alkyl, C₂-C₄ alkenyl, C₂-C₄ alkynyl and
35 C₃-C₈ cycloalkyl;

X is a bond;

C₆-C₁₀ aryl substituted with 0-3 R^{Xb};

C₃-C₁₀ carbocycle substituted with 0-3 R^{Xb}; or
5 to 10 membered heterocycle substituted with 0-3 R^{Xb};

5 R^{Xb}, at each occurrence, is independently selected from H,
OH, C₁-C₆ alkyl, C₁-C₄ alkoxy, Cl, F, Br, I, CN, NO₂,
NR¹⁵R¹⁶, or CF₃;

Y is a bond or -(CR⁹R^{9a})_t-V-(CR⁹R^{9a})_u-;

10 t is 0 to 3;

u is 0 to 3;

15 R⁹ and R^{9a}, at each occurrence, are independently selected
from H, C₁-C₆ alkyl or C₃-C₈ cycloalkyl;

V is a bond, -C(=O)-, -O-, -S-, -S(=O)-, -S(=O)₂-, -N(R¹⁹)-,
-C(=O)NR^{19b}-, -NR^{19b}C(=O)-, -NR^{19b}S(=O)₂-, -S(=O)₂NR^{19b}-,
-NR^{19b}S(=O)-, -S(=O)NR^{19b}-, -C(=O)O-, or -OC(=O)-;

20

Z is H;

C₁-C₈ alkyl substituted with 0-2 R¹²;

C₂-C₄ alkenyl substituted with 0-2 R¹²;

C₂-C₄ alkynyl substituted with 0-2 R¹²;

25 C₆-C₁₀ aryl substituted with 0-4 R^{12b};

C₃-C₁₀ carbocycle substituted with 0-4 R^{12b}; or

5 to 10 membered heterocycle substituted with 0-3 R^{12b};

R¹² is C₆-C₁₀ aryl substituted with 0-4 R^{12b};

30 C₃-C₁₀ carbocycle substituted with 0-4 R^{12b}; or

5 to 10 membered heterocycle substituted with 0-3 R^{12b};

35 R^{12b}, at each occurrence, is independently selected from H,
OH, C₁-C₆ alkyl, C₁-C₄ alkoxy, Cl, F, Br, I, CN, NO₂,
NR¹⁵R¹⁶, or CF₃;

B is a 5 to 10 membered lactam, wherein the lactam is
saturated, partially saturated or unsaturated; wherein

each additional lactam carbon is substituted with 0-2 R¹¹; and, optionally, the lactam contains a heteroatom selected from -O-, -S-, -S(=O)-, -S(=O)₂-, -N=, and -N(R¹⁰)-;

5

R¹⁰ is H, C(=O)R¹⁷, C(=O)OR¹⁷, C(=O)NR¹⁸R¹⁹, S(=O)₂NR¹⁸R¹⁹, S(=O)₂R¹⁷;

C₁-C₆ alkyl optionally substituted with R^{10a};

C₆-C₁₀ aryl substituted with 0-4 R^{10b};

10 C₃-C₁₀ carbocycle substituted with 0-3 R^{10b}; or

5 to 10 membered heterocycle optionally substituted with 0-3 R^{10b};

R^{10a}, at each occurrence, is independently selected from H, C₁-C₆ alkyl, C₃-C₆ cycloalkyl, OR¹⁴, Cl, F, Br, I, =O, CN, NO₂, NR¹⁵R¹⁶, phenyl or CF₃;

15

R^{10b}, at each occurrence, is independently selected from H, OH, C₁-C₆ alkyl, C₁-C₄ alkoxy, Cl, F, Br, I, CN, NO₂, NR¹⁵R¹⁶, or CF₃;

20

R¹¹ is C₁-C₄ alkoxy, Cl, F, Br, I, =O, CN, NO₂, NR¹⁸R¹⁹, C(=O)R¹⁷, C(=O)OR¹⁷, C(=O)NR¹⁸R¹⁹, S(=O)₂NR¹⁸R¹⁹, CF₃;

C₁-C₆ alkyl optionally substituted with R^{11a};

C₆-C₁₀ aryl substituted with 0-3 R^{11b};

25

C₃-C₁₀ carbocycle substituted with 0-3 R^{11b}; or

5 to 10 membered heterocycle substituted with 0-3 R^{11b};

alternatively, two R¹¹ substituents on the same carbon atoms may be combined to form a C₃-C₆ carbocycle;

30

alternatively, two R¹¹ substituents on adjacent carbon atoms may be combined to form a C₃-C₆ carbocycle or a benzo fused radical, wherein said benzo fused radical is substituted with 0-3 R¹³;

35

R^{11a}, at each occurrence, is independently selected from H, C₁-C₆ alkyl, OR¹⁴, Cl, F, Br, I, =O, CN, NO₂, NR¹⁵R¹⁶, phenyl or CF₃;

5 R^{11b}, at each occurrence, is independently selected from H, OH, C₁-C₆ alkyl, C₁-C₄ alkoxy, Cl, F, Br, I, CN, NO₂, NR¹⁵R¹⁶, or CF₃;

10 R¹³, at each occurrence, is independently selected from H, OH, C₁-C₆ alkyl, C₁-C₄ alkoxy, Cl, F, Br, I, CN, NO₂, NR¹⁵R¹⁶, or CF₃;

R¹⁴ is H, phenyl, benzyl, C₁-C₆ alkyl, or C₂-C₆ alkoxyalkyl;

15 R¹⁵, at each occurrence, is independently selected from H, C₁-C₆ alkyl, benzyl, phenethyl, -C(=O)-(C₁-C₆ alkyl) and -S(=O)₂-(C₁-C₆ alkyl);

20 R¹⁶, at each occurrence, is independently selected from H, OH, C₁-C₆ alkyl, benzyl, phenethyl, -C(=O)-(C₁-C₆ alkyl) and -S(=O)₂-(C₁-C₆ alkyl);

R¹⁷ is H, phenyl, benzyl, C₁-C₆ alkyl, or C₂-C₆ alkoxyalkyl;

25 R¹⁸, at each occurrence, is independently selected from H, C₁-C₆ alkyl, benzyl, phenethyl, -C(=O)-(C₁-C₆ alkyl) and -S(=O)₂-(C₁-C₆ alkyl); and

30 R¹⁹, at each occurrence, is independently selected from H, OH, C₁-C₆ alkyl, phenyl, benzyl, phenethyl, -C(=O)-(C₁-C₆ alkyl) and -S(=O)₂-(C₁-C₆ alkyl);


R^{19b} is H, C₁-C₆ alkyl, C₃-C₈ cycloalkyl, phenyl, benzyl or phenethyl; and

35

R²⁰ is H or C₁-C₆ alkyl.

In an even more preferred fourth embodiment the present invention provides a method wherein the tagged inhibitor of beta-amyloid production comprises a compound of the Formula (I-7T):

5




(I-7T)

wherein m is about 2.

10 In another preferred fourth embodiment the present invention provides a method wherein the tagged inhibitor of beta-amyloid production is radiolabeled and photoaffinity labeled.


15 In a more preferred fourth embodiment the present invention provides a method wherein the tagged inhibitor of beta-amyloid production comprises a compound of the Formula (I-11T):



(I-11T)

wherein m is about 2.

25 In an even further more preferred fourth embodiment the present invention provides a method wherein the tagged inhibitor of beta-amyloid production comprises a compound of the Formula (I-43T):



(I-43T)


wherein m is about 2.

5 In fifth embodiment the present invention provides a macromolecule involved in APP processing which a tagged inhibitor of beta-amyloid production binds to specifically.

10 In a preferred fifth embodiment the present invention provides a macromolecule wherein the the tagged inhibitor of beta-amyloid production comprises a radiolabeled inhibitor of beta-amyloid production, a fluorescence labeled inhibitor of beta-amyloid production, a biotin labeled inhibitor of beta-amyloid production, a photoaffinity labeled inhibitor of
15 beta-amyloid production, or any combination of tags thereof in one inhibitor of beta-amyloid production.

In a preferred fifth embodiment the present invention provides a macromolecule wherein the tagged inhibitor of
20 beta-amyloid production comprises a radiolabeled inhibitor of beta-amyloid production.


In a more preferred fifth embodiment the present invention provides a macromolecule wherein the tagged
25 inhibitor of beta-amyloid production comprises a compound of the Formula (I-7T):



(I-7T)

wherein m is about 2.


- 5 In another preferred fifth embodiment the present invention provides a macromolecule wherein the tagged inhibitor of beta-amyloid production comprises a compound of the Formula (I-11T):



(I-11T)

wherein m is about 2.

- 15 In another preferred fifth embodiment the present invention provides a macromolecule wherein the tagged inhibitor of beta-amyloid production comprises a compound of the Formula (I-43T):



(I-43T)

wherein m is about 2.


- 25 In another preferred fifth embodiment the present invention provides a macromolecule involved in APP processing which macromolecule is presenilin 1 or a fragment of presenilin 1.

In another preferred fifth embodiment the present invention provides a macromolecule involved in APP processing which macromolecule is presenilin 2 or a fragment of presenilin 2.


5

In a sixth embodiment the present invention provides an inhibitor of beta-amyloid production comprising a compound which interacts with a binding site on a macromolecule involved in the production of beta-amyloid peptide; wherein said binding site is identified by a compound of Formula (I-7T) or (I-43T):

10



(I-7T)



(I-43T)

15

wherein m is about 2.

In the sixth embodiment the binding site is identified as a specific binding site for a compound of Formula (I-7T) or (I-43T), wherein m is about 2.

20

In a preferred sixth embodiment the macromolecule involved in the production of beta-amyloid peptide is presenilin 1 or a fragment of presenilin 1.

25

In a preferred sixth embodiment the macromolecule involved in the production of beta-amyloid peptide is presenilin 2 or a fragment of presenilin 2.

30

In another preferred sixth embodiment the invention provides an inhibitor of beta-amyloid production comprising a compound which interacts with a binding site on a macromolecule involved in the production of beta-amyloid

peptide; wherein said binding site is a specific binding site for a compound of Formula (I-7T), wherein m is about 2; and the compound demonstrates a half maximal inhibitory concentration less than 10 micromolar for beta-amyloid production.


In a more preferred sixth embodiment the invention provides an inhibitor of beta-amyloid production comprising a compound which interacts with a binding site on presenilin 1 or a fragment of presenilin 1; wherein said binding site is a specific binding site for a compound of Formula (I-7T), wherein m is about 2; and the compound demonstrates a half maximal inhibitory concentration less than 10 micromolar for beta-amyloid production.

In another preferred sixth embodiment the invention provides an inhibitor of beta-amyloid production comprising a compound which interacts with a binding site on a macromolecule involved in the production of beta-amyloid peptide; wherein said binding site is a specific binding site for a compound of Formula (I-43T), wherein m is about 2; and the compound demonstrates a half maximal inhibitory concentration less than 10 micromolar for beta-amyloid production.

In another more preferred sixth embodiment the invention provides an inhibitor of beta-amyloid production comprising a compound which interacts with a binding site on presenilin 1 or a fragment of presenilin 1; wherein said binding site is a specific binding site for a compound of Formula (I-43T), wherein m is about 2; and the compound demonstrates a half maximal inhibitory concentration less than 10 micromolar for beta-amyloid production.

In a seventh embodiment the present invention provides a tagged inhibitor of beta-amyloid production comprising a tagged compound which interacts with a binding site on a macromolecule involved in the production of beta-amyloid

peptide; wherein said binding site is identified by a compound of Formula (I-7T):



(I-7T)

wherein m is about 2;

In the seventh embodiment the binding site is identified as a specific binding site for a compound of Formula (I-7T) or (I-43T), wherein m is about 2.

In a preferred seventh embodiment the macromolecule involved in the production of beta-amyloid peptide is presenilin 1 or a fragment of presenilin 1.

In a preferred seventh embodiment the macromolecule involved in the production of beta-amyloid peptide is presenilin 2 or a fragment of presenilin 2.

In another preferred seventh embodiment the invention provides a tagged inhibitor of beta-amyloid production comprising a tagged compound which interacts with a binding site on a macromolecule involved in the production of beta-amyloid peptide; wherein said binding site is a specific binding site for a compound of Formula (I-7T), wherein m is about 2; and the tagged compound demonstrates a half maximal inhibitory concentration less than 10 micromolar for beta-amyloid production.

In a more preferred seventh embodiment the invention provides a tagged inhibitor of beta-amyloid production comprising a tagged compound which interacts with a binding

site on presenilin 1 or a fragment of presenilin 1; wherein said binding site is a specific binding site for a compound of Formula (I-7T), wherein m is about 2; and the tagged compound demonstrates a half maximal inhibitory concentration less than 10 micromolar for beta-amyloid production.

In another preferred seventh embodiment the invention provides a tagged inhibitor of beta-amyloid production comprising a tagged compound which interacts with a binding site on a macromolecule involved in the production of beta-amyloid peptide; wherein said binding site is a specific binding site for a compound of Formula (I-43T), wherein m is about 2; and the tagged compound demonstrates a half maximal inhibitory concentration less than 10 micromolar for beta-amyloid production.

In another more preferred seventh embodiment the invention provides a tagged inhibitor of beta-amyloid production comprising a tagged compound which interacts with a binding site on presenilin 1 or a fragment of presenilin 1; wherein said binding site is a specific binding site for a compound of Formula (I-43T), wherein m is about 2; and the tagged compound demonstrates a half maximal inhibitory concentration less than 10 micromolar for beta-amyloid production.

In yet another preferred embodiment the present invention provides a tagged inhibitor of beta-amyloid production comprising a compound selected from US 5,703,129; PCT application WO98/28268; PCT application WO98/22441; PCT application WO98/22433; PCT application WO98/22430; PCT application WO98/22493; PCT application WO98/22494; PCT application WO98/38177; or PCT application WO95/09838; wherein the compound has been tagged for purposes of the invention.

In an eighth embodiment the present invention provides a use of a macromolecule or complex of macromolecules involved

in APP processing, which a tagged inhibitor of beta-amyloid production binds to specifically, for the identification or assaying of inhibitors as therapeutics for neurological and other disorders involved in APP processing and beta-amyloid production.

In a preferred eighth embodiment the present invention provides a use of a macromolecule or complex of macromolecules involved in APP processing, which macromolecule or complex of macromolecules is presenilin 1 or a fragment of presenilin 1.

In a more preferred eighth embodiment the present invention provides a method of identifying inhibitors as therapeutics for neurological and other disorders involved in APP processing and beta-amyloid production comprising

(1) contacting at least one macromolecule involved in APP processing and beta-amyloid production, which macromolecule a tagged inhibitor of beta-amyloid production binds to specifically, with a potential inhibitor of beta-amyloid production; and

(2) determining the level of inhibition of APP processing and beta-amyloid production.

In an even more preferred eighth embodiment the present invention provides a method wherein the macromolecule is a complex of macromolecules.

In an even more preferred eighth embodiment the present invention provides a method of wherein the macromolecule is presenilin 1 or a fragment of presenilin 1.

In an even more preferred eighth embodiment the present invention provides a method of wherein the macromolecule is presenilin 2 or a fragment of presenilin 2.

In a ninth embodiment the present invention provides a method of treating Alzheimer's disease comprising

administering to a host in need of such treatment a therapeutically effective amount of an inhibitor of beta-amyloid production, or a pharmaceutically acceptable salt or prodrug form thereof, wherein said inhibitor of beta-amyloid
5 production binds to a binding site on a macromolecule involved in the production of beta-amyloid peptide and effects a decrease in production of beta-amyloid peptide; wherein said binding site is a specific binding site for a compound of Formula (I-7T) or (I-43T) wherein m is about 2.

10 In a preferred ninth embodiment the macromolecule comprises presenilin-1, a fragment of presenilin-1, presenilin-2, or a fragment of presenilin-2.

15 In another preferred ninth embodiment the binding site is a specific binding site for a compound of Formula (I-43T) wherein m is about 2.

20 In a more preferred ninth embodiment the macromolecule comprises presenilin-1 or a fragment of presenilin-1.

In another more preferred ninth embodiment the macromolecule comprises presenilin-2 or a fragment of presenilin-2.

25 DEFINITIONS

As used herein, the term "A β " denotes the protein designated A β , β -amyloid peptide, and sometimes β /A4, in the art. A β is an approximately 4.2 kilodalton (kD) protein of
30 about 39 to 43 amino acids found in amyloid plaques, the walls of meningeal and parenchymal arterioles, small arteries, capillaries, and sometimes, venules. The isolation and sequence data for the first 28 amino acids are described in U.S. Pat. No 4,666,829. The 43 amino acid sequence is:

35
1
Asp Ala Glu Phe Arg His Asp Ser Gly Tyr
11

Glu	Val	His	His	Gln	Lys	Leu	Val	Phe	Phe
21									
Ala	Glu	Asp	Val	Gly	Ser	Asn	Lys	Gly	Ala
31									
Ile	Ile	Gly	Leu	Met	Val	Gly	Gly	Val	Val
41									
Ile	Ala	Thr.							

However, a skilled artisan knows that fragments generated by enzymatic degradation can result in loss of amino acids 1-10 and/or amino acids 39-43. Thus, amino acid sequence 1-43 represents the maximum sequence of amino acids for A β

5 peptide.

The term "APP", as used herein, refers to the protein known in the art as β amyloid precursor protein. This protein is the precursor for A β and through the activity of "secretase" enzymes, as used herein, it is processed into A β .

10 Differing secretase enzymes, known in the art, have been designated β secretase, generating the N-terminus of A β , α secretase cleaving around the 16/17 peptide bond in A β , and "gamma secretases", as used herein, generating C-terminal A β fragments ending at position 38, 39, 40, 41, 42, and 43 or
15 generating C-terminal extended precursors which are subsequently truncated to the above polypeptides.

The compounds herein described may have asymmetric centers. Compounds of the present invention containing an asymmetrically substituted atom may be isolated in optically
20 active or racemic forms. It is well known in the art how to prepare optically active forms, such as by resolution of racemic forms or by synthesis from optically active starting materials. Many geometric isomers of olefins, C=N double bonds, and the like can also be present in the compounds
25 described herein, and all such stable isomers are contemplated in the present invention. Cis and trans geometric isomers of the compounds of the present invention are described and may be isolated as a mixture of isomers or as separated isomeric forms. All chiral, diastereomeric,
30 racemic forms and all geometric isomeric forms of a structure

are intended, unless the specific stereochemistry or isomeric form is specifically indicated.

The term "substituted," as used herein, means that any one or more hydrogens on the designated atom is replaced with a selection from the indicated group, provided that the designated atom's normal valency is not exceeded, and that the substitution results in a stable compound. When a substituent is keto (i.e., =O), then 2 hydrogens on the atom are replaced.

When any variable (e.g., R^{5b}) occurs more than one time in any constituent or formula for a compound, its definition at each occurrence is independent of its definition at every other occurrence. Thus, for example, if a group is shown to be substituted with 0-2 R^{5b} , then said group may optionally be substituted with up to two R^{5b} groups and R^{5b} at each occurrence is selected independently from the definition of R^{5b} . Also, combinations of substituents and/or variables are permissible only if such combinations result in stable compounds.

When a bond to a substituent is shown to cross a bond connecting two atoms in a ring, then such substituent may be bonded to any atom on the ring. When a substituent is listed without indicating the atom via which such substituent is bonded to the rest of the compound of a given formula, then such substituent may be bonded via any atom in such substituent. Combinations of substituents and/or variables are permissible only if such combinations result in stable compounds.

As used herein, "alkyl" or "alkylene" is intended to include both branched and straight-chain saturated aliphatic hydrocarbon groups having the specified number of carbon atoms; for example, "C₁-C₆ alkyl" denotes alkyl having 1 to 6 carbon atoms. Examples of alkyl include, but are not limited to, methyl, ethyl, n-propyl, i-propyl, n-butyl, i-butyl, sec-butyl, t-butyl, pentyl, and hexyl. Preferred "alkyl" group, unless otherwise specified, is "C₁-C₄ alkyl".

As used herein, "alkenyl" or "alkenylene" is intended to include hydrocarbon chains of either a straight or branched

configuration and one or more unsaturated carbon-carbon bonds which may occur in any stable point along the chain.

Examples of "C₂-C₆ alkenyl" include, but are not limited to,

ethenyl, 1-propenyl, 2-propenyl, 1-butenyl, 2-butenyl, 3-

5 butenyl, 3-methyl-2-butenyl, 2-pentenyl, 3-pentenyl, hexenyl, and the like.

As used herein, "alkynyl" or "alkynylene" is intended to include hydrocarbon chains of either a straight or branched configuration and one or more carbon-carbon triple bonds

10 which may occur in any stable point along the chain, such as ethynyl, 1-propynyl, 2-propynyl, 1-butyne, 2-butyne, 3-butyne, and the like.

"Alkoxy" or "alkyloxy" represents an alkyl group as defined above with the indicated number of carbon atoms

15 attached through an oxygen bridge. Examples of alkoxy include, but are not limited to, methoxy, ethoxy, n-propoxy, i-propoxy, n-butoxy, s-butoxy, t-butoxy, n-pentoxo, and s-pentoxo. Preferred alkoxy groups are methoxy, ethoxy, n-propoxy, i-propoxy, n-butoxy, s-butoxy, t-butoxy.

20 Similarly, "alkylthio" or "thioalkoxy" is represents an alkyl group as defined above with the indicated number of carbon atoms attached through a sulphur bridge.

"Halo" or "halogen" as used herein refers to fluoro, chloro, bromo, and iodo. Unless otherwise specified,

25 preferred halo is fluoro and chloro. "Counterion" is used to represent a small, negatively charged species such as chloride, bromide, hydroxide, acetate, sulfate, and the like.

"Haloalkyl" is intended to include both branched and straight-chain saturated aliphatic hydrocarbon groups having the specified number of carbon atoms, substituted with 1 or

30 more halogen (for example -C_vF_w where v = 1 to 3 and w = 1 to (2v+1)). Examples of haloalkyl include, but are not limited to, trifluoromethyl, trichloromethyl, pentafluoroethyl, pentachloroethyl, 2,2,2-trifluoroethyl, 2,2-difluoroethyl,

35 heptafluoropropyl, and heptachloropropyl. "Haloalkoxy" is intended to mean a haloalkyl group as defined above with the indicated number of carbon atoms attached through an oxygen bridge; for example trifluoromethoxy, pentafluoroethoxy,

2,2,2-trifluoroethoxy, and the like. "Halothioalkoxy" is intended to mean a haloalkyl group as defined above with the indicated number of carbon atoms attached through a sulphur bridge.

5 "Cycloalkyl" is intended to include saturated ring groups, having the specified number of carbon atoms. For example, "C₃-C₆ cycloalkyl" denotes such as cyclopropyl, cyclobutyl, cyclopentyl, or cyclohexyl.

As used herein, "carbocycle" is intended to mean any
10 stable 3- to 7-membered monocyclic or bicyclic or 7- to 13-membered bicyclic or tricyclic, any of which may be saturated, partially unsaturated, or aromatic. Examples of such carbocycles include, but are not limited to, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl,
15 cycloheptyl, adamantyl, cyclooctyl, [3.3.0]bicyclooctane, [4.3.0]bicyclononane, [4.4.0]bicyclodecane (decalin), [2.2.2]bicyclooctane, fluorenyl, phenyl, naphthyl, indanyl, adamantyl, or tetrahydronaphthyl (tetralin). Preferred "carbocycle" are cyclopropyl, cyclobutyl, cyclopentyl, and
20 cyclohexyl.

As used herein, the term "heterocycle" or "heterocyclic ring" is intended to mean a stable 5- to 7- membered monocyclic or bicyclic or 7- to 14-membered bicyclic heterocyclic ring which is saturated partially unsaturated or
25 unsaturated (aromatic), and which consists of carbon atoms and 1, 2, 3 or 4 heteroatoms, preferably 1, 2, or 3 heteroatoms, independently selected from the group consisting of N, O and S and including any bicyclic group in which any of the above-defined heterocyclic rings is fused to a benzene
30 ring. The nitrogen and sulfur heteroatoms may optionally be oxidized. The heterocyclic ring may be attached to its pendant group at any heteroatom or carbon atom which results in a stable structure. The heterocyclic rings described herein may be substituted on carbon or on a nitrogen atom if
35 the resulting compound is stable. If specifically noted, a nitrogen in the heterocycle may optionally be quaternized. It is preferred that when the total number of S and O atoms in the heterocycle exceeds 1, then these heteroatoms are not


adjacent to one another. It is preferred that the total number of S and O atoms in the heterocycle is not more than 1.

Examples of heterocycles include, but are not limited to, 1H-indazole, 2-pyrrolidonyl, 2H,6H-1,5,2-dithiazinyl, 2H-pyrrolyl, 3H-indolyl, 4-piperidonyl, 4aH-carbazole, 4H-quinolizinyl, 6H-1,2,5-thiadiazinyl, acridinyl, azocinyl, benzimidazolyl, benzofuranyl, benzothiofuranyl, benzothiophenyl, benzoxazolyl, benzthiazolyl, benztriazolyl, benztetrazolyl, benzisoxazolyl, benzisothiazolyl, benzimidazalonyl, carbazolyl, 4aH-carbazolyl, b-carbolinyl, chromanyl, chromenyl, cinnolinyl, decahydroquinolinyl, 2H,6H-1,5,2-dithiazinyl, dihydrofuro[2,3-b]tetrahydrofuran, furanyl, furazanyl, imidazolidinyl, imidazolinyl, imidazolyl, 1H-indazolyl, indolenyl, indolinyl, indolizinyl, indolyl, isobenzofuranyl, isochromanyl, isoindazolyl, isoindolinyl, isoindolyl, isoquinolinyl, isothiazolyl, isoxazolyl, morpholinyl, naphthyridinyl, octahydroisoquinolinyl, oxadiazolyl, 1,2,3-oxadiazolyl, 1,2,4-oxadiazolyl, 1,2,5-oxadiazolyl, 1,3,4-oxadiazolyl, oxazolidinyl, oxazolyl, oxazolidinylperimidinyl, phenanthridinyl, phenanthrolinyl, phenarsazinyl, phenazinyl, phenothiazinyl, phenoxathiinyl, phenoxazinyl, phthalazinyl, piperazinyl, piperidinyl, pteridinyl, piperidonyl, 4-piperidonyl, pteridinyl, purinyl, pyranyl, pyrazinyl, pyrazolidinyl, pyrazolinyl, pyrazolyl, pyridazinyl, pyridoazole, pyridoimidazole, pyridothiazole, pyridinyl, pyridyl, pyrimidinyl, pyrrolidinyl, pyrrolinyl, pyrrolyl, quinazolinyl, quinolinyl, 4H-quinolizinyl, quinoxalinyl, quinuclidinyl, carbolinyl, tetrahydrofuranyl, tetrahydroisoquinolinyl, tetrahydroquinolinyl, 6H-1,2,5-thiadiazinyl, 1,2,3-thiadiazolyl, 1,2,4-thiadiazolyl, 1,2,5-thiadiazolyl, 1,3,4-thiadiazolyl, thianthrenyl, thiazolyl, thienyl, thienothiazolyl, thienooxazolyl, thienoimidazolyl, thiophenyl, triazinyl, 1,2,3-triazolyl, 1,2,4-triazolyl, 1,2,5-triazolyl, 1,3,4-triazolyl, xanthenyl. Preferred 5 to 10 membered heterocycles include, but are not limited to, pyridinyl, pyrimidinyl, triazinyl, furanyl, thienyl, thiazolyl,

pyrrolyl, pyrazolyl, imidazolyl, oxazolyl, isoxazolyl, tetrazolyl, benzofuranyl, benzothiofuranyl, indolyl, benzimidazolyl, 1H-indazolyl, oxazolidinyl, isoxazolidinyl, benzotriazolyl, benzisoxazolyl, oxindolyl, benzoxazoliny, quinolinyl, and isoquinolinyl. Preferred 5 to 6 membered heterocycles include, but are not limited to, pyridinyl, pyrimidinyl, triazinyl, furanyl, thienyl, thiazolyl, pyrrolyl, piperazinyl, piperidinyl, pyrazolyl, imidazolyl, oxazolyl, isoxazolyl, tetrazolyl; more preferred 5 to 6 membered heterocycles include, but are not limited to, pyridinyl, pyrimidinyl, triazinyl, furanyl, thienyl, thiazolyl, piperazinyl, piperidinyl, pyrazolyl, imidazolyl, and tetrazolyl. Also included are fused ring and spiro compounds containing, for example, the above heterocycles.

As used herein, the term "aryl", "C₆-C₁₀ aryl" or aromatic residue, is intended to mean an aromatic moiety containing the specified number of carbon atoms; for example phenyl, pyridinyl or naphthyl. Unless otherwise specified, "aryl" may be unsubstituted or substituted with 0 to 3 groups selected from H, -OH, -OCH₃, Cl, F, Br, I, CN, -NO₂, -NH₂, -N(CH₃)H, -N(CH₃)₂, -CF₃, -OCF₃, -C(=O)CH₃, -SCH₃, -S(=O)CH₃, -S(=O)₂CH₃, -CH₃, -CH₂CH₃, -CO₂H, and -CO₂CH₃.


The phrase "additional lactam carbons", as used herein, is intended to denote the number of optional carbon atoms in the lactam ring B of Formula (I). Formula (I"):




represents the lactam ring B of Formula (I). Additional lactam carbons are carbons in lactam ring B other than the carbons numbered 2 and 3 in the backbone of the formula. The additional lactam carbons may be optionally replaced by a heteroatom selected from oxygen, nitrogen and sulfur. Lactam ring B contains 1, 2, 3, 4, 5, 6 or 7 optional carbons, wherein one optional carbon may optionally be replaced by a heteroatom, such that the total number of members of lactam

ring B, including atoms numbered 1, 2 and 3 in the backbone, does not exceed 10. It is preferred that the total number of atoms of lactam ring B is 6, 7 or 8; it is more preferred that the total number of atoms of lactam ring B is seven.


5 Examples of lactam ring B include:




B1




B2




B3




B4




B5




B6




B7




B8




B9




B10




B11




B12




B13



B14



B15



B16

5

but are not intended to limit the invention. Preferred examples of lactam ring B are B1, B2, B5, B6, B8, B9, B13, and B16; more preferred examples of lactam ring B are B1, B6, B8, B9, and B13. Even more preferred examples of lactam ring B are B1 and B6. Preferred examples of substituent R¹⁰ or R¹¹ on lactam B are methyl, ethyl, phenyl, 4-fluorophenyl, 4-chlorophenyl, 4-trifluorophenyl, (4-fluorophenyl)methyl, (4-chlorophenyl)methyl, and (4-trifluorophenyl)methyl.

As used herein, "macromolecule" or "complex of macromolecules", is intended to mean a cellular component involved directly or indirectly in APP processing and the production of A β peptide. By indirectly, its effect on APP processing may be mediated by intervening molecules. An example of a "macromolecule" or "complex of macromolecules" is presenilin 1 or endogenous cleavage N terminal or C terminal fragments of presenilin 1. Additional examples of a "macromolecule" or "complex of macromolecules" is presenilin 2, a homolog of presenilin 1 or a homolog of presenilin 2.

It is envisaged that the scope of "macromolecule" or "complex of macromolecules" involved in APP processing can be found in a wide variety of sources. Sources of a "macromolecule" or "complex of macromolecules" are considered to be materials suspected or known to contain a macromolecule

involved in APP processing. Examples of a material suspected or known to contain a macromolecule involved in APP processing include, but are not limited to, purified proteins; suspensions of proteins; cells, tissues or organs, derived from prokaryotes or eucaryotes; and macromolecules derived from recombinant expression systems. Examples of cells include, but are not limited to, HEK293 cells, IMR 32 cells, RAJI cells, CHO cells, U-937 cells, and THP-1 cells; preferably HEK293 or TNP-1 cells. Examples of tissues or organs include, but are not limited to, spleen, brain, and testes. Examples of prokaryotes include, but are not limited to, bacteria, more preferably *E. coli*. Examples of eucaryotes include, but are not limited to, mouse, rat, guinea pig, bovine, porcine, monkey, human, and nematodes (preferably *C. elegans*). An example of a suspension of protein includes, but is not limited to, lipid systems. An example of a macromolecule derived from recombinant expression systems includes, but is not limited to, *C. elegans* knockout of Sel-12 and reintroduction of PS-1. (See Levitan, D. and Greenwald, I., *Nature*, 377, pp351-354, 1995.)

It is understood that one skilled in the art can readily determine the scope of the term "binding site" and "specific binding site" as used herein. For further guidance, the tagged compounds of the present invention, for example (I-7T), (I-11T), and (I-43T), bind to a specific site on one or more macromolecules involved directly or indirectly in APP processing and the production of A β peptide, and thus effect a decrease in the production of A β peptide. One skilled in the art can readily determine whether other compounds, which are inhibitors of beta-amyloid production, bind to a same site as the tagged compounds of the present invention by using the assays disclosed herein. However, it is understood that within the scope of the present disclosure the phrase "is identified by a compound of Formula (I-#)" or "is a specific binding site for a compound of Formula (I-#)" refers to defining the physical site on the macromolecule wherein a compound of Formula (I-#) binds to and not to a molecular reaction of binding. Thus, the phrase "a specific binding

site for a compound of Formula (I-#)" does not require the compound of Formula (I-#) to be present.

As used herein, "potential inhibitor of beta-amyloid production" is intended to mean any compound which is being
5 screened for activity to inhibit the production of beta-amyloid peptide, or the proteolytic activity leading to the production of beta-amyloid peptide, using the assay of the invention described herein. It is understood that a
"potential inhibitor of beta-amyloid production", which is
10 active in the assay of the invention for inhibiting the production of beta-amyloid peptide, can subsequently be used in the assay of the invention as a "beta-amyloid peptide inhibitor", as defined below, once the compound has been tagged. It is also understood that a "potential inhibitor of
15 beta-amyloid production", which is active in the assay of the invention for inhibiting the production of beta-amyloid peptide, can subsequently be used in pharmaceutical compositions for the treatment of degenerative neurological disorders involving beta-amyloid production, preferably for
20 the treatment of Alzheimer's disease.

As used herein, "beta-amyloid peptide inhibitor" or "inhibitor of beta-amyloid production" is intended to mean any compound which inhibits the production of beta-amyloid peptide, or the proteolytic activity leading to the
25 production of beta-amyloid peptide. Examples of a beta-amyloid peptide inhibitor include, but are not limited to, the scope of compounds of Formula (I), examples of which are disclosed herein. However, it is contemplated for use in the invention that compounds beyond the scope of compounds of
30 Formula (I) may be used in the invention. Additional examples of a beta-amyloid peptide inhibitor, contemplated by the invention, include, but are not limited to, 5-amino-6-cyclohexyl-4-hydroxy-hexanamide derivatives disclosed in United States patent US 5,703,129, issued Dec. 30, 1997; N-
35 aryl amino acid esters and N-heteroaryl amino acid esters disclosed in PCT application WO98/22441 (published May 28, 1998; priority USSN 08/755,444); N-arylacetyl amino acid amides, N-heteroarylacetyl amino acid amides, and N-

alkylacetyl amino acid amides disclosed in PCT application WO98/22433 (published May 28, 1998; priority USSN 08/807,538); N-arylacetyl amino acid esters, N-heteroarylacetyl amino acid esters, and N-alkylacetyl amino acid esters disclosed in PCT application WO98/22430 (published May 28, 1998; priority USSN 08/754,895); N-aryl amino acid derivatives and N-heteroaryl amino acid derivatives disclosed in PCT application WO98/22493 (published May 28, 1998; priority USSN 08/755,334); amino acid derivatives disclosed in PCT application WO98/22494 (published May 28, 1998; priority USSN 08/808,528, 08/807,528, 08/807,427); cycloalkyl, lactam, lactone and related compounds disclosed in PCT application WO98/28268 (published July 2, 1998, priority USSN 08/780,025); all references of which are hereby incorporated by reference in their entirety.

As used herein, "tagged inhibitor of beta-amyloid production", is intended to mean "beta-amyloid peptide inhibitor" compounds which are tagged. By "tagged" or "tagged inhibitor of beta-amyloid production" or "tagged compound", it is meant that the subject beta-amyloid peptide inhibitor compounds contain a tag which is suitable for detection in an assay system or upon administration to a mammal. Suitable tags are known to those skilled in the art and include, for example, radioisotopes, fluorescent groups, biotin (in conjunction with streptavidin complexation), and photoaffinity groups. Suitable radioisotopes are known to those skilled in the art and include, for example, isotopes of halogens (such as chlorine, fluorine, bromine and iodine), and metals including technetium and indium. Preferred radioisotopes include ^3H , ^{11}C , ^{14}C , ^{18}F , ^{32}P , ^{35}S , ^{123}I , ^{125}I , ^{131}I . Most preferred is ^3H . Radiolabeled compounds of the invention may be prepared using standard radiolabeling procedures well known to those skilled in the art. Suitable synthesis methodology is described in detail below. As discussed below, the beta-amyloid peptide inhibitor compounds of the invention may be radiolabeled either directly (that is, by incorporating the radiolabel directly into the

compounds) or indirectly (that is, by incorporating the radiolabel into the compounds through a chelating agent, where the chelating agent has been incorporated into the compounds). Also, the radiolabeling may be isotopic or nonisotopic. With isotopic radiolabeling, one group already present in the compounds of the invention described above is substituted with (exchanged for) the radioisotope. With nonisotopic radiolabeling, the radioisotope is added to the compounds without substituting with (exchanging for) an already existing group. Direct and indirect radiolabeled compounds, as well as isotopic and nonisotopic radiolabeled compounds are included within the phrase "radiolabeled compounds" as used in connection with the present invention. Such radiolabeling should also be reasonably stable, both chemically and metabolically, applying recognized standards in the art. Also, although the compounds of the invention may be labeled in a variety of fashions with a variety of different radioisotopes, as those skilled in the art will recognize, such radiolabeling should be carried out in a manner such that the high binding affinity and specificity of the unlabeled or untagged inhibitor of beta-amyloid production compounds of the invention to the macromolecule involved in APP processing is not significantly affected. By not significantly affected, it is meant that the binding affinity and specificity is not affected more than about 3 log units, preferably not more than about 2 log units, more preferably not more than about 1 log unit, even more preferably not more than about 500%, and still even more preferably not more than about 250%, and most preferably the binding affinity and specificity is not affected at all.

Examples of a tagged inhibitor of beta-amyloid production include, but are not limited to, the scope of compounds of Formula (I), examples of which are disclosed herein. However, it is contemplated that tagged compounds beyond the scope of compounds of Formula (I) may be used in the invention. Additional examples of a tagged inhibitor of beta-amyloid production, contemplated by the invention, include, but are not limited to, beta-amyloid peptide

inhibitors disclosed in US 5,703,129, issued Dec. 30, 1997; WO98/22441 (published May 28, 1998); WO98/22433 (published May 28, 1998); WO98/22430 (published May 28, 1998); WO98/22493 (published May 28, 1998); WO98/22494 (published May 28, 1998); and WO98/28268 (published July 2, 1998), which inhibitors can be tagged for use in the invention. Preferred examples of a tagged inhibitor of beta-amyloid production are compounds of Formula (I) and compounds of WO98/28268 (published July 2, 1998) which can be tagged. More preferred are compounds of Formula (I).

For radiolabeled compounds, the label may appear at any position on the beta-amyloid peptide inhibitor. Preferred radiolabeled compounds of the invention are beta-amyloid peptide inhibitor radiolabeled with tritium. More preferred radiolabeled compounds of the invention are radiolabeled compounds wherein the radiolabel is located on R³ of Formula (I).

As used herein, when the tagged inhibitor of beta-amyloid production is tagged with a photoaffinity group or photoaffinity labeled, the term "photoaffinity group" or "photoaffinity labeled" refers to a substituent on the inhibitor which can be activated by photolysis at an appropriate wavelength to undergo a crosslinking photochemical reaction with the macromolecule to which it is associated. An example of a "photoaffinity group" is a benzophenone substituent.

In the present invention it has also been discovered that the radiolabeled compounds above are useful as inhibitors of beta-amyloid peptide production and thus the radiolabeled compounds of the invention may also be employed for therapeutic purposes, in addition to the diagnostic usage described above.

As used herein, "inhibitory concentration" is intended to mean the concentration at which the "potential inhibitor of beta-amyloid production" compound screened in the assay of the invention inhibits a measurable percentage of beta-amyloid peptide production. Examples of "inhibitory concentration" values range from IC₅₀ to IC₉₀, and are

preferably, IC₅₀, IC₆₀, IC₇₀, IC₈₀, or IC₉₀, which represent 50%, 60%, 70%, 80% and 90% reduction in beta-amyloid peptide production, respectively. More preferably, the "inhibitory concentration" is measured as the IC₅₀ value. It is

5 understood that an designation for IC₅₀ is the half maximal inhibitory concentration.

The phrase "pharmaceutically acceptable" is employed herein to refer to those compounds, materials, compositions, and/or dosage forms which are, within the scope of sound
10 medical judgment, suitable for use in contact with the tissues of human beings and animals without excessive toxicity, irritation, allergic response, or other problem or complication, commensurate with a reasonable benefit/risk ratio.

15 As used herein, "pharmaceutically acceptable salts" refer to derivatives of the disclosed compounds wherein the parent compound is modified by making acid or base salts thereof. Examples of pharmaceutically acceptable salts include, but are not limited to, mineral or organic acid
20 salts of basic residues such as amines; alkali or organic salts of acidic residues such as carboxylic acids; and the like. The pharmaceutically acceptable salts include the conventional non-toxic salts or the quaternary ammonium salts of the parent compound formed, for example, from non-toxic
25 inorganic or organic acids. For example, such conventional non-toxic salts include those derived from inorganic acids such as hydrochloric, hydrobromic, sulfuric, sulfamic, phosphoric, nitric and the like; and the salts prepared from organic acids such as acetic, propionic, succinic, glycolic, stearic, lactic, malic, tartaric, citric, ascorbic, pantoic,
30 maleic, hydroxymaleic, phenylacetic, glutamic, benzoic, salicylic, sulfanilic, 2-acetoxybenzoic, fumaric, benzenesulfonic, toluenesulfonic, methanesulfonic, ethane disulfonic, oxalic, isethionic, and the like.

35 The pharmaceutically acceptable salts of the present invention can be synthesized from the parent compound which contains a basic or acidic moiety by conventional chemical methods. Generally, such salts can be prepared by reacting

the free acid or base forms of these compounds with a stoichiometric amount of the appropriate base or acid in water or in an organic solvent, or in a mixture of the two; generally, nonaqueous media like ether, ethyl acetate, ethanol, isopropanol, or acetonitrile are preferred. Lists of suitable salts are found in *Remington's Pharmaceutical Sciences*, 17th ed., Mack Publishing Company, Easton, PA, 1985, p. 1418, the disclosure of which is hereby incorporated by reference.

"Stable compound" and "stable structure" are meant to indicate a compound that is sufficiently robust to survive isolation to a useful degree of purity from a reaction mixture, and formulation into an efficacious therapeutic agent.

SYNTHESIS

The compounds of the present invention can be prepared in a number of ways well known to one skilled in the art of organic synthesis. The compounds of the present invention can be synthesized using the methods described below, together with synthetic methods known in the art of synthetic organic chemistry, or variations thereon as appreciated by those skilled in the art. Preferred methods include, but are not limited to, those described below. All references cited herein are hereby incorporated in their entirety herein by reference.


The novel compounds of this invention may be prepared using the reactions and techniques described in this section. The reactions are performed in solvents appropriate to the reagents and materials employed and are suitable for the transformations being effected. Also, in the description of the synthetic methods described below, it is to be understood that all proposed reaction conditions, including choice of solvent, reaction atmosphere, reaction temperature, duration of the experiment and workup procedures, are chosen to be the conditions standard for that reaction, which should be readily recognized by one skilled in the art. It is understood by one skilled in the art of organic synthesis

that the functionality present on various portions of the molecule must be compatible with the reagents and reactions proposed. Such restrictions to the substituents which are compatible with the reaction conditions will be readily apparent to one skilled in the art and alternate methods must then be used.

Methods for the synthesis of succinylamino lactams are known in the art and are disclosed in a number of references including PCT publication number WO 96/29313, which is hereby incorporated by reference.

Disubstituted succinate derivatives can be prepared by a number of known procedures. The procedure of Evans (D. A. Evans et al, *Org. Synth.* **86**, p83 (1990)) is outlined in Scheme 1 where acylation of an oxazolidinone with an acylating agent such as an acid chloride provides structures **1**. Alkylation to form **2** followed by cleavage of the chiral auxiliary and subsequent alkylation of the dianion of the carboxylic acid **3** provides a variety of disubstituted succinates which can be separated and incorporated into structures of Formula (I) by those skilled in the art. Additional examples are found in P. Becket, M. J. Crimmin, M. H. Davis, Z. Spavold, Synlett, (1993), 137-138, incorporated herein by reference.


Scheme 1



Diastereomerically pure succinate derivatives can be accessed using the chemistry outlined below, adapted from P. Becket, M. J. Crimmin, M. H. Davis, Z. Spavold, Synlett, (1993), 137-138 incorporated herein by reference. This reference provides the synthesis below to obtain compound **9**. Compound **11** is used as an intermediate and is prepared from **9** by hydrogenation of the allyl group followed by coupling of 9-fluorenmethanol under standard conditions using DCC and DMAP in CH₂Cl₂. Deprotection of the *tert*-butyl ester is accomplished by treatment with 50% trifluoroacetic acid.

Additional methods useful for the preparation of succinate derivatives are known by those skilled in the art. Such references include, McClure and Axt, Bioorganic & Medicinal Chemistry Letters, **8** (1998) 143-146; Jacobson and Reddy, Tetrahedron Letters, Vol 37, No. 46, 8263-8266 (1996); Pratt et al., SYNLETT, May 1998, p. 531.


Scheme 2



A variety of compounds of Formula (I) can be prepared by methods described in Scheme 4. The protected α -amine **3** of

the α -amino- ϵ -caprolactam can be prepared by methods well known in the literature for amino protecting groups as discussed in Theodora W. Greene's book "Protective Groups in Organic Synthesis", such as *N*-Boc using di-*t*-butyldicarbonate in an appropriate solvent like DMSO. A sulfur atom can be introduced into the ring providing L- α -amino- β -thio- ϵ -caprolactam according to the procedure in S. A. Ahmed et al, FEBS Letters, (1984), vol. 174, pages 76-9 (Scheme 3). One skilled in the art can extend this methodology to the synthesis of β -amino and oxygen containing rings by analogy. The sulfur-containing molecules can also be oxidized to the sulfoxide and sulfone by methods known to one skilled in the art.


Scheme 3



The lactam nitrogen of compound **13** can be alkylated by generating the anion with bases such as LDA, lithium bis(trimethylsilyl)amide or sodium hydride in solvents like THF, with or without cosolvents such as DMPU or HMPA and reacting this with a variety of groups containing leaving groups (X") like bromide, iodide, mesylate or tosylate. Alkylating agents such as α -bromo amides, ketones and acids can be prepared by a number of literature methods including halogenation of amino acids by diazotization or are commercially available. Other suitable alkylating agents such as alkyl, allylic and benzylic halides can be formed from a variety of precursors such as free-radical addition of halides or activation of alcohols, and other chemistries known to those skilled in the art. For discussion of these types of reactions, see Carey, F.A. and Sundberg, R. J., Advanced Organic Chemistry, Part A, New York: Plenum Press, 1990, pages 304-305, 342-347, 695-698.

The *N*-Boc protecting group can be removed by any number of methods well known in the literature like TFA in methylene chloride to give the compound **15**. The amine **15** can be coupled to an appropriately substituted carboxylic acid or acid chloride by methods well described in the literature for making amide bonds, like TBTU in DMF with a base like NMM to give the elaborated compound **16**. Compounds **16** can be alkylated using standard bases like LDA, NaH, or NaHMDS to deprotonate the amide followed by addition of an alkylating agent with an appropriate leaving group like halide, mesylate, or triflate in an appropriate solvent to provide compounds **17** with an R^6 substituent. The *t*-butyl ester is then removed by treatment with TFA in methylene chloride to give the carboxylic acid **17**.

Scheme 4




The final compounds **18** were prepared by treating the activated carboxylic acid of **17** with an appropriately substituted amine. For instance, activation of the carboxylic acid with HATU (*O*-(7-azabenzotriazol-1-yl)-1,1,3,3,-tetramethyluronium hexafluorophosphate) or PyBOP

(benzotriazole-1-yl-oxy-tris-pyrrolidino-phosphonium hexafluorophosphate) or other coupling agents known to those skilled in the art allows condensation with ammonia to form primary amides. Similarly, condensation of the activated
5 acid with hydroxylamine hydrochloride provides the hydroxamic acid, or reaction with a primary or secondary amine provides the substituted amine derivative. Activation of the acid with PyBrOP (bromo-tris-pyrrolidino-phosphonium hexafluorophosphate) followed by addition of an alcohol and
10 4-dimethylaminopyridine allows formation of the ester directly. For additional acylation reactions see for example Carey, F.A. and Sundberg, R. J., Advanced Organic Chemistry, Part A, New York: Plenum Press, 1990, pages 475-479.

Additional Examples of compounds of Formula (I) can be
15 prepared as shown in Scheme 5. A suitable resin for solid phase synthesis such as Fmoc (Fluorenylmethylcarbonyl)-protected hydroxylamine bound to polystyrene beads can be purchased from Novabiochem, Inc. Deprotection of the Fmoc group under standard conditions using 20% piperidine in DMF
20 provides trityl-linked hydroxylamine resin. Coupling of a fluorenylmethyl-protected succinic acid derivative such as 20 with a coupling agent such as HATU in a suitable solvent like DMF or N-methylpyrrolidinone provides the support-bound hydroxamate 21. The Fluorenylmethyl ester can be removed
25 using 20% piperidine in DMF to provide the free carboxylic acid which can be coupled to amines like the caprolactam 22 (which is available using chemistry outlined in Scheme 4) using PyBOP (benzotriazole-1-yl-oxy-tris-pyrrolidino-phosphonium hexafluorophosphate) and a suitable base like
30 DIEA in DMF or NMP. The support-bound intermediate 23 can then be elaborated to biaryl structures of the type 24 using typical Suzuki coupling conditions employing a catalyst such as Palladium complexes like tetrakis(triphenylphosphine)-palladium with 2M aqueous sodium carbonate as a base in a
35 suitable solvent like THF or DME and an excess of a boronic acid. The final compounds are liberated from the support employing dilute (5%) trifluoroacetic acid in CH₂Cl₂ and purified by conventional chromatography.

Scheme 5



5

General procedure for solid-phase synthesis according to Scheme 5.

Resin 20 of Scheme 5: Fmoc-protected resin **19** (2.0 g, 0.78 mmol/g, 1.56 mmol) is purchased from Novabiochem and swelled in 20 mL of CH₂Cl₂ for 1 hour. The CH₂Cl₂ is removed and the resin is then treated with 25% v/v piperidine in DMF (8 mL) and allowed to shake slowly for 16 h. The solvent was removed by filtration and the resin was shaken with an additional 8 mL of 25% v/v piperidine in DMF for 2 h at rt. The solvents were removed by filtration, and the resin **20** was rinsed 3 x with 20 mL of DMF, 3 x with 20 mL of methanol, and 3 x with 20 mL of CH₂Cl₂ and dried in vacuo.

Succinate 10 of Scheme 2: Succinate **9** is prepared according to the literature procedure (P. Becket, M. J.

Crimmin, M. H. Davis, Z. Spavold, Synlett, (1993), 137-138). Succinate **9** (17.8 g, 66 mmol) is dissolved in 250 mL of ethyl acetate and placed in a Parr shaker bottle. To the solution is added 890 mg of 5% palladium on carbon, and the bottle is pressurized to 40 psi with hydrogen gas and shaken for 2.5 h at rt. The hydrogen is removed and the palladium catalyst is removed by filtration through a pad of celite. Concentration of the ethyl acetate solution provides 17.5 g (98%) of succinate **10**. No further purification is necessary. MS (M-H)⁺ = 271.

Succinate 21 of Scheme 5: Succinate **10** (6.3 g, 23.1 mmol) is dissolved in 125 mL of CH₂Cl₂ and 4.8 g (23.3 mmol) of dicyclohexylcarbodiimide is added. The solution is stirred at rt for 30 min and then 4.6 g (23.4 mmol) of 9-fluorenmethanol is added followed by 122 mg (1 mmol) of 4-dimethylaminopyridine. After 5 h of stirring at rt, the reaction solution was diluted with an additional 100 mL of CH₂Cl₂ and filtered through a pad of celite to remove precipitated dicyclohexylurea. The solution was then washed 3 x with 50 mL of a 1N HCl solution, 3 x with 50 mL of a saturated sodium bicarbonate solution, and 2 x with 50 mL of brine. The crude product was dried over MgSO₄ and concentrated onto 15 g of silica gel. Chromatography eluting with a gradient of 2.5% to 5% ethyl acetate/hexanes provided 6.4 g (61%) of the diester as an oil. The purified diester (6.4 g 14.2 mmol) is then dissolved in 25 mL of CH₂Cl₂, 25 mL of trifluoroacetic acid is added, and the reaction solution is stirred at rt for 2 h. The reaction solution is directly concentrated *in vacuo* to an oil which is then redissolved in 25 mL of toluene and reconcentrated, followed by drying *in vacuo* to provide 6.3 g (98%) of the desired succinate **9** as an oil which solidifies on standing. MS (M+Na)⁺ = 471, (M+2Na)⁺ = 439.

Caprolactam 23 of Scheme 5: Boc-caprolactam **14** (5.0 g, 21.9 mmol) is dissolved in 60 mL of THF and chilled to -78°C. To the chilled solution is added 24 mL of a 1.0 M solution of lithium bis(trimethylsilyl)amide in THF, and the solution was brought to 0°C and stirred for 15 min. To the

anion solution was added 6.5 g (22 mmol) of 3-iodobenzyl bromide (Aldrich) and the the solution was allowed to warm to rt and stirred for 18 h. The reaction solution was diluted with 50 mL of water and extracted 3x with ethyl acetate. The combined organic layers were dried over MgSO₄ and concentrated *in vacuo*. The crude product was purified by chromatography eluting with a gradient of 5-20% ethyl acetate/hexanes to afford 7.0 g (72%) of the title compound as a white solid. MS (M+Na)⁺ = 467.

Resin 22 of Scheme 5: Resin 22 (2.0 g, 0.78 mmol/g, 1.56 mmol) was swollen in 3 mL of DMF. In a separate flask, 1.85 g (4.68 mmol) of succinate 21 was dissolved in 3 mL of DMF and 2.5 mL of *N,N*-diisopropylethylamine (14 mmol) was added, followed by 1.81 g (4.68 mmol) of HATU. The solution containing the active ester was added to the slurried resin and the reaction suspension was slowly shaken for 18 h. The resin was then washed 3 x with 20 mL of DMF, 3 x with 20 mL of methanol, and 3 x with 20 mL of CH₂Cl₂. Loading of the resin was determined by Fmoc quantitation to be 0.25 mmol/g, see Reddy, M. P.; Voelker, P.J. *Int. J. Pept. Protein Res.* 1998, **31**, 345-348.


Resin 24 of Scheme 5: Resin 22 (2.0 g, 0.25 mmol/g, 0.5 mmol) was suspended in 10 mL of 25% piperidine in DMF. The suspended resin was shaken for 30 min at rt, and then the resin was washed 3 x with 20 mL of DMF, 3 x with 20 mL of methanol, and 3 x with 20 mL of CH₂Cl₂. Deprotected resin (1.0 g, 0.25 mmol) was swollen in 2 mL of DMF. To the slurry was added 650 mg (1.25 mmol) of PyBOP and 217 mL (1.25 mmol) of DIEA. Separately, 443 mg (0.97 mmol) of caprolactam 23 was dissolved in 2 mL of DMF and 436 mL (2.5 mmol) of DIEA was added. The caprolactam solution was added to the resin slurry and the resin was mixed for 18 h at rt. The solvents were then removed and the coupling was repeated, with shaking at rt for 6 h. The resin was then washed 3 x with 10 mL of DMF, 3 x with 10 mL of methanol, and 3 x with 10 mL of CH₂Cl₂.

Products 25 of Scheme 5: A 70 mg (17.5 mmol) portion of resin 24 was suspended in 1 mL of THF in a screw-

cap vial. To the slurry was added a boronic acid (0.15 mmol), 150 mL of a 2 M solution of sodium carbonate, and 15 mg (13 mmol) of tetrakis(triphenylphosphine)palladium. The vial was tightly closed and heated to 60°C for 16 h using a dry heater on a shaker table. The solvents were then removed by filtration and the resin was washed 3 x with THF (2 mL), 3 x with methanol (2 mL), 3 x with water, and 3 x with CH₂Cl₂. The resins were then placed in a glass vial and cleaved with 1 mL of 5% trifluoroacetic acid in CH₂Cl₂ for 30 min. The solution was filtered off and the resin was washed with an additional 2 mL of CH₂Cl₂ and the combined filtrates were evaporated to dryness to yield the crude products 25. The products were purified by chromatography eluting with 10-100% ethyl acetate in hexanes to yield 13.0 to 6.0 mg (14-60%) of the final products.

Additional Examples of compounds of Formula (I) can be prepared as shown in Scheme 6. A suitable resin for solid phase synthesis such as Fmoc (Fluorenylmethylcarbonyl)-protected peptide amide linker (PAL)-derivatized polystyrene beads can be purchased from Perkin Elmer Biosystems, Inc. Deprotection of the Fmoc group under standard conditions using 20% piperidine in DMF provides the free benzylamine. Coupling of a succinic acid derivative such as 28 (which is available using chemistry outlined in Scheme 4) with a coupling agent such as HATU in a suitable solvent like DMF or N-methylpyrrolidinone provides the support-bound amide 29. The support-bound intermediate 29 can then be elaborated to biaryl structures of the type 24 using typical Suzuki coupling conditions employing a catalyst such as Palladium complexes like tetrakis(triphenylphosphine)-palladium with 2M aqueous sodium carbonate as a base in a suitable solvent like THF or DME and an excess of a boronic acid. The final compounds are liberated from the support employing 50% trifluoroacetic acid in CH₂Cl₂ and can be purified by conventional chromatography or preparative HPLC.

Scheme 6



5 **General procedure for solid-phase synthesis according to Scheme 6**

Resin 27 of Scheme 6: Fmoc-protected PAL resin **26**

(0.80 g, 0.50 mmol/g, 0.40 mmol) is purchased from Advanced Chemtech and swelled in 20 mL of CH_2Cl_2 for 1 hour. The CH_2Cl_2 is removed and the resin is then treated with 25% v/v piperidine in DMF (6 mL) and allowed to shake slowly for 1 h. The solvents were removed by filtration, and the resin **27** was rinsed 3 x with 20 mL of DMF, 3 x with 20 mL of methanol, and 3 x with 20 mL of CH_2Cl_2 . and dried in vacuo.

15 **Acid 28 of Scheme 6:** To a solution of 0.100 g (367

mmol) of succinate **10** dissolved in 2.0 mL of dry DMF was added 0.120 mL (1.10 mmol) of N-methylmorpholine. A second solution containing 0.139 g (0.403 mmol) of caprolactam **23** of Scheme 5 dissolved in 2.0 mL of DMF was then added. To the mixed solution was added 229 mg (0.440 mmol) of PyBop and the reaction solution was stirred for 16 h at rt. The reaction solution was diluted with water (20 mL) and extracted 3 x with 100 mL of ethyl acetate. The combined organic layers

were dried with Na_2SO_4 and concentrated under reduced pressure. The resulting oil was purified by chromatography eluting with a gradient of 5-20% ethyl acetate in hexanes to provide 0.195 g (0.360 mmol, 98%) of the *tert*-butyl ester of
5 Acid **28** (MS $M+\text{Na}=621$). The purified ester (0.195 g, 0.360 mmol) was dissolved in 10 mL of 25% trifluoroacetic acid in CH_2Cl_2 and stirred for 2 h at rt. The solvents were removed under reduced pressure and the acid was redissolved in 5 mL of toluene and reconcentrated 2 x to remove residual TFA.

10 The crude acid was found to be pure by ^1H NMR and was used in Scheme 6 without further purification.

Resin 29 of Scheme 6. Resin 27 (800 mg, 0.40 mmol) was solvated in 4.0 mL of dry DMF and and 0.63 mL (3.6 mmol) of diisopropylethylamine was added followed by a solution of
15 Acid **28** dissolved in 4 mL of DMF. To the slurry was then added 0.465 g (1.2 mmol) of HATU and the slurry was shaken for 26 h at rt. The solvents were removed by filtration, and the resin **29** was rinsed 3 x with 20 mL of DMF, 3 x with 20 mL of methanol, and 3 x with 20 mL of CH_2Cl_2 . and dried in
20 vacuo.

Products 30 of Scheme 6: A 75 mg (0.38 mmol/g, 28.8 μmol) portion of resin **24** was suspended in 1 mL of THF in a screw-cap vial. To the slurry was added a boronic acid (0.33 mmol), 150 mL of a 2 M solution of sodium carbonate, and 15
25 mg (13 mmol) of tetrakis(triphenylphosphine)palladium. The vial was tightly closed and heated to 60°C for 16 h using a dry heater on a shaker table. The solvents were then removed by filtration and the resin was washed 3 x with THF (2 mL), 3 x with methanol (2 mL), 3 x with water, and 3 x with CH_2Cl_2 .
30 The resins were then placed in a glass vial and cleaved with 1 mL of 5% trifluoroacetic acid in CH_2Cl_2 for 2 h. The solution was filtered off and the resin was washed with an additional 2 mL of CH_2Cl_2 and the combined filtrates were evaporated to dryness to yield the crude products **25**. The
35 products were purified by chromatography eluting with 10-100% ethyl acetate in hexanes to yield 0.5 to 2.0 mg (14-60%) of the final products.

The internal phenyl ring can be exchanged for a pyridine ring using chemistry outlined in Scheme 7. The chloromethyl pyridine 33 is prepared using a known procedure reported in Nutaitis, Charles F.; Ledebner, Mark W. Org. Prep. Proced.


5 Int. (1992), 24(2), 143-6 Incorporated herein by reference. After freebasing the pyridine, alkylation with the Boc-caprolactam provides pyridine intermediate 34, which can be elaborated to the protected amide 35 with succinate 10.

10 Substitution can then be introduced using Suzuki methodology employing a palladium source such as tetrakis(triphenylphosphine) palladium(0) or bis(diphenylphosphinoferrocene) palladium(II) dichloride and a suitable base such as sodium carbonate or triethylamine in a solvent such as THF or toluene containing 10% methanol.

15 Stille chemistry is also possible using a suitable palladium source such as tetrakis(triphenylphosphine)palladium(0) and an aryl or vinyl tin derivative in a solvent such as benzene, toluene, or xylenes. The tert-butyl ester is then deprotected under standard acidic conditions using

20 trifluoroacetic acid and the amide is formed under standard conditions to provide products 36.

Scheme 7

5 **General procedure for synthesis according to Scheme 7**

The chloromethyl pyridine HCl salt **33** is prepared using a known procedure reported in Nutaitis, Charles F.; Ledebor, Mark W. Org. Prep. Proced. Int. (1992), 24(2), 143-6.


Caprolactam **34**: Pyridine HCl salt **33** (2.0 g, 8.3 mmol) is dissolved in 50 mL of a saturated NaHCO_3 solution and the solution is extracted with 30 mL of CH_2Cl_2 3 x followed by concentration of the organic layers to provide the free base. Separately, 1.8 g (7.8 mmol) of caprolactam **13** is dissolved in 40 mL of dry THF and chilled to -78°C . To the solution was added 8.7 mL of a 1M solution of sodium bis(trimethylsilyl) amide. The solution was brought to 0°C and stirred for 30 min. To the resultant anion was added a solution of 1.7 g (8.3 mmol) of pyridine **33** free base dissolved in 40 mL of THF. The resulting reaction solution was stirred at rt for 18 h and then heated to 50°C and stirred an additional 3 h. The reaction solution was allowed to cool and then 50 mL of water was added and the aqueous layer was extracted 2 x with 100 mL of ethyl acetate. The combined organic layers were dried and concentrated under reduced pressure to provide the crude product which was

purified by chromatography eluting with 20 to 100% ethyl acetate in hexanes to provide 1.5 g (51%) of caprolactam **34** as an oil.

Amide **35**: Caprolactam **34** (0.40 g, 1.0 mmol) is dissolved in 20 mL of 50% trifluoroacetic acid in CH₂Cl₂ and stirred at rt for 30 min. The solvents were then removed under reduced pressure and the resulting oil was redissolved in 5 mL of toluene and reconcentrated to remove residual TFA. Separately, 0.270 g (1.0 mmol) of succinate **10** was dissolved in 5.0 mL of dry DMF and 0.44 mL (4 mmol) of *N*-methylmorpholine was added followed by 0.50 g (1.3 mmol) of HATU and the resulting solution was stirred at rt for 30 min. The crude deprotected caprolactam from above was dissolved in 5.0 mL of dry DMF and added to the succinate solution and the resulting solution was heated to 50 °C and stirred for 2 days. The solution was then diluted with 20 mL of water and extracted with 3 50 mL portions of ethyl acetate. The combined organic layers were dried and concentrated under reduced pressure to provide an oil which was purified by chromatography eluting with 20 to 50% ethyl acetate in hexanes to provide 0.40 g (70%) of the Amide **35**.


The compounds of Formula (I) of the present invention can also be prepared from aminolactam **42** and succinic acid derivatives **41** using amide bond syntheses known in the art, including methods commonly used in peptide syntheses, such as HATU, TBTU, BOP, pyBOP, EDC, CDI, DCC, hydroxysuccinimide, mixed carboxylic anhydride, and phenyl ester mediated couplings, as illustrated in Scheme 9 for the synthesis of aminolactam **43**, an embodiment of the present invention.

Scheme 9



Depending on the structure of the final product, it is appreciated by those skilled in the art that protecting groups or precursor functionality convertible to the desired groups may be desirable. Protecting groups and their use in synthesis are described in Green and Wuts, *Protective Groups in Organic Synthesis*, (Wiley 1991). The use of protecting groups is further illustrated in Scheme 10, in which the succinate half-ester **44** (Becket et al., Synlett 1993, 137-138) is coupled to the aminobenzodiazepine **45** (Sherrill and Sugg, J. Org. Chem. 1995, 60, 730-734; Bock et al., J. Med. Chem., 1993, 36, 4276-4292) to give ester **46**, followed by conversion of the ester group to the primary amide **47**.

Scheme 10



Methods for the synthesis of lactams as contemplated by the present invention in lactam ring B in Formula (I), including amino benzodiazepines, are known in the art and are disclosed in a number of references including PCT publication number WO 98/28268, which is hereby incorporated by reference. Additional references include Bock, et al, J. Org. Chem., **1987**, 52, 3232-3239 and Sherrill et al, J. Org.

Chem., 1995, 60, 730-734; Walsh, D. A., Synthesis, September 1980, p.677.


Examples

5 Chemical abbreviations used in the Examples are defined as follows: "DMPU" for 1,3-dimethyl-3,4,5,6-tetrahydro-2(1H)-pyrimidone, "TBTU" for O-(1H-benzotriazol-1-yl)-N,N,N',N'-tetramethyluronium tetrafluoroborate, and "BOP" for benzotriazol-1-yloxytris-(dimethylamino)phosphonium
10 hexafluorophosphate. It is understood that one skilled in the art can discern compounds used in the synthesis of Examples of the invention may be referred to by structure and number. For example, Resin 20 refers to the resin of structure 20 in Scheme 5; succinate 9 refers to the structure
15 9 found in Scheme 2 which is a succinate compound.

"HPLC" is an abbreviation used herein for high pressure liquid chromatography. Reverse-phase HPLC was carried out using a Vydac C-18 column with gradient elution from 10% to 100 % buffer B in buffer A (buffer A: water containing 0.1%
20 trifluoroacetic acid, buffer B: 10% water, 90% acetonitrile containing 0.1% trifluoroacetic acid).

Example 1

(2R,3S) N1-[(3S)-hexahydro-1-(3,3-diphenylpropyl)-2-oxo-1H-
25 azepin-3-yl]-N4-(hydroxy)-2-(2-methylpropyl)-3-(propyl)-
butanediamide.



Step (1a): Di-tert-butyl dicarbonate (10.2 g, 46.7 mmol) was added portionwise to a solution of L-(-)- α -amino- ϵ -caprolactam (5.0 g, 39.0 mmol) in dimethyl sulfoxide (30 mL). After 5 h at rt, the reaction was partitioned between water (100 mL) and ethyl acetate. The combined organic
30

extracts were washed successively with 1 M HCl (50 mL),
brine, and dried (MgSO₄) and concentrated *in vacuo*. The
residue was recrystallized in 1:1 v/v ether-hexanes, two
crops yielded the desired product (6.26 g, 70%) as white
5 solid. MS (M+H-BOC)⁺ = 129.

Step (1b): Triphenylphosphine (3.0 g, 11.4 mmol) and
carbon tetrabromide (3.75 g, 11.7 mmol) were added
successively to a cooled (0°C) solution of 3,3-biphenyl-1-
10 propanol (1.5 mL, 7.5 mmol) in dichloromethane (20 mL).
After 1.5 hours at rt, the mixture was concentrated *in vacuo*.
The residue was purified by flash chromatography on silica
gel (hexanes) to give the desired product (1.93 g, 93% yield)
as a clear oil. MS (M-BrC₂H₄)⁺ = 167

Step (1c): A 1.0 M tetrahydrofuran solution of lithium
bis(trimethylsilyl)amide (1.3 mL) was added over 15 minutes
to compound of Step (1a) (0.29 g, 1.27 mmol) in
tetrahydrofuran (3 mL) and DMPU (2 mL) at -78°C. The iodo
20 compound prepared from compound (1b) (0.85 g, 3.09 mmol) by
typical Finkelstein methodology, in tetrahydrofuran (4 mL)
was added and the reaction was allowed to warm to rt slowly.
This was stirred for 10 hours at ambient temperature,
partitioned between water and ethyl acetate. The combined
25 organic extracts were washed successively with water (20 mL),
brine (20 mL), and dried (MgSO₄) and concentrated *in vacuo*.
The resulting residue was purified by silica gel column
(ethyl acetate:hexanes, 5:95 then ethyl acetate:hexanes,
15:85) to give the desired product (0.16 g, 30%). MS (M-Ot-
30 Bu)⁺ = 349.

Step (1d): Trifluoroacetic acid (3 mL) was added to a
solution of compound of Step (1c) (0.16 mg, 0.38 mmol) in
dichloromethane (9 mL). After 2 h at rt, the solvent was
35 removed *in vacuo*. The residual trifluoroacetic acid was
removed by azeotrope with dichloromethane (50 mL), toluene
(50 mL), and dichloromethane (50 mL) successively to give the

desired product (0.17 g, 99%) as a yellow oil. MS (M+H)⁺ = 323.

5 Step (1e): 4-Methylmorpholine (0.6 mL, 5.46 mmoles) and TBTU
(0.11 g, 0.34 mmoles) were added to a solution of succinate
acid (P. Becket, M. J. Crimmin, M. H. Davis, Z. Spavold,
Synlett, (1993), 137-138) (0.085 g, 0.31 mmoles) in *N,N*-
dimethylformamide (3 mL). After 30 minutes at rt, the
10 compound from step (1d) (0.17 g, 0.39 mmoles) was added to
the mixture. The reaction was stirred for 16 h at rt, then
partitioned between 1 M HCl (20 mL) and ethyl acetate. The
combined organic extracts were washed successively with
saturated aqueous sodium bicarbonate (20 mL), water (20 mL),
brine (20 mL), dried (MgSO₄) and concentrated *in vacuo*. The
15 residue was purified by silica gel chromatography (ethyl
acetate:hexanes, 7:93 gradient to ethyl acetate:hexanes
25:75) to give the desired product (120 mg, 67%) as a clear
oil. MS (M+NH₄-Ot-Bu)⁺ = 521.


20 Step (1f): Trifluoroacetic acid (3 mL) was added to a
solution of compound of Step (1e) (120 mg, 0.21 mmoles) in
dichloromethane (9 mL). After 3 hours at rt, the mixture was
concentrated *in vacuo*. The residual trifluoroacetic acid was
removed by azeotrope with toluene (1 X 50 mL) and
25 dichloromethane (1 X 50 mL). The residue was triturated with
Et₂O:Hexanes 95:5, to give the desired product (75 mg, 70%)
as a white solid. MS (M-H)⁻ = 519.

30 Step (1g): 4-Methylmorpholine (0.05 mL, 0.45 mmoles) and BOP
(73 mg, 0.17 mmoles) were added to a solution of compound of
Step (1f) (60 mg, 0.12 mmoles) in *N,N*-dimethylformamide (2
mL). Hydroxylamine (33 mg, 0.47 mmoles) was added to the
mixture, the reaction was stirred for 16 h at rt, was
concentrated *in vacuo*, was acidified with trifluoroacetic
35 acid, then purified by reverse phase HPLC on a Vydac C-18
column, to give the desired hydroxamic acid as a white solid
(45 mg, 75%). MS (M-H)⁻ = 534.

Example 2

(2R,3S) N1-[(3S)-hexahydro-1-(3-phenoxybenzyl)-2-oxo-1H-azepin-3-yl]-N4-(hydroxy)-2-(2-methylpropyl)-3-(propyl)-butanediamide.

5



Step (2a): Triphenylphosphine (3.40 g, 13.0 mmoles) and carbontetrabromide (4.20 g, 13.0 mmoles) were added successively to a solution of m-phenoxybenzyl alcohol (1.5 mL, 8.6 mmoles). After 4 h at rt the mixture was concentrated and was purified by silica gel column (hexanes, then ethyl acetate:hexanes, 5:95) to give the desired bromide (1.3 g, 57%) as a yellow oil. MS (M-Br)⁺ = 183.

Step (2b): A 1 M solution of lithium bis(trimethylsilyl)amide was added dropwise to a solution of compound of Step (1a) (0.3 g, 1.31 mmoles) in tetrahydrofuran (5 mL) at -78°C. After 30 minutes a solution of compound of Step (2a) (0.43 g, 1.63 mmoles) in tetrahydrofuran (4 mL) was added to the mixture dropwise. The reaction was allowed to come to ambient temperature, stirred for 16 h, then partitioned between water and ethyl acetate. The combined organic extracts were washed successively with water (20 mL), brine (20 mL), dried (MgSO₄) and concentrated *in vacuo*. The crude residue was purified by silica gel chromatography (ethyl acetate:hexanes, 5:95 then ethyl acetate:hexanes, 15:85) to give the desired product (360 mg, 67%) as a clear oil. MS (M-Ot-Bu)⁺ = 337.

Step (2c): Trifluoroacetic acid (5 mL) was added to a solution of compound of Step (2b) in dichloromethane (15 mL). After 3 h at rt the solution was concentrated *in vacuo*. The residual trifluoroacetic acid was removed from residue by

azeotrope with toluene (50 mL) then dichloromethane (30 mL) to yield the desired amine (390 mg, 99%) as a clear oil. MS $(M+H)^+ = 311$.

- 5 Step (2d): Following a procedure analogous to the preparation of Step (1e), but using the compound from of Step (2c) (390 mg, 0.88 mmol) the amide was prepared. The crude compound was purified by silica gel chromatography to give the desired product (0.38 g, 92%) as a yellow oil. MS $(M+H)^+ = 311$.


- 10 Step (2e): Following a procedure analogous to the preparation of step (1f), but using the compound from Step (2d) (380 mg, 0.67 mmol), the carboxylic acid was prepared. 15 The product was precipitated from ethyl ether with hexanes, to give the desired acid (227 mg, 66%) as a white solid. MS $(M-H)^- = 507$.

- 20 Step (2f): Following a procedure analogous to the preparation of compound of Step (1g), but using the compound from step (2e) (150 mg, 0.29 mmol) the title compound was prepared. The crude was purified by reverse phase HPLC on a Vydac C-18 column to give the desired product (90 mg, 58%) as a white solid. MS $(M-H)^- = 522$.

25

Example 3

(2R,3S) N1-[(3S)-hexahydro-1-(phenyl)-2-oxo-1H-azepin-3-yl]-N4-(hydroxy)-2-(2-methylpropyl)-3-(propyl)-butanediamide.



30

- Step (3a): Triethylamine (1.5 mL, 10.8 mmol), copper (II) acetate (0.95 g, 5.2 mmol) and phenylboric acid (1.6 g, 13.1 mmol) were added successively to a solution of

compound of Step (1a) (1.0 g, 4.4 mmol) in dichloromethane (20 mL). After 2.5 h at rt, more phenylboric acid (0.5 g, 4.1 mmol) was added to the mixture. After an additional 3 hours at rt more phenylboric acid (0.5 g, 4.1 mmol) was added to the mixture. After 65 h at rt, the mixture was filtered over celite. The filtrate was concentrated *in vacuo*, and the residue was purified by silica gel chromatography (ethyl acetate:hexanes, 5:95 then 15:85) to give the desired product (250 mg, 19%). MS (M-Ot-Bu)⁺ = 231.

Step (3b): Following a procedure analogous to the preparation of compound of Step (2c), but using compound of Step (3a) (250 mg, 0.82 mmol), the amine (300 mg, 99%) was prepared as a yellow oil. MS (M+H)⁺ = 205.


Step (3c): Following a procedure analogous to the preparation of compound of Step (1e), but using compound from Step (3b) (0.3g, 0.94 mmol), the amide was prepared. The residue was purified by silica gel chromatography (ethyl acetate:hexanes, 5:95 to 20:80 in 5% increments, 500 mL each ratio) to give the desired product (210 mg, 60%) as a clear oil. MS (M+H-t-Bu)⁺ = 403.

Step (3d): Following a procedure analogous to the preparation of compound of Step (1f), but using compound from sStep (3c) (200 mg, 0.44 mmol) the acid was prepared. The crude oil was triturated with ether:hexanes 1:1 to give the desired acid (114 mg, 65%) as a white solid. MS (M-OH)⁺ = 385.

Step (3e): Following a procedure analogous to the preparation of compound of Step (1g), but using compound from Step (3d) (82 mg, 0.20 mmol) the title compound was prepared. The crude product was purified by reverse phase HPLC on a Vydac C-18 column to give the desired product (80 mg, 94%). MS (M-H)⁻ = 416.

Example 4


(2R,3S) N1-[(3S)-hexahydro-1-(3-phenoxybenzyl)-2-oxo-1H-azepin-3-yl]-N4-(methyl)-2-(2-methylpropyl)-3-(propyl)-butanediamide.



Following a procedure analogous to the preparation of Example 3, compound of Step (2e) (100 mg, 0.20 mmol) was treated with HATU (O-(7-azabenzotriazol-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate) (114 mg, 0.30 mmol) and N-methyl morpholine (66 mL, 0.6 mmol) in 2 mL of DMF for 15 min at rt. A solution of 2.0 M methylamine in THF (0.2 mL, 0.4 mmol) was added and the reaction solution was stirred for 1 h at rt. The reaction solution was diluted with 1N HCl (5 mL) and extracted 3 x with 10 mL of ethyl acetate. The combined organic layers were washed with a saturated sodium bicarbonate solution (5 mL) and brine (5 mL), dried over magnesium sulfate, and concentrated in vacuo to provide the crude amide. Purification by reverse phase HPLC on a Vydac-18 column provided the desired amide (30 mg, 30%). MS (M+Na)⁺ = 544.

Example 5

(2R,3S) N1-[(3S)-hexahydro-1-(3-phenoxybenzyl)-2-oxo-1H-azepin-3-yl]-N4-(methoxy)-N4-(methyl)-2-(2-methylpropyl)-3-(propyl)-butanediamide.



Following a procedure analogous to the preparation of Example 4, compound of Step (2e) (100 mg, 0.20 mmol) was


activated and condensed with *N,O*-dimethylhydroxylamine hydrochloride (40 mg, 0.40 mmol). Purification by reverse phase HPLC on a Vydac-18 column provided the desired amide (30 mg, 30%). MS (M+Na)⁺ = 574.

5

Example 6

(2*R*,3*S*) N1-[(3*S*)-hexahydro-1-(3-phenoxybenzyl)-2-oxo-1*H*-azepin-3-yl]-N4-(methoxy)-2-(2-methylpropyl)-3-(propyl)-butanediamide.

10




Following a procedure analogous to the preparation of Example 4, compound of Step (2e) (100 mg, 0.20 mmol) was activated and condensed with *O*-methylhydroxylamine hydrochloride (40 mg, 0.40 mmol). Purification by reverse phase HPLC on a Vydac-18 column provided the desired amide (30 mg, 30%). MS (M+Na)⁺ = 560.

15

Example 7


(2*R*,3*S*) N1-[(3*S*)-hexahydro-1-(3-phenoxybenzyl)-2-oxo-1*H*-azepin-3-yl]-2-(2-methylpropyl)-3-(propyl)-butanediamide.

20



Following a procedure analogous to the preparation of Example 4, compound of Step (2e) (100 mg, 0.20 mmol) was activated and condensed with a 2.0 M solution of ammonia in dioxane (0.2 mL, 0.4 mmol). Purification by reverse phase HPLC on a Vydac-18 column provided the desired amide (30 mg, 30%). MS (M+Na)⁺ = 530.

25


Example 7T

Example 7T was synthesized by reducing the double bond
 5 present in the compound of Example 8. Thus, the compound of
 Example 8 was dissolved in tetrahydrofuran and hydrogenated
 using tritium gas, by methods known to one skilled in the art
 organic synthesis. Purification by reverse phase HPLC on a
 Vydac-18 column provided the desired tritiated amide Example
 10 7T wherein m is approximately 2.

Example 8

(2R,3S) N1-[(3S)-hexahydro-1-(3-phenoxybenzyl)-2-oxo-1H-
 azepin-3-yl]-2-(2-methylpropyl)-3-(propyl)-butanediamide.


15



Example 8 was synthesized following a procedure
 analogous to the preparation of Example 7, but using
 succinate 9 (Scheme 2). The compound was purified by
 20 chromatography eluting with 5% methanol in CH₂Cl₂ to afford
 approx. 500 mg of Example 8. MS (M+Na)⁺ = 528.

Example 9


(2R,3S) N1-[(3S)-hexahydro-1-(3-phenoxybenzyl)-2-oxo-1H-
 25 azepin-3-yl]-N4-(hydroxy)-2-(2-methylpropyl)-3-(allyl)-
 butanediamide.



Example 9 was synthesized following a procedure analogous to the preparation of Example 2, but using succinate **9** (Scheme 2). Purification by reverse phase HPLC on a Vydac-18 column provided 150 mg of Example (9). MS (M+Na)⁺ = 544.

Example 10

(2R,3S) N1-[(3S)-hexahydro-1-(benzophenon-3-yl)-2-oxo-1H-azepin-3-yl]-2-(2-methylpropyl)-3-(allyl)-butanediamide.



(Step 10-a): **3-Bromomethylbenzophenone**. A solution of 3-methylbenzophenone (20 g, 102 mmol) dissolved in 40 mL of 1,2-dibromoethane was heated to reflux. Over a period of about 3 hours a solution of 105 mmol of bromine dissolved in 6 mL of 1,2-dibromoethane was added to the refluxing solution. After the addition was complete the solution was allowed to cool to rt and diluted with 100 mL of dichloromethane. The organic layer was extracted with 1 x 25 mL of 1 N HCl, 2 x 15 mL of NaHCO₃ Solution, and 2 x 25 mL of brine. The organic layers were dried over magnesium sulfate and concentrated *in vacuo*. The residue was then distilled to afford the product, 16.5 g (60 %) as an oil that solidified upon standing, b.p. 160°C at 300 mTorr. ¹H NMR analysis shows that the product contains approximately 7% of the dibromide.


Step (10-b): **3-(1,1-dimethylethylcarbomethoxy-N-(benzophenone-3-yl-methyl)caprolactam.**

Diisopropylamine (4.2 mL, 30 mmol) was dissolved in 25 mL of THF and chilled to -78°C. To the solution was added 10 mL of 2.5M n-butyllithium in hexanes and the solution was warmed to 0°C and allowed to stir for 10 min. A solution of Boc-protected aminocaprolactam **1a** (5.0 grams, 22 mmol) dissolved in 25 mL of THF was then added and the reaction solution was stirred for 1 h at 0°C. Solid 3-bromomethyl-benzophenone was then added and the reaction solution was allowed to warm to rt and stir overnight. The reaction solution was diluted with water and extracted into ethyl acetate (100 mL). The organic layer was rinsed with 2x 25 mL of 1 N HCl, 2 x 25 mL of saturated NaHCO₃ and 2 x 25 mL of brine, dried over magnesium sulfate, and dried in vacuo. Chromatography eluting with a gradient of 30% to 40% ethyl acetate in hexanes afforded the pure benzophenone-substituted caprolactam derivative (7.4 g, 80%). MS (M+Na)⁺ = 445.

The title compound, Example 10, was synthesized in a manner analogous to the synthesis of the compound of Example 8 using succinate **9** and the benzophenone-substituted caprolactam derivative of the previous step. The compound was purified by crystallization from ethyl acetate to afford 0.26 g of crystals. MS (M+Na)⁺ = 540.

Example 11


(2R,3S) N1-[(3S)-hexahydro-1-(benzophenon-3-yl)-2-oxo-1H-azepin-3-yl]-2-(2-methylpropyl)-3-(propyl)-butanediamide.



The compound of Example 11 was synthesized in a manner analogous to the synthesis of the compound of Example 8 using succinate **10** and the benzophenone-substituted caprolactam

derivative of Step (10-b). The compound was purified by crystallization from ethyl acetate to afford 0.25 g of crystals. MS (M+Na)⁺ = 542.


5

Example 11T

Example 11T was synthesized by reducing the double bond present in the compound of Example 10. Thus, the compound of Example 11T was dissolved in tetrahydrofuran and hydrogenated using tritium gas, by methods known to one skilled in the art organic synthesis. Purification by reverse phase HPLC on a Vydac-18 column provided the desired tritiated amide Example 11T wherein m is approximately 2.

Example 13


(2R,3S) N1-[(3S)-hexahydro-1-(3-(4-fluorophenyl)benzyl)-2-oxo-1H-azepin-3-yl]-N4-(hydroxy)-2-(2-methylpropyl)-3-(propyl)-butanediamide.



The general procedure reported for Scheme 5 was followed using 4-fluorophenyl boronic acid. Purification afforded 5.0 mg (54%) of the desired product. MS (M+Na)⁺ = 548.

Example 16


(2R,3S) N1-[(3S)-hexahydro-1-(3-(3-methylphenyl)benzyl)-2-oxo-1H-azepin-3-yl]-N4-(hydroxy)-2-(2-methylpropyl)-3-(propyl)-butanediamide.



The general procedure reported for Scheme 5 was followed using 3-methylphenyl boronic acid. Purification afforded 3.0 mg (33%) of the desired product. MS (M+Na)⁺ = 544.

Example 22

(2R,3S) N1-[(3S)-hexahydro-1-(3-(2-naphthyl)benzyl)-2-oxo-1H-azepin-3-yl]-N4-(hydroxy)-2-(2-methylpropyl)-3-(propyl)-butanediamide.




The general procedure reported for Scheme 5 was followed using 2-naphthyl boronic acid. Purification afforded 3.0 mg (31%) of the desired product. MS (M+Na)⁺ = 580.

It will be understood by one skilled in the art that Scheme 6 can be followed in a manner analogous to the procedure for Scheme 5.

Example 23


(2R,3S) N1-[(3S)-hexahydro-1-(3-(4-methoxyphenyl)benzyl)-2-oxo-1H-azepin-3-yl]-N4-(hydroxy)-2-(2-methylpropyl)-3-(propyl)-butanediamide.



The general procedure reported for Scheme 6 was followed using 4-methoxyphenyl boronic acid. Purification afforded 0.5 mg of the desired product. MS $(M+Na)^+ = 544$.

Example 24


(2R,3S) N1-[(3S)-hexahydro-1-(3-(3-fluorophenyl)benzyl)-2-oxo-1H-azepin-3-yl]-2-(2-methylpropyl)-3-(propyl)-butanediamide.



The general procedure reported for Scheme 6 was followed using 3-fluorophenyl boronic acid. Purification afforded 1.6 mg of the desired product. MS $(M+Na)^+ = 532$.

Example 25

(2R,3S) N1-[(3S)-hexahydro-1-(3-(4-trifluoromethylphenyl)benzyl)-2-oxo-1H-azepin-3-yl]-2-(2-methylpropyl)-3-(propyl)-butanediamide.




The general procedure reported for Scheme 6 was followed using 4-trifluoromethylphenyl boronic acid. Purification

afforded 2.0 mg (40%) of the desired product. MS (M+Na)⁺ = 582.

Example 26


5 (2R,3S) N1-[(3S)-hexahydro-1-(3-(4-methoxyphenyl)benzyl)-2-oxo-1H-azepin-3-yl]-2-(2-methylpropyl)-3-(propyl)-butanediamide.



10 The general procedure reported for Scheme 6 was followed using 4-methoxyphenyl boronic acid. Purification afforded 0.5 mg of the desired product. MS (M+Na)⁺ = 544.

Example 27


15 (2R,3S) N1-[(3S)-hexahydro-1-(3-(2,4-dichlorophenyl)benzyl)-2-oxo-1H-azepin-3-yl]-2-(2-methylpropyl)-3-(propyl)-butanediamide.



20 The general procedure reported for Scheme 6 was followed using 2,6-dichlorophenyl boronic acid. Purification afforded 1.8 mg (11 %) of the desired product. MS (M+Na)⁺ = 582.

Example 28

25 (2R,3S) N1-[(3S)-hexahydro-1-(3-(4-methylphenyl)benzyl)-2-oxo-1H-azepin-3-yl]-2-(2-methylpropyl)-3-(propyl)-butanediamide.




The general procedure reported for Scheme 6 was followed using 4-tolyl boronic acid. Purification afforded 1.8 mg (12 %) of the desired product. MS (M+Na)⁺ = 528.

5

Example 29

(2R,3S) N1-[(3S)-hexahydro-1-(3-(3-chloro-4-fluorophenyl)-benzyl)-2-oxo-1H-azepin-3-yl]-2-(2-methylpropyl)-3-(propyl)-butanediamide.

10




The general procedure reported for Scheme 6 was followed using 4-fluoro-3-chlorophenyl boronic acid. Purification afforded 0.5 mg (3.3 %) of the desired product. MS (M+Na)⁺ = 567.

15

Example 30

(2R,3S) N1-[(3S)-hexahydro-1-(3-(3-methoxyphenyl)benzyl)-2-oxo-1H-azepin-3-yl]-2-(2-methylpropyl)-3-(propyl)-butanediamide.


20



The general procedure reported for Scheme 6 was followed using 2-methoxyphenyl boronic acid. Purification afforded 0.8 mg (5.3 %) of the desired product. MS (M+Na)⁺ = 544.

Example 31

(2R,3S) N1-[(3S)-hexahydro-1-(3-(2-methoxyphenyl)benzyl)-2-oxo-1H-azepin-3-yl]-2-(2-methylpropyl)-3-(propyl)-butanediamide.




The general procedure reported for Scheme 6 was followed using 2-methoxyphenyl boronic acid. Purification afforded 1.5 mg (10 %) of the desired product. MS (M+Na)⁺ = 544.

It will be understood by one skilled in the art that Scheme 7 can be followed in a manner analogous to the procedure for Schemes 5 and 6.

Example 32

(2R,3S) N1-[(3S)-hexahydro-1-(3-(4-methoxyphenyl)pyrid-5-ylmethyl)-2-oxo-1H-azepin-3-yl]-2-(2-methylpropyl)-3-(propyl)-butanediamide.




Amide **35** of Scheme 7 (0.10 g, 0.18 mmol) was dissolved in 5 mL of toluene and 41 mg (0.27 mmol) of 4-methoxyphenyl boronic acid was added, followed by 31 mg (0.0147 mmol) of tetrakis(triphenylphosphine)palladium, 0.5 mL of a 2M sodium carbonate solution and 0.5 mL of methanol. The reaction solution was heated to reflux for 16 h and then allowed to

cool to rt. The reaction solution was diluted with 10 mL of water and extracted 2 x with 50 mL of ethyl acetate. The combined organic layers were dried and concentrated and the resulting oil was purified by chromatography eluting with 30 to 100% ethyl acetate in hexanes as a solvent to provide 30 mg (29%) of biaryl product. MS (M+H)⁺ = 580.

The purified biaryl product was dissolved in 10 mL of 1:1 trifluoroacetic acid/CH₂Cl₂ and stirred at rt for 2 h. The solvents were then removed under reduced pressure and the resulting oil was redissolved in 5 mL of toluene and reconcentrated to remove residual TFA. The crude acid (25 mg, 0.047 mmol) was then dissolved in 1 mL of DMF and 10 µL of N-methylmorpholine (0.094 mmol) and 42 mg (0.062 mmol) HATU were added and the reaction solution was stirred at rt for 45 min. Gaseous ammonia was then bubbled in at a gentle rate for about 1 minute and the solution was stirred for an additional 1 min. The reaction solution was then diluted with 10 mL of water and extracted 3 x with 30 mL of ethyl acetate. The combined organic layers were dried and concentrated under reduced pressure to a solid which was purified by reversed phase HPLC to provide 3.5 mg (10%) of the compound of Example 30 as its trifluoroacetic acid salt. MS (M+H)⁺ = 523.

Example 33

(2R,3S) N1-[(3S)-hexahydro-1-(3-(4-trifluoromethylphenyl)pyrid-5-ylmethyl)-2-oxo-1H-azepin-3-yl]-2-(2-methylpropyl)-3-(propyl)-butanediamide.




The general procedure reported for the compound of Example 32 was followed using 4-trifluoromethylphenyl boronic acid. Purification by HPLC afforded 6.0 mg of the desired

product from as its trifluoroacetic acid salt. MS (M+Na)⁺ = 583.

Example 34

5 (2R,3S) N1-[(3S)-hexahydro-1-(3-(3-chloro-4-fluorophenyl)pyrid-5-ylmethyl)-2-oxo-1H-azepin-3-yl]-2-(2-methylpropyl)-3-(propyl)-butanediamide.




10 Amide **35** (0.30 g, 0.54 mmol) was dissolved in 3 mL of DMF and 123 mg (0.70 mmol) of 4-methoxyphenyl boronic acid was added, followed by 44 mg (0.0543 mmol) of bis(diphenylphosphinoferrocene) palladium (II) dichloride and 1.0 mL (7.18 mmol) of triethylamine. The reaction solution
15 was heated to 80°C for 24 h and then allowed to cool to rt. The reaction solution was diluted with 10 mL of water and extracted 2 x with 50 mL of ethyl acetate. The combined organic layers were dried and concentrated and the resulting oil was purified by chromatography eluting with 20 to 100%
20 ethyl acetate in hexanes as a solvent to provide 140 mg (50%) of biaryl product. MS (M+Na)⁺ = 624.

The general procedure reported for the compound of Example 32 was then followed to provide the amide. Purification by chromatography eluting with 20 to 100% ethyl
25 acetate in hexanes afforded 45 mg of the desired product of Example 34 as its trifluoroacetic acid salt. MS (M+Na)⁺ = 567.

Example 39

30 (2R,3S) N1-[(3S)-hexahydro-1-(4-(4-trifluoromethylphenyl)-benzyl)-2-oxo-1H-azepin-3-yl]-2-(2-methylpropyl)-3-(propyl)-butanediamide.



Step (39-a) 3-(1,1-dimethylethylcarbomethoxy-N-(4-bromophenylmethyl)caprolactam.

5 The title compound was synthesized in a manner analogous to the preparation of 3-(1,1-dimethylethylcarbomethoxy-N-(benzophenone-3-yl-methyl)caprolactam in Example 10 but using 4-bromobenzyl bromide as the alkylating agent. The compound was purified by chromatography eluting with 5-20% ethyl
10 acetate in hexanes as eluent to provide 7.0 g (70%) of the title compound as a solid. MS (M+Na)+ = 419.

Step (39-b) 3-(1,1-dimethylethylcarbomethoxy-N-(4, -(4'-trifluoromethylphenyl)phenylmethyl)caprolactam.

15 To a solution of 3-(1,1-dimethylethylcarbomethoxy-N-(4-bromophenylmethyl)caprolactam (0.5 g, 1.26 mmol) dissolved in 10 mL of toluene was added 263 mg (1.38 mmol) of 4-trifluoromethylphenyl boronic acid, 1 mL of methanol, and 1 mL of a 2M solution of potassium carbonate. The solution was
20 degassed by nitrogen bubbling for 5 min, and then 33 mg of tris(dibenzylideneacetone)dipalladium(0) chloroform adduct and 66 mg of triphenylphosphine was added. The solution was heated to reflux for 16 h and then allowed to cool and diluted with 20 mL of water. The aqueous layer was extracted
25 3 x with 25 mL of ethyl acetate and concentrated. The resulting oil was purified by chromatography eluting with 20% ethyl acetate in hexanes to afford 0.47g (81%) of an oil which crystallized on standing.


30 Step (39-d) The title compound, Example 39, was synthesized in a manner analogous to the synthesis of the compound of Example 8 using succinate 10 (280 mg, 1.04 mmol) and 3-(1,1-dimethylethylcarbomethoxy-N-(4, -(4'-trifluoromethylphenyl)-

phenylmethyl)caprolactam. The compound was purified by chromatography eluting with 20-100% ethyl acetate in hexanes to afford 40 mg of a white powder. MS (M+H)+ = 560.

5

Example 40

(2S,3R) N1-[(3S)-hexahydro-1-(3-(2-tetrazolylphenyl)benzyl)-2-oxo-1H-azepin-3-yl]-2-(propyl)-3-(2-methylpropyl)-butanediamide.



10

Step (40-a): The compound of Example 40 was synthesized in a manner analogous to the synthesis of the compound of Example 39, but using the substituted acid 28 of Scheme 6 (50 mg, 0.10 mmol) and o-((N-trityl)-tetrazole)phenylboronic acid under the conditions for the formation of the compound (39-b). The desired biaryl acid was isolated as an impure mixture (134 mg) and used directly in Step (40-b).


20

Step (40-b): The acid from Step (40-a) (134 mg, impure mixture) was converted to the amide under the conditions reported for the compound of Example 7. The crude amide was then dissolved in 2 mL of 10% trifluoroacetic acid in methanol and allowed to stir at rt for 30 min. The solvents were removed and the residue was purified by chromatography eluting with 10% methanol in ethyl acetate to provide 40 mg (71%, 2 steps) of the compound of Example 40 as a sticky powder. MS (M+Na)+ = 582.

30

Example 41

(2S,3R) N1-[(3S)-hexahydro-1-(3-phenoxybenzyl)-2-oxo-1H-azepin-3-yl]-2-(propyl)-3-(2-methylpropyl)-butanediamide.




Step (41-a): The compound of Example **41** is formed by coupling Succinate **23** (480 mg, 1.21 mmol) with the substituted caprolactam TFA salt **2c** under the conditions reported for the synthesis of the compound of Example **8**. The crude fluorenylmethyl ester was used in the next step with out further purification. MS (M+Na)+ = 709.

Step (41-b): The crude fluorenylmethyl ester is dissolved in 2 mL of a 50% solution of piperidine in CH₂Cl₂ and stirred for 3 h at rt. A 10 mL portion of 1N HCl was then added and the mixture was extracted 3 x with 10 mL of ethyl acetate. The crude acid was used in the next step with out further purification. MS (M+H)+ = 509.

The compound of Example **41** was then prepared using the acid from Step (41-b) under the conditions reported for compound of Example **7**. The compound was purified by chromatography eluting with 5% methanol in CH₂Cl₂ to afford 120 mg (19%, 3 steps) of a white powder. MS (M+H)+ = 508.

Example 42


(2S,3R) N1-[1,3-dihydro-1-(3-phenoxybenzyl)-2-oxo-5-(phenyl)-2H-1,4-benzodiazepin-3-yl]-2-(2-methylpropyl)-3-(allyl)-butanediamide.



Step (42-a) 3-Phenoxybenzyl iodide:


To a solution of 3-phenoxybenzyl chloride (10.0 g, 45.7mmol) in 200 ml acetone was added sodium iodide (7.6 g, 507mmol). The mixture was stirred at temperature overnight. The mixture was diluted with 300ml hexane and the organic layer was washed twice with 5% sodium bicarbonate, once with brine and then dried over MgSO_4 . Evaporation of the filtrate gave a light yellow oil. The product was used in next step without purification. ^1H NMR (CDCl_3) 4.4 (s, 2H), 6.8-7.4 (m, 9H).

Step (42-b):



To a solution of benzodiazepine **50** (910 mg, 3.63mmol), succinate **9** (980 mg, 3.63mmol), hydroxybenzotriazole (980 mg., 7.25mmol) and EDC (870 mg, 4.54mmol) in 100 ml CH_2Cl_2 at 0 degrees was added triethylamine (0.76 ml, 5.45mmol). The reaction mixture was washed with saturated sodium bicarbonate solution, 1.0N HCl, brine and dried over MgSO_4 . Evaporation of the organic layer and purification by column chromatography on silica gel with hexane-ethyl acetate (7:3) gave 610 mg of benzodiazepine **51** as a white solid. $\text{M}+\text{H} = 504.37$. ^1H NMR (CDCl_3) 0.8-1.0 (m, 6H), 1.0-1.2 (m, 1H), 1.4-1.5 (d, 9H), 1.6-1.9 (m, 2H), 2.2-2.8 (m, 4H), 4.9-5.2 (m, 2H), 5.6 (dd, 1H), 5.6-6.0 (m, 1H), 7.0-7.6 (m, 9H).

Step (42-c):




To a solution of benzodiazepine **51** (440 mg, 0.875mmol) in DMF (20 ml) at 0 degrees was added NaH (45 mg, 1.12mmol). The mixture was stirred at 0 degrees for 1.5 hr and then a solution of 3-phenoxybenzyl iodide (330 mg, 1.06mmol) in 10 ml DMF was added dropwise. The reaction mixture was allowed to warm to room temperature and stirred overnight. TLC using hexanes:EtOAc 6:4 (product Rf = 0.31) indicated that the reaction was complete. The reaction mixture was quenched with water, and the solvent was evaporated under high vacuum, which provided a viscous yellow oil. The product benzodiazepine **52** was dissolved in ethyl acetate, which was washed with water (2x), brine and then dried over MgSO₄.

Evaporation of solvent gave 600mg of benzodiazepine **52** as a yellow oil which was not further purified. M+H = 686.3, M+Na = 708.3. ¹H NMR (CDCl₃) 0.8-1.0 (m, 6H), 1.0-1.3 (m, 1H), 1.4-1.5 (d, 9H), 1.5-1.9 (2H), 2.2-2.7 (4H), 4.6-4.8 (d, 1H), 4.9-5.2 (m, 2H), 5.6-5.9 (m, 3H), 6.6-7.6 (m, 18H).

A solution of benzodiazepine **52** in 40 ml of TFA/CH₂Cl₂ (1:1) was stirred overnight at room temperature then evaporated to dryness. Repeated addition of toluene and evaporation provided 560 mg. of **53** as a yellow solid. (M - H = 629.1)

Step (42-d):




To a solution of benzodiazepine **53** and HATU (410mg, 1.08mmol) in 30 ml DMF was added diisopropylethylamine (0.6 ml, 3.44mmol) at 0 degrees. After 10 minutes, ammonia gas was bubbled through the solution for two minutes, and the reaction mixture was allowed to warm to room temperature and stirred overnight. Addition of water and solvent evaporation under high vacuum provided a yellow solid. The solid was taken up in ethyl acetate-water (1:1), and the organic layer was washed with water (2x), brine and then dried over MgSO₄. Evaporation of solvent gave a light yellow solid. Chromatographic purification on silica gel using CH₂Cl₂ : methanol (10:0.5) gave 256 mg of Example 42. M+H = 629.2


¹H NMR (CDCl₃) 0.8-1.0 (m, 6H), 1.2-1.4 (m, 1H), 1.6-2.0 (m, 2H), 2.2-2.8 (4H), 4.6-4.8 (m, 1H), 5.0-5.2 (m, 2H), 5.6-5.9 (m, 3H), 6.2-7.8 (m, 18H).

Example 43

(2S,3R) N1-[1,3-dihydro-1-methyl-2-oxo-5-(phenyl)-2H-1,4-benzodiazepin-3-yl]-2-(2-methylpropyl)-3-(allyl)-butanediamide.



Step (43-a):




A solution of tert-butyl succinate ester 9 (1.1 eq.) in
 5 DMF (0.25 M) under N₂ at 0°C was added HATU (1.1 eq.), then
 Hunig's base (4.0eq.). The mixture was stirred at 0°C for 10
 mins. A solution of 2,3-dihydro-1-methyl-3-amino-5-phenyl-
 1H-1,4-benzodiazepin-2-one 54 in DMF (0.8 M) (1.0 eq.) was
 added to this solution. The reaction mixture was stirred
 10 overnight at room temperature and then transferred to a
 separatory funnel containing water. 30% n-Hexane in ethyl
 acetate was added which gave a clear organic layer. The
 aqueous solution was extracted twice with 30% n-hexane in
 ethyl acetate. The combined organic layers were washed with
 15 water and brine, dried over magnesium sulfate, and
 concentrated *in vacuo*. The residue was purified by
 chromatography on flash grade silica gel using 20% ethyl
 acetate in n-hexane. The compound 55 was isolated as an
 amorphous white solid (85%). R_f = 0.25 (7:3 n-hexane:ethyl
 20 acetate).

¹H-NMR: (CDCl₃): δ 7.61-7.21 (m, 10H); 5.77-5.73 (m, 1H); 5.57-
 5.54 (d, 1H); 5.20-4.97 (m, 2H); 3.47 (s, 3H); 2.63-2.33 (m,
 4H); 1.80-1.76 (m, 2H); 1.47-1.46 (d, 9H); 1.43-1.11 (m,
 25 1H); 1.01-0.86 (m, 6H).

MS: C₃₁H₃₉N₃O₄ (M+H) 518.3 (M+Na) 540.3.

Step (43-b):

30



A solution of **55** in 50% TFA in methylene chloride (0.15M) was stirred at room temperature overnight. The solution was concentrated *in vacuo*, washed and concentrated four times with toluene *in vacuo* to give compound **56** as an amorphous solid (95%). *R_f* = 0.64 (9.5 : 0.5 methylene chloride : methanol). MS: C₂₇H₃₁N₃O₄ (M+H) 462.

Step (43-c):



To a solution of **56** (1.0 eq.) in DMF (0.25 M) under N₂ at 0°C was added HATU (1.1 eq.), and then Hunig's base (4.0eq.). The mixture was stirred at 0°C for 10 mins, and then anhydrous ammonia bubbled through the solution for two minutes. The reaction mixture was stirred overnight at room temperature and then transferred to a separatory funnel containing water and diluted with 30% n-hexane in ethyl. The aqueous solution was extracted twice with 30% n-hexane in ethyl acetate. The combined organic layers were washed with water and brine, dried over magnesium sulfate, and concentrated *in vacuo*. The residue was purified by chromatography on flash grade silica gel using 4% methanol in methylene chloride. The title compound, Example 43, was

isolated as an amorphous white solid (87%). $R_f = 0.43$ (9:1 methylene chloride:methanol).


$^1\text{H NMR}$: (CDCl_3): δ 7.63-7.22 (m, 10H); 6.25-6.13 (d, 1H);
5.88-5.73 (m, 1H); 5.53-5.51 (dd, 1H); 5.44-5.41 (d, 1H);
5.22-5.04 (m, 2H); 3.47-3.46 (d, 3H); 2.74-2.31 (m, 4H);
1.81-1.61 (m, 2H); 1.34-1.22 (m, 1H); 0.99-0.87 (m, 6H).

MS: $\text{C}_{27}\text{H}_{32}\text{N}_4\text{O}_3$ (M+H) 461.

It is understood that the (R) or (S)-benzodiazepine diastereomer of Example 43 can be prepared using methods analogous to the present example but employing the (R) or (S) stereoisomer of intermediate 2a in Step (43-a), respectively.

Example 43T

Tritiated (2S,3R) N1-[1,3-dihydro-1-methyl-2-oxo-5-(phenyl)-2H-1,4-benzodiazepin-3-yl]-2-(2-methylpropyl)-3-(n-propyl)-butanediamide.



Example 43T was synthesized by reducing the double bond present in the (S)-benzodiazepine diastereomer of Example 43. The (S) diastereomer of Example 43 may be separated from the product of Step (43-c) by means known to one skilled in the art and the single isomer reduced. Alternatively, this diastereomer may be prepared directly as stated above. Thus, the (S)-benzodiazepine diastereomer of Example 43 was dissolved in tetrahydrofuran and hydrogenated using tritium gas, by methods known to one skilled in the art organic synthesis. Purification by reverse phase HPLC on a Vydac-18

column provided the desired tritiated amide Example 43T wherein m is approximately 2.

It is understood that one skilled in the art of organic synthesis can synthesize radiolabeled compounds of the present invention for use as a tagged inhibitor of beta-amyloid production using radiolabeling techniques well known in the art. For example tritiation, using catalysts such as Pd/C or Wilkinson's catalyst and $^3\text{H}_2$ gas, one skilled in the art can reduce olefin precursors. Examples of olefin precursors are Examples 8, 10, 42, 43, intermediate Succinate 10 and intermediate Benzodiazepine 51.

UTILITY

A β production has been implicated in the pathology of Alzheimer's Disease (AD). The compounds of the present invention as well as compounds determined from the present invention have utility for the prevention and treatment of AD by inhibiting the proteolytic activity leading to A β production. Methods of treatment target formation of A β production through the enzymes involved in the proteolytic processing of β amyloid precursor protein. Compounds that inhibit β or γ secretase activity, either directly or indirectly, control the production of A β . Such inhibition of β or γ secretases reduces production of A β , and is expected to reduce or prevent the neurological disorders associated with A β peptide, such as Alzheimer's Disease.

Cellular screening methods for inhibitors of A β production, testing methods for the *in vivo* suppression of A β production, and assays for the detection of secretase activity are known in the art and have been disclosed in numerous publications, including PCT publication number WO 98/22493, EPO publication number 0652009, US patent 5703129 and US patent 5593846; all hereby incorporated by reference.

The compounds of the present invention as well as compounds determined from the present invention have utility for the prevention and treatment of disorders involving A β production, such as cerebrovascular disorders.

Compounds of Formula (I) are expected to possess γ -secretase inhibitory activity. The γ -secretase inhibitory activity of the compounds of the present invention is demonstrated using assays for such activity, for example, using the assay described below. Compounds within the scope of the present invention have been shown to inhibit the activity of γ -secretase, as determined using assays for such activity.

Compounds provided by this invention should also be useful as standards and reagents in determining the ability of a potential pharmaceutical to inhibit A β production. These would be provided in commercial kits comprising a compound of this invention.

As used herein " μ g" or "ug" denotes microgram, "mg" denotes milligram, "g" denotes gram, " μ L" denotes microliter, "mL" denotes milliliter, "L" denotes liter, "nM" denotes nanomolar, " μ M" or "uM" denotes micromolar, "mM" denotes millimolar, "M" denotes molar, "nm" denotes nanometer, "SDS" denotes sodium dodecyl sulfate, and "DMSO" denotes dimethyl sulfoxide, and "EDTA" denotes ethylenediaminetetraacetate.

A compound is considered to be active if it has an IC₅₀ or K_i value of less than about 100 μ M for the inhibition of A β production or inhibition of proteolytic activity leading to A β production. Compounds, as demonstrated by use of the invention, have demonstrated IC₅₀ values, for the inhibition of A β production, of less than about 100 μ M. Preferably compounds, as demonstrated by use of the invention, demonstrate IC₅₀ values, for the inhibition of A β production, of less than about 1 μ M. More preferably compounds, as demonstrated by use of the invention, demonstrate IC₅₀ values, for the inhibition of A β production, of less than about 100 nM. Even more preferably compounds, as demonstrated by use of the invention, demonstrate IC₅₀ values, for the inhibition of A β production, of less than about 50 nM.

β Amyloid Precursor Protein Accumulation Assay (β APPA assay)

An assay to evaluate the accumulation of A β protein was developed to detect potential inhibitors of secretases. The assay uses the CHO N 9 cell line, characterized for expression of exogenous APP by immunoblotting and immunoprecipitation.

The effect of test compounds on the accumulation of A β in the conditioned medium is tested by immunoprecipitation. N 9 cells are grown to confluency in 6-well plates and washed twice with 1 x Hank's buffered salt solution. The cells are starved in methionine/cysteine deficient media for 30 min., followed by replacement with fresh deficient media containing 150uCi Tran35S-LABELTM (ICN). Test compounds dissolved in DMSO (final concentration 1%) are added, over a range of 1 picomolar to 100 micromolar, together with the addition of the fresh media containing Tran35S-LABELTM. The cells are incubated for 4 h at 37°C in a tissue culture incubator.

At the end of the incubation period, the conditioned medium is harvested and pre-cleared by the addition of 5 μ l normal mouse serum and 50ul of protein A Sepharose (Pharmacia), mixed by end-over-end rotation for 30 minutes at 4°C, followed by a brief centrifugation in a microfuge. The supernatant is then harvested and transferred to fresh tubes containing 5ug of a monoclonal antibody (examples of antibodies include but are not limited by, clone 1101.1, directed against an internal peptide sequence in A β ; or 6E10 from Senetek; or 4G8 from Senetek; additionally polyclonals from rabbit antihuman A β from Boehringer Mannheim) and 50 μ l protein A Sepharose. After incubation overnight at 4°C, the samples are washed three times with high salt washing buffer (50mM Tris, pH 7.5, 500mM NaCl, 5mM EDTA, 0.5% Nonidet P-40), three times with low salt wash buffer (50mM Tris, pH 7.5, 150mM NaCl, 5mM EDTA, 0.5% Nonidet P-40), and three times with 10mM Tris, pH 7.5. The pellet after the last wash is resuspended in SDS sample buffer (Laemmli U.K. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 227, 680-5, 1970.) and boiled for 3 minutes. The supernatant is then fractionated on either 10-20% Tris/Tricine SDS gels or on 16.5% Tris/Tricine SDS gels.

The gels are dried and exposed to X-ray film or analyzed by phosphorimaging. The resulting image is analyzed for the presence of A β polypeptides. The steady-state level of A β in the presence of a test compound is compared to wells treated with DMSO (1%) alone. A typical test compound in this assay blocks A β accumulation in the conditioned medium, and is considered active with an IC₅₀ less than 100 μ M.

C-Terminus β Amyloid Precursor Protein Accumulation Assay
(CTF assay)

The effect of test compounds on the accumulation of C-terminal fragments is determined by immunoprecipitation of APP and fragments thereof from cell lysates. N 9 cells are metabolically labeled, as above, with media containing Tran35S-LABELTM, in the presence or absence of test compounds. At the end of the incubation period, the conditioned medium are harvested and cells lysed in RIPA buffer (10 mM Tris, pH 8.0 containing 1% Triton X-100, 1% deoxycholate, 0.1% SDS, 150mM NaCl, 0.125% NaN₃). Again, lysates are precleared with 5ul normal rabbit serum/50ul protein A Sepharose, followed by the addition of BC-1 antiserum (15 μ l;) and 50 μ l protein A Sepharose for 16 hours at 4°C. The immunoprecipitates are washed as above, bound proteins eluted by boiling in SDS sample buffer and fractionated by Tris/Tricine SDS-PAGE. After exposure to X-ray film or phosphorimager, the resulting images are analyzed for the presence of C-terminal APP fragments. The steady-state level of C-terminal APP fragments is compared to wells treated with DMSO (1%) alone. A typical test compound in this assay stimulates C-terminal fragment accumulation in the cell lysates, and is considered active with an IC₅₀ less than 100 μ M.

Accumulation-Release Assay

This immunoprecipitation assay is specific for γ secretase activity (i.e., proteolytic activity required to generate the C-terminal end of A β either by direct cleavage or generating a C-terminal extended species which is

subsequently further proteolyzed). N 9 cells are pulse labeled with media containing Tran35S-LABEL™ in the presence of a reported γ secretase inhibitor (MDL 28170; Higaki J, Quon D, Zhong Z, Cordell B. Inhibition of beta-amyloid formation identifies proteolytic precursors and subcellular site of catabolism. Neuron 14, 651-659, 1995) for 1 h, followed by washing to remove ³⁵S radiolabel and MDL 28170. The media is replaced and test compounds are added over a dose range (for example 0.1nM to 100uM). The cells are chased for increasing periods of times and A β is isolated from the conditioned medium and C-terminal fragments from cell lysates (see accumulation assay above). The activity of test compounds are characterized by whether a stabilization of C-terminal fragments is observed and whether A β is generated from these accumulated precursor. A typical test compound in this assay prevents the generation of A β out of accumulated C-terminal fragments and is considered active with an IC₅₀ less than 100 μ M.

20 Radioligand Competition Binding Assay (RCB Assay):

The following assay, of the invention, discloses a novel assay to rapidly screen and evaluate potential inhibitors of secretases. The assay enables screening for inhibitors of A β production or inhibitors of proteolytic activity leading to the production of A β by using a competitive binding assay wherein more than one chemical entity competes for a binding site identified for A β production. For example, in a competitive binding assay of the invention competition occurs between potential A β production inhibitors (i.e. compounds being investigated for inhibitory activity) and a standard known for A β production inhibitory activity which standard has been tagged by a radiolabel. Example 7T radiolabeled with tritium is a standard identified for A β production inhibitory activity; however, any radiolabelled or tagged compound binding to the same site as Example 7T could be used in this assay. It is understood that the theory of competitive binding is well known to one skilled in the art of pharmacology. The compounds identified by this invention

may have utility for the prevention and treatment of neurological disorders relating to A β production, including Alzheimer's disease, by inhibiting A β production.

5 Materials:

Assay buffer: Hepes 50 mM pH 7.0.

Competing compounds/potential inhibitors: weigh and dilute in 100% DMSO at a concentration of 1×10^{-2} M. From that stock, a second (6×10^{-4} M) stock is made in 100% DMSO.

10 The working stock (6×10^{-5} M) is made from the second in assay buffer containing 6% DMSO.

Wash buffer: Phosphate buffered saline containing 0.01% triton X-100, pH 7.0 at 4°C.

Membrane: HEK₂₉₃ control membranes (Receptor Biology, Inc.), or rat whole brain homogenates prepared as follows: Frozen pellets of approximately 10 mg protein HEK₂₉₃ cell membranes are thawed on ice and homogenized in 10 ml of assay buffer, using a Brinkman Polytron (PT-10) setting 6 for 10 sec. The homogenate was centrifuged at 48,000 X g for 12 minutes and the resulting pellet washed by repeating the homogenization and centrifugation steps. The final cell pellet was resuspended in buffer to yield a protein concentration of approximately 0.35 mg/ml as assayed by the method of Bradford (1976) using bovine serum albumin as the standard.

20 Rats: for the rat whole brain homogenates, (male Sprague-Dawley rats 200 to 300 g., Charles River) are decapitated and brains dissected on an ice-chilled glass plate. Brains weighing ~2g are homogenized in 20 ml of assay buffer and prepared by the method described above for the cell homogenates. The final pellet is resuspended to yield a protein conc. of ~5 mg/ml original wet weight.

35 Radiolabeled standard: [³H] I-7T (Example 7T; synthesized by Dupont Pharm. Co.) S.A. 87.5 Ci/mMol, (11.43 μ M I-7T).

Radioligand Competition Binding Assay Method:

Assays are initiated by addition of 150 μ l membrane suspension (~0.35 mg protein/ml) to 150 μ l of assay buffer containing 1% DMSO, 5 to 30 nM [3 H] **I-7T**, and various concentrations of inhibitors over a range of 1 picomolar to 100 micromolar. Binding assays are preformed in duplicate in disposable polypropylene 96 well plates, (Costar Corp., Cambridge, MA) in a final volume of 0.3 ml. Nonspecific binding is defined in the presence of 3 μ M **I-7T**. Optimum incubation time at 23°C is 1 hour. The separation of bound radioligand **I-7T** from free radioligand **I-7T** is accomplished by rapid vacuum filtration of the incubation mixture over GFF glass fiber filters (Inotech Biosystems International, Lansing, MI) presoaked for 2 hours in 0.3% polyethylinamine (pH 13) using an Inotech cell harvester. Filters were washed 2 times with 0.3 ml of ice-cold phosphate buffered saline pH 7.0 containing 0.01% Triton X100. Filters are accessed for radioactivity by liquid scintillation counting using a Packard 2500 TR (Packard Instrument Co., Downers Grove, IL), having a counting efficiency for tritium of ~56%.

Alternatively, it is well known in the art that a homogenous assay format, such as a scintillation proximity assay (SPA), could be employed in the radioligand competition binding assay of the invention. For example, membranes or membrane extracts can be immobilized onto the SPA support, afterwhich the support is then incubated with a tagged inhibitor of beta amyloid production in the presence of a potential inhibitor of beta amyloid production. The SPA support, by nature of its construction, magnifies the radioactive scintillation signal of bound radioactive compounds while not magnifying the radioactive signal of radioactive compounds free in solution. Therefore, the bound tagged inhibitor of beta amyloid production is detected and quantified by scintillation counting in the presence of free tagged inhibitor of beta amyloid production.

It is understood that the process of separating bound tagged inhibitor of beta amyloid production from free tagged inhibitor of beta amyloid production, for example bound


radioligand **I-7T** from free radioligand **I-7T**, can be conducted in a number of methods. For example the process of separating includes, but is not limited to, filtration or centrifugation. The process of separating is intended to facilitate quantification of bound tagged inhibitor of beta amyloid production. Therefore, the process of separating is also intended to encompass homogeneous techniques, for example SPA, where free tagged inhibitor of beta amyloid production in situ is separated from the tagged inhibitor of beta amyloid production bound to the solid support of the scintillant. Thus, in a homogeneous technique such as SPA, the free and bound inhibitors are considered separated from each other within the meaning of the invention.

Radioligand Competition Binding Data Analysis:

Resulting disintegrations per minute (dpm's) are expressed as percent inhibition of [³H] **I-7T** specific binding. IC₅₀ values of competing compounds are calculated using the program GraphPad Prism by GraphPad Software, (San Diego, CA). It is understood that one skilled in the art can determine these values using this program.


A good correlation for inhibition of proteolytic activity leading to A β production has been found between compounds identified in functional assays for determination of A β production, for example the β Amyloid Precursor Protein Accumulation Assay, and compounds identified in the Radioligand Competitive Binding Assay. The correlation is demonstrated by plotting the IC₅₀ values of compounds identified in the functional assay verses the IC₅₀ values of compounds identified in the RCB Assay. Compounds from several chemical series, including Examples disclosed herein, have exhibited, over a range of potencies, similar IC₅₀ values in the RCB Assay as seen in an accumulation assay.

Example 98




The compound of Example 98 was synthesized according to procedures disclosed in PCT Application WO98/28268, published July 2, 1998.

Example 98b



The compound of Example 98b was synthesized according to procedures disclosed in PCT Application WO98/28268, published July 2, 1998.

Example 99



Step (99a): The compound of Step (99a) is formed by coupling succinate **7** (115 mg, 0.5 mmol) with the substituted caprolactam TFA salt (212 mg, 0.5 mmol) from Step (2c) of Example 2 under the conditions reported for the synthesis of the compound of Example 8. The crude *tert*-butyl ester was taken on without further purification.

Step (99b): The compound of Step (99b) is formed by dissolving the crude product from Step (99a) in 5 mL of a 1:1 solution of TFA/CH₂Cl₂ and stirring at room temperature for 2

hours. Concentration followed by reconcentration twice from 10 mL of toluene provides the crude acid which was taken on with no further purification.

Step (99c): The title compound, Example 99, was prepared using the acid from Step (99b) under the conditions reported for the compound of Example 7. The compound was purified by chromatography eluting with 5% methanol in CH₂Cl₂ to afford 50 mg (21%, 3 steps) of a white powder. MS (M+Na)⁺ = 488.

Example 100

Binding of Example 7T to cell membranes:

A survey of different cell lines was performed using the radioligand competition binding assay, of the invention, with Example 7T to identify membranes rich in binding sites for Example 7. Cell lines useful for performance of the RCB Assay are preferentially human or mammalian cell lines. It is more preferred that the cell lines express presenilin 1, presenilin 2 and/or presenilin homologs (for example SEL-12). The cell lines surveyed included HEK293 cells (ATCC CRL-1573), IMR 32 (ATCC CCL-127), RAJI (ATCC CCL-86), CHO (ATCC CRL-9096), U-937 (ATCC CRL-1593), and THP-1 (ATCC TIB-202). Of the cell lines surveyed the best signal to noise ratio (i.e., ratio of specific binding and non-specific binding) was obtained using THP-1 cell membranes.

Example 101

Characterization of the Example 11T in the Radioligand Competition Binding Assay:

Example 11, a benzophenone derivative of Example 7, was synthesized. When Example 11 was assayed in the β APPA Assay and separately in the RCB Assay with Example 7T as the radiolabeled standard, a statistically significant correlation of IC₅₀ values was observed between the two Assays.

Radiolabeled Example 11, i.e. Example 11T, was synthesized and tested in the RCB Assay for equivalency to Example 7T. The apparent K_i was calculated for four

compounds (Example 7, Example 11, Example 98, and Example 99) and an statistically significant correlation was observed between results obtained whether the RCB Assay was conducted with Example 7T or Example 11T, indicating that Example 11
5 binds to the same molecular target(s) in cell membranes. Therefore, it was found that Example 11T could be used instead of Example 7T as the radioactive tracer in the RCB Assay.

Analogously, it has also been found that Example 43T can
10 be used instead of Example 7T as the radioactive tracer in the RCB Assay.

Example 102

Example 11 reduces the Bmax of Example 7T:

15 Cell membranes (THP-1) were incubated with Example 11 at approximately 3 times the K_d concentration for 1 hour at room temperature under the conditions outlined for the RCB Assay. Membranes were photolysed at 365nm for 1 hour on ice. Control membranes were incubated in parallel on ice. The
20 membranes were harvested (centrifuged at 40,000G, 4°C, 20 minutes) and extensively washed with assay buffer. The membranes were subsequently analyzed in the RCB Assay using Example 7T. A bmax of 938fmol/mg membranes was observed for unphotolysed membranes, whereas the bmax was reduced to
25 238fmol/mg membranes after photolysing. However, the K_d for Example 7T was not statistically significantly changed. These results indicate that Example 11 is cross-linked to the membrane binding site of Example 7.

Bmax is understood by one skilled in the art to
30 represent the maximum number of binding sites in a cell membrane. See Mary Keen (Ed.) Receptor binding techniques. Methods in Molecular Biology, Vol 106, Humana Press, Totowa, New Jersey, 1999.

In this experiment the membranes were photolysed at
35 365nm, which is appropriate for activation of the benzophenone moiety of Example 11. It is understood that photolysation of the membranes can occur at any wavelength that activates a photoactive tag to cross link to the

protein. Such wavelengths generally occur in the 250 to 450 nm range.

Example 103

5 **Analysis of cross-linked polypeptides by SDS-PAGE:**

THP-1 cell membranes were incubated with Example 11T exactly as outlined under the methods for the RCB Assay of the invention in the presence of an unlabeled competing compound; for Example 98 or Example 99. After 1 hour
10 incubation at room temperature, the membranes were analyzed by the RCB assay (top panel, Figure 1). The membranes in parallel wells were photolysed (365nm, as in Example 102) for 30 minutes on ice (alternatively, at room temperature). Membranes were collected, boiled in SDS-containing buffer in
15 the absence (middle panel Figure 1) or presence of dithiothreitol (50mM) (bottom panel Figure 1) and fractionated by SDS-PAGE (12% acrylamide in the separating gel). The polyacrylamide was fixed in 10% acetic acid/20% methanol/70% water for 45 minutes at room temperature and
20 soaked for another 45 minutes in Amplify™ (Amersham). After drying, the gel was exposed to X-ray film. In the absence of a competing compound, labeling of a number of polypeptides was observed. However, based on the ability of unlabeled compounds to compete with the cross-linking reaction, major
25 polypeptides, that could be specifically cross-linked with Example 11T, of molecular sizes of 30 (band A), 25 (band B), 20 (band C), and 10-12 (band D) kD were identified.

Dose-response experiments using increasing concentrations in the range of 1 picomolar to 100 micromolar
30 of an unlabeled competing compound were performed. The resulting samples were either analyzed by the RCB Assay of the invention prior to photolysis or by SDS-PAGE after photolysis. A statistically significant correlation was observed between the competition in the radioligand
35 competition binding assay and the radioactivity incorporated into the 30 (band A), 25 (band B), 20kD (band C), and 10-12 kD (band D) bands as revealed by SDS-PAGE and fluorography.

Thus, the quantitative reduction of cross-linking by unlabeled compounds to the 30, 25, 20, and 10-12 kD bands accurately tracks the reduction of specific binding in the binding assay. These results indicate that identification of the cross-linked species will identify the site of interaction in the binding assay.

Figure 1 illustrates the correlation between results of the RCB assay and the cross-linking assay for DMSO (lane 1), Example 7 (lane 2), Example 98b (lane 3), Example 43 (lane 4), Example 99 (lane 5), and Example 11 (lane 6) at 1 micromolar. Figure 1, top panel, illustrates results of the RCB Assay for these compounds. Figure 1, middle panel, illustrates results of the cross-linking assay for these compounds under non-reducing conditions. Figure 1, bottom panel, illustrates results of the cross-linking assay for these compounds under reducing conditions. Membranes were incubated with Example 11T and DMSO or a number of unlabeled compounds and analyzed by RCB assay. The total radioactivity associated with the filter off is indicated. Parallel wells were photolysed as in Example 103, and the membrane extracts were analyzed by SDS-PAGE followed by fluorography. The mobility of molecular weight markers (in kD) is indicated to the right. Note specific cross-linking to polypeptides of 30 (band A), 25 (band B), 20 (band C), and 10-12 (band D) polypeptides. The radioactivity associated with band A is stronger than that in bands B to D, suggesting that band A might be a mixture of two polypeptides (i.e., presenilin 1 and presenilin 2; see Figure 4).

Example 104

Immunological identification of the 30kD and 20kD cross-linked polypeptides of Example 103:

THP-1 cell membranes (1mg/ml) in 50mM TRIS buffer, pH 7.4-7.5, were incubated with Example 11T for 1 hour at room temperature and photolysed (as stated above) at room temperature for 30 minutes. The membranes were collected by centrifugation. The membranes were extracted with 50mM Tris, pH 7.5 containing 100mM KCl, 2mM EDTA, 2% CHAPS and 1

complete protease inhibitor tablet per 25 ml buffer (COMPLETE™, Boehringer Mannheim; product number 1697 498)) for 1 hour at 4°C. The detergent soluble fraction was recovered by centrifugation (40,000 g, 30 min, 4°C). The
5 membrane extract was diluted one half with water. 500ul of the membrane extract were pre-incubated with 10ul of normal mouse IgG and 50ul anti-mouse IgG Sepharose (Sigma) for 1 hour at 4°C. The supernatant was recovered by centrifugation. Subsequently, 10ug of preimmune IgG (Sigma)
10 or 10ug of a monoclonal antibody to presenilin 1 was added in the presence of 50ul anti-mouse IgG Sepharose. Examples of commercially available antibodies to presenilin 1 are Chemicon International: rat anti-human Presenilin 1 monoclonal antibody; product number MAB 1563; or Santa Cruz
15 Biotechnology: goat anti Presenilin 1; product number SC-1244; or Santa Cruz Biotechnology: goat anti Presenilin 1; product number SC-1245. For use with goat antibodies, the immunoprecipitation was altered as follows: normal goat IgG and protein G Sepharose was used for the pre-absorption and
20 protein G Sepharose was used in the presence of the goat antibodies to presenilin 1. The membrane extract was incubated for 5 hours at 4°C. The Sepharose beads were collected by centrifugation and washed 3 times with 25mM Tris, pH 7.5 containing 50mM KCl, 1mM EDTA and 1% CHAPS,
25 followed by 3 washes with phosphate buffered saline. Radioactivity bound to the Sepharose beads was dissociated by boiling in SDS sample buffer (4x) containing 50mM dithiothreitol. The supernatant was loaded onto a 12% SDS-PAGE and the gel was processed as above. Fluorography
30 revealed the presence of the approximately 30 (band A), 20 (band C), and 10kD (band D) polypeptides in the immunoprecipitation with antibodies to presenilin 1, but not with normal mouse IgG. (Figure 2) These results indicate that the membrane binding assay determines, at least in part,
35 the binding of radiolabeled secretase inhibitors to presenilin 1 fragments.

Subsequent experiments established that the lack of polypeptide B in the initial immunoprecipitation experiments

was due to aggregation upon boiling of the sample in reduced SDS sample buffer, indicating that all specifically labeled polypeptides (A to D) can be specifically immunoprecipitated with antibodies to presenilin 1 under non-denaturing conditions.

Figure 2 illustrates a fluorography of a 12% SDS-PAGE. The relative mobility of molecular weight standards (in kD) is indicated to the left. THP-1 membranes were incubated (30 minutes; room temperature) with Example 43T (30nM) alone (panel A) or Example 43T (30nM) in the presence of Example 98 (panel B). The membranes were photolysed at 365nm for 30 minutes and the membranes harvested by centrifugation. The membranes were extracted with 50mM Tris, pH 7.5 containing 100mM KCl, 2mM EDTA, 2% CHAPS in the presence of protease inhibitors for 1 hour at 4°C. The membrane extracts were either directly fractionated by SDS-PAGE (lanes 1 and 6) or after immunoprecipitation with preimmune IgG (lanes 2 and 4) or antibodies to human presenilin 1 (lanes 3 and 5). Note the immunoprecipitation of specifically labeled bands of approximately 30, 20, and 10 kD after cross-linking in the absence of Example 98, but not in the presence of Example 98. The higher molecular weight bands may represent the presenilin 1 holoprotein and/or presenilin 1 aggregates formed in the presence of SDS.

Example 105

Purification of cross-linked polypeptides by affinity chromatography

THP-1 membranes were prepared and cross-linked as in Example 104. The membranes were extracted as in Example 104 at a protein concentration of 10mg membrane protein / 1ml extraction buffer. Normal mouse IgG (Sigma) or monoclonal antibody to the C-terminal loop of presenilin 1 was immobilized on agarose beads at 2mg IgG per 1ml of beads. The membrane extract was diluted one half with water and applied to a normal mouse IgG precolumn, followed by anti-presenilin 1 IgG. The column material was extensively washed

with one half diluted extraction buffer, one half diluted extraction buffer containing 1M KCl, and eluted with 0.1M glycine, pH 2.5 in one half diluted extraction buffer. The resulting polypeptides were analyzed by SDS-PAGE (12% acrylamide in the separating gel), followed by fluorography (left top panel, Figure 3), silver staining (right top panel, Figure 3), immunoblotting using antibodies to the N-terminus of presenilin (left middle panel, Figure 3) or the C-terminus of presenilin 1 (right middle panel, Figure 3). In addition, the silver stain (right top panel, Figure 3) was soaked in Amplify™ (Amersham), dried, and exposed the x-ray film. It is concluded that the specifically cross-linked bands A, B, and C can be enriched by presenilin 1 affinity chromatography. It should be noted that using an antibody to the N-terminus of presenilin 1, also band D could be enriched. Polypeptides A and C are major silver stained protein bands containing the cross-linker of Example 11T and are immunoreactive with antibodies to presenilin 1. It should be noted that the extraction procedure used will not dissociate the association of macromolecules in the presenilin complex. Accordingly, one skilled in the art will understand that this technique can be employed to identify macromolecules associated with the binding site that are involved in beta amyloid precursor processing.

Figure 3 illustrates isolation of cross-linked polypeptides by presenilin 1 affinity chromatography. THP-1 membranes were cross-linked as in Figure 2 and the resulting membrane extracts were applied to a normal mouse IgG Sepharose, followed by an anti-presenilin 1 Sepharose. The starting material (lanes 1), flow-through normal mouse IgG (lanes 2), flow-through presenilin 1 Sepharose (lanes 3), last wash prior to elution (lanes 4), and elution by lowering the pH (lanes 5) are indicated. The relative mobility of molecular weight markers is indicated. The left top panel shows a fluorography of a 12% SDS-PAGE. Note the enrichment of bands A to C on the presenilin 1 affinity column. The silver stain (top right panel) reveals that bands A and C are

clearly enriched, distinguishable from contaminating proteins, and present in purity sufficient for sequence analysis. The silver stain was soaked in Amplify™ (Amersham), dried, and exposed to x-ray film (bottom left panel). It should be noted that major polypeptides in the elution fraction as revealed by silver staining perfectly align with the radioactivity as revealed by fluorography. The identify of band A as presenilin 1 N-terminal fragments was revealed by immunoblotting using N-terminal-specific antibodies (left middle panel), whereas band C was identified as presenilin C-terminal fragments (right middle panel).

It is understood by one skilled in the art that this or similar purification schemes can be employed to isolate radiolabeled binding polypeptides in sufficient quantities to allow for N-terminal amino acid or mass spectrosctropy analysis. Also, one skilled in the art understands that isolated radiolabeled polypeptides can be further fractionated after chemical or proteolytic digestion to isolate one or several radiolabeled polypeptides in the sizes of approximately 2 to 100 amino acids. Sequence analysis will reveal the location of the smaller polypeptides in the protein sequence of the binding site molecules. In addition, this method can be used to define specifically cross-linked amino acids in the binding site. This information can ultimately be used in rational drug design for Alzheimer's disease. It should be noted that both N- and C-terminal presenilin 1 fragments are labeled by Example 11T. This observation is consistent with the notion that the binding site is contained in proteolytic fragments of presenilin 1 generated upon incorporation in the presenilin 1 complex.

Example 106

Evidence for the involvement of presenilin 2 in the binding site

THP-1 membranes were prepared and analyzed as in Example 104. The presenilin 1 antibodies were replaced with rabbit polyclonal antibodies specific for presenilin 2. The

following modifications were included in comparison to Example 104: samples were pre-absorbed with normal rabbit IgG and protein A Sepharose was used instead of anti-mouse IgG Sepharose. The resulting immunoprecipitates were analyzed by SDS-PAGE (12% acrylamide in the separating gel) followed by fluorography. (See Figure 4) Bands A and B was specifically precipitated with an antibody to presenilin 2 (N-terminus), whereas antibodies to the C-terminus of presenilin 2 preferentially identified band B. These results indicate that the membrane binding assay determines, at least in part, the binding of radiolabeled secretase inhibitors to presenilin 2 fragments. One skilled in the art will realize that the cross-linking assay can be used to identify compounds with preferential affinity for either presenilin 1 or 2. Membranes derived from organisms lacking either presenilin 1 or 2, or both, might be used for the same purpose.

Figure 4 illustrates a fluorography of a 12% SDS-PAGE. The relative mobility of molecular weight standards (in kD) is indicated to the right. THP-1 membranes were incubated (30 minutes; room temperature) with Example 11T, photolyzed at 365nm for 30 minutes, and the membranes harvested by centrifugation. The membranes were extracted with 50mM Tris, pH 7.5 containing 100mM KCl, 2mM EDTA, 2% CHAPS in the presence of protease inhibitors for 1 hour at 4°C. The membrane extracts were either directly fractionated by SDS-PAGE (lane 1) or after immunoprecipitation with preimmune IgG (lane 4) or antibodies to human presenilin 2 (lane 2, PS-2 N-terminal specific antibody; lane 3, PS-2 C-terminal specific antibody). Note the immunoprecipitation of specifically labeled bands A and B of approximately 30 and 25 kD.

It is understood by one skilled in the art that the assays disclosed herein, specifically the Radio Competition Binding Assay and the cross-linking Assay may be employed to differentiate between inhibitors specific for presenilin-1 and presenilin-2. For example, differential competition for radioactivity incorporation in bands A to D would indicate

presenilin-1 and/or presenilin-2 specific compounds.

Moreover, binding to membranes derived from mammalian cells deficient in either PS-1 or PS-2 may be employed to identify PS-1 or PS-2 specific compounds. For example these cells may be derived from organisms, for example murine, which are gene targeted for PS-1 or PS-2. Examples of cells include fibroblasts, neurons, and whole embryonic membranes.

It is understood that the isolation and sequence data for presenilin-1 (PS-1) cloning has been published in Sherrington R et al., Nature, Vol 375, pp754-760, 1995, herein incorporated by reference. It is also understood that the isolation and sequence data for presenilin-2 (PS-2) cloning has been published in Rogaev E.I. et al., Nature, Vol 376, pp774-778, 1995, herein incorporated by reference.

Dosage and Formulation

The compounds determined from the present invention can be administered orally using any pharmaceutically acceptable dosage form known in the art for such administration. The active ingredient can be supplied in solid dosage forms such as dry powders, granules, tablets or capsules, or in liquid dosage forms, such as syrups or aqueous suspensions. The active ingredient can be administered alone, but is generally administered with a pharmaceutical carrier. A valuable treatise with respect to pharmaceutical dosage forms is Remington's Pharmaceutical Sciences, Mack Publishing.

The compounds determined from the present invention can be administered in such oral dosage forms as tablets, capsules (each of which includes sustained release or timed release formulations), pills, powders, granules, elixirs, tinctures, suspensions, syrups, and emulsions. Likewise, they may also be administered in intravenous (bolus or infusion), intraperitoneal, subcutaneous, or intramuscular form, all using dosage forms well known to those of ordinary skill in the pharmaceutical arts. An effective but non-toxic amount of the compound desired can be employed to prevent or treat neurological disorders related to β -amyloid production

or accumulation, such as Alzheimer's disease and Down's Syndrome.

The compounds of this invention can be administered by any means that produces contact of the active agent with the agent's site of action in the body of a host, such as a human or a mammal. They can be administered by any conventional means available for use in conjunction with pharmaceuticals, either as individual therapeutic agents or in a combination of therapeutic agents. They can be administered alone, but generally administered with a pharmaceutical carrier selected on the basis of the chosen route of administration and standard pharmaceutical practice.

The dosage regimen for the compounds determined from the present invention will, of course, vary depending upon known factors, such as the pharmacodynamic characteristics of the particular agent and its mode and route of administration; the species, age, sex, health, medical condition, and weight of the recipient; the nature and extent of the symptoms; the kind of concurrent treatment; the frequency of treatment; the route of administration, the renal and hepatic function of the patient, and the effect desired. An ordinarily skilled physician or veterinarian can readily determine and prescribe the effective amount of the drug required to prevent, counter, or arrest the progress of the condition.

Advantageously, compounds determined from the present invention may be administered in a single daily dose, or the total daily dosage may be administered in divided doses of two, three, or four times daily.

The compounds identified using the present invention can be administered in intranasal form via topical use of suitable intranasal vehicles, or via transdermal routes, using those forms of transdermal skin patches well known to those of ordinary skill in that art. To be administered in the form of a transdermal delivery system, the dosage administration will, of course, be continuous rather than intermittent throughout the dosage regimen.

In the methods of the present invention, the compounds herein described in detail can form the active ingredient,

and are typically administered in admixture with suitable pharmaceutical diluents, excipients, or carriers (collectively referred to herein as carrier materials) suitably selected with respect to the intended form of administration, that is, oral tablets, capsules, elixirs, syrups and the like, and consistent with conventional pharmaceutical practices.

For instance, for oral administration in the form of a tablet or capsule, the active drug component can be combined with an oral, non-toxic, pharmaceutically acceptable, inert carrier such as lactose, starch, sucrose, glucose, methyl cellulose, magnesium stearate, dicalcium phosphate, calcium sulfate, mannitol, sorbitol and the like; for oral administration in liquid form, the oral drug components can be combined with any oral, non-toxic, pharmaceutically acceptable inert carrier such as ethanol, glycerol, water, and the like. Moreover, when desired or necessary, suitable binders, lubricants, disintegrating agents, and coloring agents can also be incorporated into the mixture. Suitable binders include starch, gelatin, natural sugars such as glucose or β -lactose, corn sweeteners, natural and synthetic gums such as acacia, tragacanth, or sodium alginate, carboxymethylcellulose, polyethylene glycol, waxes, and the like. Lubricants used in these dosage forms include sodium oleate, sodium stearate, magnesium stearate, sodium benzoate, sodium acetate, sodium chloride, and the like. Disintegrators include, without limitation, starch, methyl cellulose, agar, bentonite, xanthan gum, and the like.

The compounds determined from the present invention can also be administered in the form of liposome delivery systems, such as small unilamellar vesicles, large unilamellar vesicles, and multilamellar vesicles. Liposomes can be formed from a variety of phospholipids, such as cholesterol, stearylamine, or phosphatidylcholines.

Compounds of the present invention may also be coupled with soluble polymers as targetable drug carriers. Such polymers can include polyvinylpyrrolidone, pyran copolymer, polyhydroxypropylmethacrylamide-phenol,

polyhydroxyethylaspartamidephenol, or polyethyleneoxide-polylysine substituted with palmitoyl residues. Furthermore, the compounds determined from the present invention may be coupled to a class of biodegradable polymers useful in achieving controlled release of a drug, for example, polylactic acid, polyglycolic acid, copolymers of polylactic and polyglycolic acid, polyepsilon caprolactone, polyhydroxy butyric acid, polyorthoesters, polyacetals, polydihydropyrans, polycyanoacylates, and crosslinked or amphipathic block copolymers of hydrogels.

Gelatin capsules may contain the active ingredient and powdered carriers, such as lactose, starch, cellulose derivatives, magnesium stearate, stearic acid, and the like. Similar diluents can be used to make compressed tablets.

Both tablets and capsules can be manufactured as sustained release products to provide for continuous release of medication over a period of hours. Compressed tablets can be sugar coated or film coated to mask any unpleasant taste and protect the tablet from the atmosphere, or enteric coated for selective disintegration in the gastrointestinal tract.

Liquid dosage forms for oral administration can contain coloring and flavoring to increase patient acceptance.

In general, water, a suitable oil, saline, aqueous dextrose (glucose), and related sugar solutions and glycols such as propylene glycol or polyethylene glycols are suitable carriers for parenteral solutions. Solutions for parenteral administration preferably contain a water soluble salt of the active ingredient, suitable stabilizing agents, and if necessary, buffer substances. Antioxidizing agents such as sodium bisulfite, sodium sulfite, or ascorbic acid, either alone or combined, are suitable stabilizing agents. Also used are citric acid and its salts and sodium EDTA. In addition, parenteral solutions can contain preservatives, such as benzalkonium chloride, methyl- or propyl-paraben, and chlorobutanol.

Suitable pharmaceutical carriers are described in Remington's Pharmaceutical Sciences, Mack Publishing Company, a standard reference text in this field.


CLAIMS

What is claimed is:

- 5 **1.** A method of screening for inhibitors of beta-amyloid
production comprising,
- 10 1) contacting a potential inhibitor of beta-amyloid
production and a tagged inhibitor of beta-amyloid
production with at least one macromolecule involved
in the processing of APP and the production of beta-
amyloid peptide, said macromolecule containing a
binding site specific for said tagged inhibitor of
beta-amyloid production;
- 15 2) separating the tagged inhibitor of beta-amyloid
production bound to said macromolecule from the
tagged inhibitor of beta-amyloid production free from
said macromolecule; and
- 20 3) determining an inhibitory concentration of the
potential inhibitor of beta-amyloid production from
the concentration of tagged inhibitor of beta-amyloid
production bound to said macromolecule.
- 25 **2.** The method of Claim 1 wherein the tagged inhibitor of
beta-amyloid production comprises a radiolabeled inhibitor of
beta-amyloid production, a fluorescence labeled inhibitor of
beta-amyloid production or a biotin labeled inhibitor of
beta-amyloid production.
- 30 **3.** The method of Claim 1 wherein the tagged inhibitor of
beta-amyloid production comprises a radiolabeled inhibitor of
beta-amyloid production.
- 35 **4.** The method of Claim 1 wherein the tagged inhibitor of
beta-amyloid production comprises a tritium or iodine
radiolabeled inhibitor of beta-amyloid production.

5. The method of Claim 1 wherein the tagged inhibitor of beta-amyloid production comprises a tritium radiolabeled inhibitor of beta-amyloid production.

5 6. The method of Claim 1 wherein the tagged inhibitor of beta-amyloid production comprises a compound of the Formula (I):



(I)

wherein:

at least one atom of the compound of the Formula (I) is radiolabeled;

15 Q is NH₂;

R³ is C₁-C₆ alkyl substituted with 0-1 R⁴;

20 R⁴ is H, OH, C₁-C₆ alkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, C₃-C₁₀ carbocycle, C₆-C₁₀ aryl, or 5 to 10 membered heterocycle;

R⁵ is H, OR¹⁴;

25 C₁-C₆ alkyl substituted with 0-3 R^{5b};
 C₁-C₆ alkoxy substituted with 0-3 R^{5b};
 C₂-C₆ alkenyl substituted with 0-3 R^{5b};
 C₂-C₆ alkynyl substituted with 0-3 R^{5b};
 C₃-C₁₀ carbocycle substituted with 0-3 R^{5c};
 C₆-C₁₀ aryl substituted with 0-3 R^{5c}; or
 30 5 to 10 membered heterocycle substituted with 0-3 R^{5c};

R^{5b}, at each occurrence, is independently selected from:
 H, C₁-C₆ alkyl, CF₃, OR¹⁴, Cl, F, Br, I, =O, CN, NO₂,
 NR¹⁵R¹⁶;

35 C₃-C₁₀ carbocycle substituted with 0-3 R^{5c};

C₆-C₁₀ aryl substituted with 0-3 R^{5c}; or
5 to 10 membered heterocycle substituted with 0-3 R^{5c};

R^{5c}, at each occurrence, is independently selected from H,
5 OH, C₁-C₆ alkyl, C₁-C₄ alkoxy, Cl, F, Br, I, CN, NO₂,
NR¹⁵R¹⁶, or CF₃;

R⁶ is H;

C₁-C₆ alkyl substituted with 0-3 R^{6a};
10 C₃-C₁₀ carbocycle substituted with 0-3 R^{6b}; or
C₆-C₁₀ aryl substituted with 0-3 R^{6b};

R^{6a}, at each occurrence, is independently selected from H,
C₁-C₆ alkyl, OR¹⁴, Cl, F, Br, I, =O, CN, NO₂, NR¹⁵R¹⁶,
15 phenyl or CF₃;

R^{6b}, at each occurrence, is independently selected from H,
OH, C₁-C₆ alkyl, C₁-C₄ alkoxy, Cl, F, Br, I, CN, NO₂,
NR¹⁵R¹⁶, or CF₃;

20

W is -(CR⁸R^{8a})_p-;

p is 0 to 4;

25 R⁸ and R^{8a}, at each occurrence, are independently selected
from H, C₁-C₄ alkyl, C₂-C₄ alkenyl, C₂-C₄ alkynyl and
C₃-C₈ cycloalkyl;

X is a bond;

30 C₆-C₁₀ aryl substituted with 0-3 R^{Xb};
C₃-C₁₀ carbocycle substituted with 0-3 R^{Xb}; or
5 to 10 membered heterocycle substituted with 0-3 R^{Xb};

R^{Xb}, at each occurrence, is independently selected from H,
35 OH, C₁-C₆ alkyl, C₁-C₄ alkoxy, Cl, F, Br, I, CN, NO₂,
NR¹⁵R¹⁶, or CF₃;

Y is a bond or -(CR⁹R^{9a})_t-V-(CR⁹R^{9a})_u-;

t is 0 to 3;

u is 0 to 3;

5

R⁹ and R^{9a}, at each occurrence, are independently selected from H, C₁-C₆ alkyl or C₃-C₈ cycloalkyl;

10

V is a bond, -C(=O)-, -O-, -S-, -S(=O)-, -S(=O)₂-, -N(R¹⁹)-, -C(=O)NR^{19b}-, -NR^{19b}C(=O)-, -NR^{19b}S(=O)₂-, -S(=O)₂NR^{19b}-, -NR^{19b}S(=O)-, -S(=O)NR^{19b}-, -C(=O)O-, or -OC(=O)-;

Z is H;

15

C₁-C₈ alkyl substituted with 0-2 R¹²;
C₂-C₄ alkenyl substituted with 0-2 R¹²;
C₂-C₄ alkynyl substituted with 0-2 R¹²;
C₆-C₁₀ aryl substituted with 0-4 R^{12b};
C₃-C₁₀ carbocycle substituted with 0-4 R^{12b}; or
5 to 10 membered heterocycle substituted with 0-3 R^{12b};

20

R¹² is C₆-C₁₀ aryl substituted with 0-4 R^{12b};
C₃-C₁₀ carbocycle substituted with 0-4 R^{12b}; or
5 to 10 membered heterocycle substituted with 0-3 R^{12b};

25

R^{12b}, at each occurrence, is independently selected from H, OH, C₁-C₆ alkyl, C₁-C₄ alkoxy, Cl, F, Br, I, CN, NO₂, NR¹⁵R¹⁶, or CF₃;

30

B is a 5 to 10 membered lactam, wherein the lactam is saturated, partially saturated or unsaturated; wherein each additional lactam carbon is substituted with 0-2 R¹¹; and, optionally, the lactam contains a heteroatom selected from -O-, -S-, -S(=O)-, -S(=O)₂-, -N=, and -N(R¹⁰)-;

35

R¹⁰ is H, C(=O)R¹⁷, C(=O)OR¹⁷, C(=O)NR¹⁸R¹⁹, S(=O)₂NR¹⁸R¹⁹, S(=O)₂R¹⁷;
C₁-C₆ alkyl optionally substituted with R^{10a};

C₆-C₁₀ aryl substituted with 0-4 R^{10b};
C₃-C₁₀ carbocycle substituted with 0-3 R^{10b}; or
5 to 10 membered heterocycle optionally substituted with
0-3 R^{10b};

5

R^{10a}, at each occurrence, is independently selected from H,
C₁-C₆ alkyl, C₃-C₆ cycloalkyl, OR¹⁴, Cl, F, Br, I, =O,
CN, NO₂, NR¹⁵R¹⁶, phenyl or CF₃;

10 R^{10b}, at each occurrence, is independently selected from H,
OH, C₁-C₆ alkyl, C₁-C₄ alkoxy, Cl, F, Br, I, CN, NO₂,
NR¹⁵R¹⁶, or CF₃;

R¹¹ is C₁-C₄ alkoxy, Cl, F, Br, I, =O, CN, NO₂, NR¹⁸R¹⁹,
15 C(=O)R¹⁷, C(=O)OR¹⁷, C(=O)NR¹⁸R¹⁹, S(=O)₂NR¹⁸R¹⁹, CF₃;
C₁-C₆ alkyl optionally substituted with R^{11a};
C₆-C₁₀ aryl substituted with 0-3 R^{11b};
C₃-C₁₀ carbocycle substituted with 0-3 R^{11b}; or
5 to 10 membered heterocycle substituted with 0-3 R^{11b};

20

alternatively, two R¹¹ substituents on the same carbon atoms
may be combined to form a C₃-C₆ carbocycle;

alternatively, two R¹¹ substituents on adjacent carbon atoms
25 may be combined to form a C₃-C₆ carbocycle or a benzo
fused radical, wherein said benzo fused radical is
substituted with 0-3 R¹³;

R^{11a}, at each occurrence, is independently selected from H,
30 C₁-C₆ alkyl, OR¹⁴, Cl, F, Br, I, =O, CN, NO₂, NR¹⁵R¹⁶,
phenyl or CF₃;

R^{11b}, at each occurrence, is independently selected from H,
OH, C₁-C₆ alkyl, C₁-C₄ alkoxy, Cl, F, Br, I, CN, NO₂,
35 NR¹⁵R¹⁶, or CF₃;

R¹³, at each occurrence, is independently selected from H, OH, C₁-C₆ alkyl, C₁-C₄ alkoxy, Cl, F, Br, I, CN, NO₂, NR¹⁵R¹⁶, or CF₃;

5 R¹⁴ is H, phenyl, benzyl, C₁-C₆ alkyl, or C₂-C₆ alkoxyalkyl;

R¹⁵, at each occurrence, is independently selected from H, C₁-C₆ alkyl, benzyl, phenethyl, -C(=O)-(C₁-C₆ alkyl) and -S(=O)₂-(C₁-C₆ alkyl);

10

R¹⁶, at each occurrence, is independently selected from H, OH, C₁-C₆ alkyl, benzyl, phenethyl, -C(=O)-(C₁-C₆ alkyl) and -S(=O)₂-(C₁-C₆ alkyl);

15 R¹⁷ is H, phenyl, benzyl, C₁-C₆ alkyl, or C₂-C₆ alkoxyalkyl;

R¹⁸, at each occurrence, is independently selected from H, C₁-C₆ alkyl, benzyl, phenethyl, -C(=O)-(C₁-C₆ alkyl) and -S(=O)₂-(C₁-C₆ alkyl); and

20

R¹⁹, at each occurrence, is independently selected from H, OH, C₁-C₆ alkyl, phenyl, benzyl, phenethyl, -C(=O)-(C₁-C₆ alkyl) and -S(=O)₂-(C₁-C₆ alkyl);


25 R^{19b} is H, C₁-C₆ alkyl, C₃-C₈ cycloalkyl, phenyl, benzyl or phenethyl; and

R²⁰ is H or C₁-C₆ alkyl.

30 7. The method of Claim 6 wherein R³ is C₃-C₆ alkyl.

8. The method of Claim 6 wherein R³ is C₃-C₆ alkyl substituted with about 1 to about 4 ³H.

35 9. The method of Claim 6 wherein the tagged inhibitor of beta-amyloid production comprises a compound of the Formula (II):




(II)

wherein:


at least one atom of the compound of the Formula (II) is
 5 radiolabeled.

10. The method of Claim 9 wherein R^3 is C_3 - C_6 alkyl substituted with about 1 to about 4 3H .


10 11. The method of Claim 1 wherein the tagged inhibitor of beta-amyloid production comprises a compound of Formula:



or




or



wherein m is about 2.

12. The method of Claim 1 wherein the tagged inhibitor of beta-amyloid production comprises a compound of Formula (I-43T):



(I-43T)

wherein m is about 2.

13. The method of Claim 1 wherein at least one macromolecule involved in the processing of APP and the production of beta-amyloid peptide comprises presenilin 1 or a fragment of presenilin 1.

14. The method of Claim 1 wherein at least one macromolecule involved in the processing of APP and the production of beta-amyloid peptide comprises presenilin 2 or a fragment of presenilin 2.

15. The method of Claim 1 wherein the inhibitory concentration is half maximal inhibitory concentration.

16. A pharmaceutical composition comprising a pharmaceutically acceptable carrier and a therapeutically effective amount of an inhibitor of beta-amyloid production identified by the screening assay of Claims 1-15 or a pharmaceutically acceptable salt or prodrug form thereof.

17. A method for treating degenerative neurological disorders involving beta-amyloid production comprising administering to a host in need of such treatment a therapeutically effective amount of an inhibitor of beta-amyloid production identified by the screening assay of

Claims 1-15 or a pharmaceutically acceptable salt or prodrug form thereof.

18. A method for treating Alzheimer's disease comprising
5 administering to a host in need of such treatment a therapeutically effective amount of an inhibitor of beta-amyloid production identified by the screening assay of Claims 1-15 or a pharmaceutically acceptable salt or prodrug form thereof.

10 19. A method of identifying a macromolecule involved in APP processing comprising


- 1) contacting a tagged inhibitor of beta-amyloid
production with material suspected to contain a
15 macromolecule involved in APP processing;
- 2) separating a complex comprising a tagged inhibitor of beta-amyloid production and a macromolecule involved in APP processing; and
- 3) identifying the complex.

20 20. The method of Claim 19 wherein the tagged inhibitor of beta-amyloid production comprises a radiolabeled inhibitor of beta-amyloid production, a fluorescence labeled inhibitor of beta-amyloid production, a biotin labeled inhibitor of beta-amyloid production, a photoaffinity labeled inhibitor of
25 beta-amyloid production, or any combination of tags thereof in one inhibitor of beta-amyloid production.

30 21. The method of Claim 19 wherein the tagged inhibitor of beta-amyloid production comprises a radiolabeled inhibitor of beta-amyloid production.

35 22. The method of Claim 19 wherein the tagged inhibitor of beta-amyloid production comprises a tritium labeled inhibitor of beta-amyloid production.

23. The method of Claim 19 wherein the tagged inhibitor of beta-amyloid production comprises a compound of Formula (I):



(I)

wherein:

- 5 at least one atom of the compound of the Formula (I) is radiolabeled;

Q is NH₂;

- 10 R³ is C₁-C₆ alkyl substituted with 0-1 R⁴;

R⁴ is H, OH, C₁-C₆ alkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, C₃-C₁₀ carbocycle, C₆-C₁₀ aryl, or 5 to 10 membered heterocycle;

15

R⁵ is H, OR¹⁴;

C₁-C₆ alkyl substituted with 0-3 R^{5b};

C₁-C₆ alkoxy substituted with 0-3 R^{5b};

C₂-C₆ alkenyl substituted with 0-3 R^{5b};

20

C₂-C₆ alkynyl substituted with 0-3 R^{5b};

C₃-C₁₀ carbocycle substituted with 0-3 R^{5c};

C₆-C₁₀ aryl substituted with 0-3 R^{5c}; or

5 to 10 membered heterocycle substituted with 0-3 R^{5c};

25

R^{5b}, at each occurrence, is independently selected from:

H, C₁-C₆ alkyl, CF₃, OR¹⁴, Cl, F, Br, I, =O, CN, NO₂, NR¹⁵R¹⁶;

C₃-C₁₀ carbocycle substituted with 0-3 R^{5c};

C₆-C₁₀ aryl substituted with 0-3 R^{5c}; or

30

5 to 10 membered heterocycle substituted with 0-3 R^{5c};

R^{5c}, at each occurrence, is independently selected from H, OH, C₁-C₆ alkyl, C₁-C₄ alkoxy, Cl, F, Br, I, CN, NO₂, NR¹⁵R¹⁶, or CF₃;

35

R⁶ is H;

C₁-C₆ alkyl substituted with 0-3 R^{6a};

C₃-C₁₀ carbocycle substituted with 0-3 R^{6b}; or

C₆-C₁₀ aryl substituted with 0-3 R^{6b};

5

R^{6a}, at each occurrence, is independently selected from H, C₁-C₆ alkyl, OR¹⁴, Cl, F, Br, I, =O, CN, NO₂, NR¹⁵R¹⁶, phenyl or CF₃;

10 R^{6b}, at each occurrence, is independently selected from H, OH, C₁-C₆ alkyl, C₁-C₄ alkoxy, Cl, F, Br, I, CN, NO₂, NR¹⁵R¹⁶, or CF₃;

W is -(CR⁸R^{8a})_p-;

15

p is 0 to 4;

R⁸ and R^{8a}, at each occurrence, are independently selected from H, C₁-C₄ alkyl, C₂-C₄ alkenyl, C₂-C₄ alkynyl and C₃-C₈ cycloalkyl;

20

X is a bond;

C₆-C₁₀ aryl substituted with 0-3 R^{Xb};

C₃-C₁₀ carbocycle substituted with 0-3 R^{Xb}; or

25 5 to 10 membered heterocycle substituted with 0-3 R^{Xb};

R^{Xb}, at each occurrence, is independently selected from H, OH, C₁-C₆ alkyl, C₁-C₄ alkoxy, Cl, F, Br, I, CN, NO₂, NR¹⁵R¹⁶, or CF₃;

30

Y is a bond or -(CR⁹R^{9a})_t-V-(CR⁹R^{9a})_u-;

t is 0 to 3;

35 u is 0 to 3;

R⁹ and R^{9a}, at each occurrence, are independently selected from H, C₁-C₆ alkyl or C₃-C₈ cycloalkyl;

V is a bond, -C(=O)-, -O-, -S-, -S(=O)-, -S(=O)₂-, -N(R¹⁹)-, -C(=O)NR^{19b}-, -NR^{19b}C(=O)-, -NR^{19b}S(=O)₂-, -S(=O)₂NR^{19b}-, -NR^{19b}S(=O)-, -S(=O)NR^{19b}-, -C(=O)O-, or -OC(=O)-;

5

Z is H;

C₁-C₈ alkyl substituted with 0-2 R¹²;

C₂-C₄ alkenyl substituted with 0-2 R¹²;

C₂-C₄ alkynyl substituted with 0-2 R¹²;

10

C₆-C₁₀ aryl substituted with 0-4 R^{12b};

C₃-C₁₀ carbocycle substituted with 0-4 R^{12b}; or

5 to 10 membered heterocycle substituted with 0-3 R^{12b};

R¹² is C₆-C₁₀ aryl substituted with 0-4 R^{12b};

15

C₃-C₁₀ carbocycle substituted with 0-4 R^{12b}; or

5 to 10 membered heterocycle substituted with 0-3 R^{12b};

R^{12b}, at each occurrence, is independently selected from H,

OH, C₁-C₆ alkyl, C₁-C₄ alkoxy, Cl, F, Br, I, CN, NO₂,

20

NR¹⁵R¹⁶, or CF₃;

B is a 5 to 10 membered lactam, wherein the lactam is

saturated, partially saturated or unsaturated; wherein

each additional lactam carbon is substituted with 0-2

25

R¹¹; and, optionally, the lactam contains a heteroatom

selected from -O-, -S-, -S(=O)-, -S(=O)₂-, -N= and

-N(R¹⁰)-;

R¹⁰ is H, C(=O)R¹⁷, C(=O)OR¹⁷, C(=O)NR¹⁸R¹⁹,

30

S(=O)₂NR¹⁸R¹⁹, S(=O)₂R¹⁷;

C₁-C₆ alkyl optionally substituted with R^{10a};

C₆-C₁₀ aryl substituted with 0-4 R^{10b};

C₃-C₁₀ carbocycle substituted with 0-3 R^{10b}; or

5 to 10 membered heterocycle optionally substituted with

35

0-3 R^{10b};

R^{10a}, at each occurrence, is independently selected from H, C₁-C₆ alkyl, C₃-C₆ cycloalkyl, OR¹⁴, Cl, F, Br, I, =O, CN, NO₂, NR¹⁵R¹⁶, phenyl or CF₃;

5 R^{10b}, at each occurrence, is independently selected from H, OH, C₁-C₆ alkyl, C₁-C₄ alkoxy, Cl, F, Br, I, CN, NO₂, NR¹⁵R¹⁶, or CF₃;

10 R¹¹ is C₁-C₄ alkoxy, Cl, F, Br, I, =O, CN, NO₂, NR¹⁸R¹⁹, C(=O)R¹⁷, C(=O)OR¹⁷, C(=O)NR¹⁸R¹⁹, S(=O)₂NR¹⁸R¹⁹, CF₃; C₁-C₆ alkyl optionally substituted with R^{11a}; C₆-C₁₀ aryl substituted with 0-3 R^{11b}; C₃-C₁₀ carbocycle substituted with 0-3 R^{11b}; or 5 to 10 membered heterocycle substituted with 0-3 R^{11b};

15

alternatively, two R¹¹ substituents on the same carbon atoms may be combined to form a C₃-C₆ carbocycle;

20

alternatively, two R¹¹ substituents on adjacent carbon atoms may be combined to form a C₃-C₆ carbocycle or a benzo fused radical, wherein said benzo fused radical is substituted with 0-3 R¹³;

25

R^{11a}, at each occurrence, is independently selected from H, C₁-C₆ alkyl, OR¹⁴, Cl, F, Br, I, =O, CN, NO₂, NR¹⁵R¹⁶, phenyl or CF₃;

30

R^{11b}, at each occurrence, is independently selected from H, OH, C₁-C₆ alkyl, C₁-C₄ alkoxy, Cl, F, Br, I, CN, NO₂, NR¹⁵R¹⁶, or CF₃;

35

R¹³, at each occurrence, is independently selected from H, OH, C₁-C₆ alkyl, C₁-C₄ alkoxy, Cl, F, Br, I, CN, NO₂, NR¹⁵R¹⁶, or CF₃;

R¹⁴ is H, phenyl, benzyl, C₁-C₆ alkyl, or C₂-C₆ alkoxyalkyl;

R¹⁵, at each occurrence, is independently selected from H, C₁-C₆ alkyl, benzyl, phenethyl, -C(=O)-(C₁-C₆ alkyl) and -S(=O)₂-(C₁-C₆ alkyl);

5 R¹⁶, at each occurrence, is independently selected from H, OH, C₁-C₆ alkyl, benzyl, phenethyl, -C(=O)-(C₁-C₆ alkyl) and -S(=O)₂-(C₁-C₆ alkyl);

R¹⁷ is H, phenyl, benzyl, C₁-C₆ alkyl, or C₂-C₆ alkoxyalkyl;

10


R¹⁸, at each occurrence, is independently selected from H, C₁-C₆ alkyl, benzyl, phenethyl, -C(=O)-(C₁-C₆ alkyl) and -S(=O)₂-(C₁-C₆ alkyl); and

15 R¹⁹, at each occurrence, is independently selected from H, OH, C₁-C₆ alkyl, phenyl, benzyl, phenethyl, -C(=O)-(C₁-C₆ alkyl) and -S(=O)₂-(C₁-C₆ alkyl);

20 R^{19b} is H, C₁-C₆ alkyl, C₃-C₈ cycloalkyl, phenyl, benzyl or phenethyl; and

R²⁰ is H or C₁-C₆ alkyl.

25 **24.** The method of Claim 19 wherein the tagged inhibitor of beta-amyloid production comprises a compound of the Formula (I-7T):



(I-7T)


30

wherein m is about 2.

25. The method of Claim 19 wherein the tagged inhibitor of beta-amyloid production comprises a compound of the Formula (I-43T), wherein m is about 2.

5 26. The method of Claim 20 wherein the tagged inhibitor of beta-amyloid production is radiolabeled and photoaffinity labeled.

10 27. The method of Claim 20 wherein the tagged inhibitor of beta-amyloid production comprises a compound of the Formula (I-11T):



(I-11T)

15


wherein m is about 2.

20 28. A macromolecule involved in APP processing comprising a macromolecule to which a tagged inhibitor of beta-amyloid production binds to specifically.

25 29. A macromolecule of Claim 28 wherein the tagged inhibitor of beta-amyloid production comprises a radiolabeled inhibitor of beta-amyloid production, a fluorescence labeled inhibitor of beta-amyloid production, a biotin labeled inhibitor of beta-amyloid production, a photoaffinity labeled inhibitor of beta-amyloid production, or any combination of tags thereof in one inhibitor of beta-amyloid production.

30 30. A macromolecule of Claim 28 wherein the tagged inhibitor of beta-amyloid production comprises a radiolabeled inhibitor of beta-amyloid production.


31. A macromolecule of Claim 28 wherein the tagged inhibitor of beta-amyloid production comprises a compound of the Formula (I-7T):



(I-7T)

wherein m is about 2.


32. A macromolecule of Claim 28 wherein the tagged inhibitor of beta-amyloid production comprises a compound of the Formula (I-11T):



(I-11T)

wherein m is about 2.

33. A macromolecule of Claim 28 wherein the tagged inhibitor of beta-amyloid production comprises a compound of the Formula (I-43T):



(I-43T)

wherein m is about 2.

34. The macromolecule of Claim 28 comprising presenilin 1 or a fragment of presenilin 1.

35. The macromolecule of Claim 28 comprising presenilin 2 or
5 a fragment of presenilin 2.

36. An inhibitor of beta-amyloid production comprising a compound which interacts with a binding site on a macromolecule involved in the production of beta-amyloid
10 peptide; wherein said binding site is a specific binding site for a compound of Formula (I-7T) or (I-43T) wherein m is about 2.

37. An inhibitor of beta-amyloid production of Claim 36
15 wherein the macromolecule involved in the production of beta-amyloid peptide is presenilin 1 or a fragment of presenilin 1.

38. An inhibitor of beta-amyloid production of Claim 36
20 wherein the macromolecule involved in the production of beta-amyloid peptide is presenilin 2 or a fragment of presenilin 2.

39. An inhibitor of beta-amyloid production of Claim 36
25 comprising a compound which interacts with a binding site on a macromolecule involved in the production of beta-amyloid peptide; wherein said binding site is a specific binding site for a compound of Formula (I-7T) wherein m is about 2; and the compound demonstrates a half maximal inhibitory
30 concentration less than 10 micromolar for beta-amyloid production.

40. An inhibitor of beta-amyloid production of Claim 36 comprising a compound which interacts with a binding site on
35 presenilin 1 or a fragment of presenilin 1; wherein said binding site is a specific binding site for a compound of Formula (I-7T) wherein m is about 2; and the compound

demonstrates a half maximal inhibitory concentration less than 10 micromolar for beta-amyloid production.

41. An inhibitor of beta-amyloid production of Claim 36
5 comprising a compound which interacts with a binding site on a macromolecule involved in the production of beta-amyloid peptide; wherein said binding site is a specific binding site for a compound of Formula (I-43T) wherein m is about 2; and the compound demonstrates a half maximal inhibitory
10 concentration less than 10 micromolar for beta-amyloid production.

42. An inhibitor of beta-amyloid production of Claim 36 comprising a compound which interacts with a binding site on
15 presenilin 1 or a fragment of presenilin 1; wherein said binding site is a specific binding site for a compound of Formula (I-43T) wherein m is about 2; and the compound demonstrates a half maximal inhibitory concentration less than 10 micromolar for beta-amyloid production.

20 43. A tagged inhibitor of beta-amyloid production comprising a tagged compound which interacts with a binding site on a macromolecule involved in the production of beta-amyloid peptide; wherein said binding site is a specific binding site
25 for a compound of Formula (I-7T) or (I-43T) wherein m is about 2.

44. A tagged inhibitor of beta-amyloid production of Claim 43 wherein the macromolecule involved in the production of
30 beta-amyloid peptide is presenilin 1 or a fragment of presenilin 1.

45. A tagged inhibitor of beta-amyloid production of Claim 43 wherein the macromolecule involved in the production of
35 beta-amyloid peptide is presenilin 2 or a fragment of presenilin 2.

46. A tagged inhibitor of beta-amyloid production of Claim 43 comprising a tagged compound which interacts with a binding site on a macromolecule involved in the production of beta-amyloid peptide; wherein said binding site is a specific binding site for a compound of Formula (I-7T) wherein m is about 2; and the tagged compound demonstrates a half maximal inhibitory concentration less than 10 micromolar for beta-amyloid production.

47. A tagged inhibitor of beta-amyloid production of Claim 43 comprising a tagged compound which interacts with a binding site on presenilin 1 or a fragment of presenilin 1; wherein said binding site is a specific binding site for a compound of Formula (I-7T) wherein m is about 2; and the tagged compound demonstrates a half maximal inhibitory concentration less than 10 micromolar for beta-amyloid production.

48. A tagged inhibitor of beta-amyloid production of Claim 43 comprising a tagged compound which interacts with a binding site on a macromolecule involved in the production of beta-amyloid peptide; wherein said binding site is a specific binding site for a compound of Formula (I-43T) wherein m is about 2; and the tagged compound demonstrates a half maximal inhibitory concentration less than 10 micromolar for beta-amyloid production.

49. A tagged inhibitor of beta-amyloid production of Claim 43 comprising a tagged compound which interacts with a binding site on presenilin 1 or a fragment of presenilin 1; wherein said binding site is a specific binding site for a compound of Formula (I-43T) wherein m is about 2; and the tagged compound demonstrates a half maximal inhibitory concentration less than 10 micromolar for beta-amyloid production.

50. A method of identifying inhibitors as therapeutics for neurological and other disorders involved in APP processing and beta-amyloid production comprising

(1) contacting at least one macromolecule involved in APP processing and beta-amyloid production, which macromolecule a tagged inhibitor of beta-amyloid production binds to specifically, with a potential beta-amyloid inhibitor; and

(2) determining the level of inhibition of APP processing and beta-amyloid production.

51. The method of Claim 50 wherein the macromolecule is a complex of macromolecules.

52. The method of Claim 50 wherein the macromolecule is presenilin 1 or a fragment of presenilin 1.

53. The method of Claim 50 wherein the macromolecule is presenilin 2 or a fragment of presenilin 2.

54. A method of treating Alzheimer's disease comprising administering to a host in need of such treatment a therapeutically effective amount of an inhibitor of beta-amyloid production, or a pharmaceutically acceptable salt or prodrug form thereof, wherein said inhibitor of beta-amyloid production binds to a binding site on a macromolecule involved in the production of beta-amyloid peptide and effects a decrease in production of beta-amyloid peptide; wherein said binding site is a specific binding site for a compound of Formula (I-7T) or (I-43T) wherein m is about 2.

55. The method of Claim 54 wherein the macromolecule comprises presenilin-1, a fragment of presenilin-1, presenilin-2, or a fragment of presenilin-2.


56. A method of Claim 54 wherein the binding site is a specific binding site for a compound of Formula (I-43T) wherein m is about 2.

57. The method of Claim 56 wherein the macromolecule comprises presenilin-1 or a fragment of presenilin-1.

5 58. The method of Claim 56 wherein the macromolecule comprises presenilin-2 or a fragment of presenilin-2.


FIG. 1

Binding



1: DMSO
2: example 7
3: example 98b
4: example 43
5: example 99
6: example 11
(2-6 at 1uM)

Non-reduced



Reduced




FIG. 2






FIG. 3



- 1: Starting material
- 2: I.P. PS-2 N-t.
- 3: I.P. PS-2 C-t. loop
- 4: I.P. normal rabbit IgG

FIG. 4



INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 99/26715

A. CLASSIFICATION OF SUBJECT MATTER
IPC 7 G01N33/68

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHEDMinimum documentation searched (classification system followed by classification symbols)
IPC 7 G01N C07K C12N

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the International search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	WO 98 15828 A (SCIOS INC ;CORDELL BARBARA (US); HIGAKI JEFFREY N (US)) 16 April 1998 (1998-04-16) abstract claims	1-15, 19-27, 50-53
A	WO 92 00374 A (DU PONT) 9 January 1992 (1992-01-09) abstract claim 11	1-15, 19-27, 50-53
A	US 5 538 845 A (KNOPS JEROEN ET AL) 23 July 1996 (1996-07-23) abstract claims	1-15, 19-27, 50-53

☐ Further documents are listed in the continuation of box C.☒ Patent family members are listed in annex.

* Special categories of cited documents:

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

- "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
- "&" document member of the same patent family

Date of the actual completion of the international search

6 March 2000

Date of mailing of the international search report

20/03/2000

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Pellegrini, P

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US 99/26715

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.: 17-18, 54-58
because they relate to subject matter not required to be searched by this Authority, namely:
Claims 17-18, 54-58 relate to a method of treatment of a human body based on therapy.
2. ☒ Claims Nos.: 16-18, 28-49, 54-58
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
see FURTHER INFORMATION sheet PCT/ISA/210
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this International application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

International Application No. PCT/US 99 26715

FURTHER INFORMATION CONTINUED FROM PCT/SA/ 210

Continuation of Box I.2

Claims Nos.: 16-18, 28-49, 54-58

Claims 16-18 are related to pharmaceutical compositions identified by the screening method disclosed in claims 1-15, and to methods of treating neurological disorders based on these compositions.

Claims 28-35 are related to macromolecules involved in APP processing capable of specifically binding tagged inhibitors of beta-amyloid production.

Claims 36-49, 54-58 are related to inhibitors of beta-amyloid production comprising a compound which interacts with a binding site on a macromolecule involved in the production of beta-amyloid peptide, wherein said binding site is a specific binding site for a compound of formula I-7T or I-43T, and to a method of treating Alzheimer's disease based on these inhibitors.

The subject-matter of claims 16-18 is defined by a result to be achieved, namely being an inhibitor of beta-amyloid production and not by any technical features of the compositions claimed. This contravenes the requirements of Article 6 and Rule 6.3(a) PCT.

The subject-matter of claims 28-35, i.e. macromolecules, is defined solely by the features of molecules, i.e. inhibitors, which do not form part of the subject-matter for which protection is sought in claims 28-35. This contravenes the requirements of Article 6 PCT, first sentence.

The subject-matter of claims 36-49 and 54-58 is also characterized by the features of molecules not claimed. This also contravenes the requirements of Article 6 PCT, first sentence.

Moreover, the claims cover not only the exemplified inhibitors (pag. 9-16, 18-27, claims 1-15, 19-27, 50-53) but also many others which are not supported by the description. This contravenes the requirements of article 5 PCT and Article 6 PCT, third sentence.

The description and claims thus fail to comply with the prescribed requirements to such an extent that a meaningful search over the whole range defined is not possible. The search is limited to claims 1-15, 19-27, 50-53.

The applicant's attention is drawn to the fact that claims, or parts of claims, relating to inventions in respect of which no international search report has been established need not be the subject of an international preliminary examination (Rule 66.1(e) PCT). The applicant is advised that the EPO policy when acting as an International Preliminary Examining Authority is normally not to carry out a preliminary examination on matter which has not been searched. This is the case irrespective of whether or not the claims are amended following receipt of the search report or during any Chapter II procedure.

INTERNATIONAL SEARCH REPORT

International Application No. PCT/ US 99 /26715

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

Continuation of Box 1.2

Claims 16-18 are related to pharmaceutical compositions identified by the screening method disclosed in claims 1-15, and to methods of treating neurological disorders based on these compositions.

Claims 28-35 are related to macromolecules involved in APP processing capable of specifically binding tagged inhibitors of beta-amyloid production.

Claims 36-49, 54-58 are related to inhibitors of beta-amyloid production comprising a compound which interacts with a binding site on a macromolecule involved in the production of beta-amyloid peptide, wherein said binding site is a specific binding site for a compound of formula I-7T or I-43T, and to a method of treating Alzheimer's disease based on these inhibitors.

The subject-matter of claims 16-18 is defined by a result to be achieved, namely being an inhibitor of beta-amyloid production and not by any technical features of the compositions claimed. This contravenes the requirements of Article 6 and Rule 6.3(a) PCT.

The subject-matter of claims 28-35, i.e. macromolecules, is defined solely by the features of molecules, i.e. inhibitors, which do not form part of the subject-matter for which protection is sought in claims 28-35. This contravenes the requirements of Article 6 PCT, first sentence.

The subject-matter of claims 36-49 and 54-58 is also characterized by the features of molecules not claimed. This also contravenes the requirements of Article 6 PCT, first sentence.

Moreover, the claims cover not only the exemplified inhibitors (pag. 9-16, 18-27, claims 1-15, 19-27, 50-53) but also many others which are not supported by the description. This contravenes the requirements of article 5 PCT and Article 6 PCT, third sentence.

The description and claims thus fail to comply with the prescribed requirements to such an extent that a meaningful search over the whole range defined is not possible. The search is limited to claims 1-15, 19-27, 50-53.

The applicant's attention is drawn to the fact that claims, or parts of the claims, relating to inventions in respect of which no international search report has been established need not be the subject of an international preliminary examination (Rule 66.1(e) PCT). The applicant is advised that the EPO policy when acting as an International Preliminary Examining Authority is normally not to carry out a preliminary examination on matter which has not

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/US 99/26715

Patent document cited in search report		Publication date	Patent family member(s)		Publication date
WO 9815828	A	16-04-1998	AU	4589297 A	05-05-1998
WO 9200374	A	09-01-1992	US	5252463 A	12-10-1993
US 5538845	A	23-07-1996	AU	3585293 A	03-09-1993
			WO	9316101 A	19-08-1993